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Abstract
Background:Inactivation of APC geneis recognised as one of the first important
genetic changes in the pathogenesis of colorectal cancer. Inactivation of APC
stabilises 6-catenin, whichtranslocates into the nucleus, activating TCF/LEF1 with
subsequenttransactivation of many target genes through the Wntsignalling pathway.
A Cre-/oxP mouse model has been previously developed, wherein an inducible loss
of Ape within the intestinal epithelium causes immediate activation of the Wnt
signalling pathway, failure in cell migration and differentiation, perturbation of the
normalcrypt/villus homeostasis, induction of cell death and proliferation (Sansom et
al., 2007). Loss of c-Myc, following losing Apc, completely rescues the phenotypes
of altered differentiation, migration, proliferation and apoptosis (Sansom etal.,
2007). Microarray analysis of the two unique mouse models haveidentified a cohort
of c-Myc-dependent Wnt regulated gene alterations for which there has been little
previousassociation with neoplasia.
Objectives: We aimed to validate the Cre-/oxP-Apc mouse model in human using
colorectal cancer tissues. We were also interested in underlying mechanismsofthe
identified gene CI/TED/Cited] that may give us an insight into colorectal
carcinogenesis.
Results: Homologous human candidate genes were detected by Taqman real-time
PCR analysis using colorectal cancer tissues with matched neighbouring normal
mucosa. Eight (out of twelve) homologous human genes weresignificantly up-
regulated, which demonstrated how transferable the candidate genes identified in the
mouse modelare to the study ofhuman colorectal cancer. One of the Myc-dependent
Wnttargets C/TED/ is up-regulated (2.74-fold, n=40, p<0.001) in human colorectal
cancer. The effects of CITED/Cited/ deficiency on colorectal carcinogenesis were
investigated both in vitro and in vivo. In HT29 and HCT116 humancolorectal cancer
cell lines, reduction in expression of C/TED/ (siRNA treatment) significantly
increases cell death and reduces cell proliferation. Losing Cited] leads to a
significantly increased life span of Min mice with reduced number of adenomasin
small intestine and large intestine. Loss of Cited] does not alter B-catenin
translocation in Min adenomas. When using Cre-/oxP-Apc early colorectal cancer
mouse model, comparing Apc/Cited/ double null mice to Apc null mice, crypt-villus
architecture was moreseverely altered with an elongated crypt-like zone in the small
intestine, as well as increased proliferation and elevated apoptosis. In Apc/Cited1
double null mice, f-catenin also translocates into nucleus as observed in the Apc null
mice.
Conclusions: Detected up-regulation of known Wht targets again validates the
process in human colorectal cancer. C/TED/Cited1 a previously unrecognised
component of colorectal carcinogenesis was identified as a novel Wnt target in
human colorectal cancer in the in vitro and in vivo studies. Data of immuno-
histochemistry assay suggests that losing Cited] is not sufficient to inhibit Wnt
signalling activity at the point of nuclear B-catenin translocation. However, the more
defined underlying molecular mechanisms of C/TED/ involved with colorectal
carcinogenesis need further investigation.
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Chapter1 Introduction
1.1 Epidemiological Studies of Colorectal Cancer
Colorectal cancer (CRC) is widespread in western countries and has a high rate of
mortality and morbidity (Huls etal., 2003; Parkin et al., 1999). Colorectal canceris
the fourth most frequent malignant neoplasm throughout the world (Watson, 2006;
Weitz et al., 2005). Every year, about 1 million people develop colorectal cancer and
half of the CRC patients have advanced disease at initial presentation (Weitz etal.,
2005). In the UK, there were 16,007 deaths from colorectal cancer in 2007 (Cancer
Stats CRUK 2007, accessed in August 2007,
http://info.cancerresearchuk.org/cancerstats/types/bowel/mortality/). The percentage
of colorectal cancer patient 5-year survivals reaches only 50%, which also depends
on the grade - Dukes A, 100% survival following surgery (Soreide et al., 2006;
Watson, 2006).
Therisk of developing CRCis influenced by both genetic and environmentalfactors
(Strate and Syngal, 2005). The lifetime colorectal cancer risk in general populationis
5%, this figure will also increase dramatically along with age (Fodde, 2002).
Although not directly inherited, first-degree relatives of patients who have single
colorectal carcinoma have a threefold greater risk of developing colorectal
carcinoma than the average population (Weitz et al., 2005). The risk of colorectal
cancer also seemsto be linked to diet: a diet high in fat and red meat, low in dietary
fibre increase the risk significantly (Weitz et al., 2005). In 2002, the incidence of
1]
colorectal cancer was 34,889 with an age-standardised rate of 54.4 in men and 35.3
in women, which showsthat genderis a risk factor (Weitz et al., 2005).
Colorectal cancer is a multi-step disease, which develops through a numberof well
characterised stages based on the degree of invasion (Watson, 2006). The
histological changes help to define the parameters for treatment of the different
stages. Staging assesses the grade of the disease, which embracesfactors, including
the size of the growth, degree of invasion, local and distant spread and the
histological differentiation of the cells (Greene, 2006). The Modified Duke’s Staging
is typically used, but more recently, the International Union Against Cancer (UICC)
or the Tumour, Node, Metastasis (TNM) systems have replaced it (Dukes and
Bussey, 1958; Greene, 2006) (Figure 1.1; Table 1.1).
Spread to other organs    
 
Normal
a. Stage IV a
Figure 1.1 Diagram of staging of colorectal cancer. Adapted from
http://visuals.nci.nih.gov/preview.cfm?imageid=7181&fileformat=jpg
accessed in August 2009
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Table 1.1 Staging of Colorectal Cancer (modified from the information on
www.cancer.org, accessed in August 2009)
 
    
UICC/TNM Modified Dukes’
Stage 0 Carcinomain situ
Stage I Tumourinvades submucosa (T1) A
Tumour invades muscularis propria (T2)
No nodal involvement, no distant metastasis
Stage II Tumourinvades beyond muscularis propria (T3) B
Tumourinvadesinto other organs (T4)
Nonodalinvolvement, no distant metastasis
Stage III 1-3 Regional lymph nodes involved — any T (N1) C
4 or moreregional lymph nodesinvolved (N2)
No distant metastasis any T
Stage IV Distant Metastasis (M1) D
Any T, any N stage  
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1.2 Molecular Pathogenesis of Colorectal Cancer
It is well knownthat colorectal cancer, like neoplasmsof other organs or systems,is
the result of the accumulation of genetic and epigenetic alterations underlying the
progress of carcinogenesis (Bodmer, 2006; Grady and Markowitz, 2002) (Figure 1.2).
The loss of genomicstability is a key event in this process and serves to create an
environment for the occurrence ofalterations in tumour suppressor genes, oncogenes
and DNArepair genes (Grady and Markowitz, 2002). Although most cancer-causing
mutations are somatic (Bodmer, 2006), there are a numberof cancers that have a
hereditary component (mutations affecting germline), which are heritable which
contributesto the initiation of carcinogenesis (Benito and Diaz-Rubio, 2006).
Colorectal cancer arises as the cumulative effect of multiple mutations within the
cells, allowing it to escape from growth and regulatory control mechanisms (Grady
and Markowitz, 2002). The majority of colorectal cancers have chromosomal
instability (CIN), referring to an increased rate of losing and gaining wholeorpart of
chromosomes during cell division (Michor, 2005; Takayamaet al., 2006). It is a
step-wise progression of mutations that facilitates the histological alterations from
normal mucosa to adenomato carcinoma (peamiacd et al., 2002). This adenomato
carcinoma sequence, associated with an increasing level of nuclear B-catenin and a
gradual series of histological transitions that was addressed firstly by Fearon and
Vogelstein in 1990, involving the accumulation of mutation in a numberof genes
and consequent progression (Fearon and Vogelstein, 1990; Giles et al., 2003; Pinto
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and Clevers, 2005b). Tumour suppressor genes (TSGs) APC (chromosome, 5q),
Smad4 (18q) and p53 (17q) and oncogene K-ras (12q) are the main targets of these
genetic alterations (Fodde, 2002).
Second hit
somatic mutation
APC
First hit K-ras Smad4 p53 otheralterations
somatic mutation
(sporadic CRC) genomic
APC
\ instability
Normal
yiiiin
APC
first hit germline
mutation (FAP)
  
B-catenin
axin
 
Chromosomalinstability (CIN)
Figure 1.2 Multiple genetic alterations in the adenomato carcinoma
sequencefor colorectal cancer. (Adapted from Pinto and Clevers, 2005)
CIN pathway is characterised by the initial allelic losses on these chromosomes
leading to increased genetic instability to drive tumour progression (Nowaketal.,
2002). CIN pathway is the model typically represented in familial adenomatous
polyposis (FAP), which happens as two hits in the APC gene, followed by the
mutation of K-Ras, subsequently mutations ofp53 and subsequently the deletion on
chromosome18q (Takayamaetal., 2006).
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1.3 Hereditary Colorectal Cancer
In human colorectal cancer, the hereditary syndromes include familial adenomatous
polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC) (Gryfe et
al., 1997; Sanchoet al., 2004). Both of the hereditary colorectal cancer syndromes
are autosomal dominantly inherited diseases with respectively almost 100% and 80%
lifetime risk of developing colorectal cancer, respectively (Fearnhead et al., 2002;
Hisamuddin and Yang, 2004; Lynch and de la Chapelle, 2003; Sanchoetal., 2004).
The presence of hundreds to thousands of adenomatous colorectal polyps makes
FAP remarkably different to HNPCC, however both conditions result in a high
family risk (Lynch and de la Chapelle, 2003). Recent studies demonstrated that
approximately 5% of the incidence of colorectal cancer could be attributed to
recognizable heritable germline mutations (Cruz-Correa and Giardiello, 2002; Jeter
et al., 2006).
1.3.1 Familial Adenomatous Polyposis (FAP) and FAP-like Syndromes
1.3.1.1 FAP Syndrome
FAPis rare, occurring at the frequency of 1 in 8000 within the population (Bodmer,
2006; Powell et al., 1993), and accounts for less than 1% of all colorectal cancer
cases seen in practice (Burt et al., 1990). However, it is a distinctively classical and
dominantly inherited syndrome, both clinically and genetically (Bodmer, 2006;
Lipton and Tomlinson, 2006). FAP affects both sexes equally and in the majority of
cases, it is inherited with a very high penetrance (Varesco, 2004). FAP wasfirst
described as a disease with clear familial inheritance in 1925 (Fearnheadet al., 2001;
16
Lockhart-Mummery, 1952). However, cases with no family history are recorded in
nearly 30% of FAP patients, which suggests the presence of a de novo genetic event
(Varesco, 2004). The APC generesponsible for FAP is involved in somatic as well
as germline mutations in cancers predicted by Knudson, whoalso hypothesised the
‘two-hit’ theory in human cancers (Knudson, 1971). Although APC gene mutation
was found in a large number of sporadic cases (Gregorieff and Clevers, 2005;
Groden et al., 1991; Nagase and Nakamura, 1993), germline mutations of the APC
gene are pre-dominantly responsible for FAP, in which CRC tumours typically
display with the progressive development of numerous adenomatous colorectal
polypsat very early stage (Gryfeet al., 1997; Sanchoet al., 2004; Su et al., 1992).
1.3.1.2 FAP-like Syndromes
In 2003, it was first reported that ‘APC-negative’ FAP patients maycarry biallelic
germline mutations in the human MutY homologue (MYH) gene (Lipton and
Tomlinson, 2004; Sieber et al., 2003; Strate and Syngal, 2005; Varesco, 2004),
which encodes DNA glycosylase MYH,acting together with MTH1 and OGGI as
part of the base excision repair machinery to repair oxidative DNA damage, whichis
also frequently deleted in several human cancers (Knudsenet al., 2003; Yamaguchi
et al., 2002). Inactivation of both copies of MYHgenereadily mispairs with adenine
(A) leading to G:C to T:A transversion mutations in the daughter strand (Al-Tassan
et al., 2002; Lipton and Tomlinson, 2006; Strate and Syngal, 2005). Recent reviewed
studies indicated that, beside APC mutations, mutations in MYH gene may be found
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in a subset of individuals with FAP at the percentage of about 7.5-20%, which are
frequently associated with a milder attenuated familial adenomatous polyposis
(AFAP) phenotype (Galiatsatos and Foulkes, 2006; Jeter et al., 2006; Lipton and
Tomlinson, 2006), in whom no germline 4PC mutation is detectable and showing a
family history compatible with recessive inheritance, carrying biallelic MYH
mutations (Galiatsatos and Foulkes, 2006; Varesco, 2004). AFAP is a phenotypic
variant of FAP characteristically displaying 100 or fewer colorectal adenomas and
delay in onset of adenomatosis and colorectal cancer (Galiatsatos and Foulkes, 2006;
Knudsenet al., 2003). In addition, another two variants of FAP syndromes, Gardner
syndrome, which is characterised by the association of colorectal polyps with
osteomasas well as soft tissues tumours (desmoids and thyroid tumours) and Turcot
syndrome, which is characterised by the association of colorectal polyps with the
development of primary central nervous system (CNS) malignancies also exist
(Gardner, 1962; Strate and Syngal, 2005; Turcot et al., 1959; Varesco, 2004).
However, characteristic mutations of HNPCCin the mismatch repair (MMR)protein
hMLH1 and hMSH2arealso found in a subset of patients with Turcot syndrome
(Hamiltonet al., 1995).
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1.3.2 Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Syndromes
Hereditary Nonpolyposis Colorectal Cancer (HNPCC) syndrome,also referred to as
Lynch Syndrome, develops adenomas at a normal rate but progress more rapidly
through the stages of carcinogenesis (Ahlquist, 1995; Hisamuddin and Yang, 2004).
HNPCCis caused by the germline mutations of mismatch repair (MMR) gene with
the hallmark of microsatellite instability (MSI) in tumours (Lynch and de la
Chapelle, 1999; Thibodeauet al., 1993). MSI also displays in approximately 15% of
sporadic CRCpatients (Sanchoet al., 2004; Soreide etal., 2006).
1.3.2.1 Mismatch repair (MMR) system
Microsatellites commonly present as short, tandemly repeated, nucleotide sequences
in great number throughout genome (Sancho et al., 2004; Soreide et al., 2006).
Microsatellite instability (MSI) showing the length variation of microsatellites with
gained or lost repeated units on the germline allele is commonly associated with
DNA mismatch repair (MMR)deficiency (Peltomaki, 2001a; Soreide et al., 2006).
The mismatch repair (MMR) system is highly conserved across different species,
from bacteria, yeast to human (Marti et al., 2002; Peltomaki, 2001b; Prolla et al.,
1996) (Table 2). In humans, as a group of TSGs (tumour suppressor genes), at least
six different MMR genes encode MMRproteins (hMSH2, hMLH1, hMSH3, hMSH6,
hPMS1 and hPMS2) required for the complete MMR mechanism, which is
responsible for the recognition and repair of base-base mispairs and single strand
insertion-deletion loops (IDLs), arising in the genome during DNA replication
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(Narayan and Roy, 2003; Peltomaki, 2001a; Prolla et al., 1996) (Table 1.2). MMR
system initiates by heterodimer hMSH2-hMSH6 (hMutSa) and heterodimer
hMSH2-hMSH3 (hMutSB) binding to the mutated sites, which are required for the
correction of base-base mispairs and IDLs, respectively (Marti et al., 2002; Palombo
et al., 1996). Subsequently, heterodimer hMLH1-hPMS2 (MutLa) is recruited by
hMutSa and hMutSB to the mismatch recognition complex, which along with other
proteins which are involved in incision, excision, resynthesis and ligation of DNA
(Hellemanet al., 2006; Jacob and Praz, 2002; Narayan and Roy, 2003) (Figure 1.3).
Initiation
 
Excision & resynthesis  
Figure 1.3 Diagram of MMR system. Modified from Hellemanetal.,
2006. See text for details.
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 E.coli __S. cerevisiae _H. sapiens Function
MutS Msh2 MSH2 * Recognizes the mismatch
Msh6 MSH6* Forms a complex with Msh2 (MSH2)
Msh3 MSH3 Forms a complex with Msh2 (MSH2)
Msh1 Notidentified Functions in mitochondrial MMR
Msh4 MSH4 Required for meiotic recombination
Msh5 MSH5 Required for meiotic recombination
MutL Mlh1 MLH1* Couples mismatch recognition and subsequentrepair
Pms1 PMS2 * Forms a complex with M/h1 (MLH1)
Mih2 PMS1 * Forms a complex with M/h1 (MLH71)
Mlh3 MLH3 Forms a complex with M/h1 (MLH1)
 
* Mutated in the germline in HNPCC families.
Table 1.2 DNA mismatchrepair gene homologin bacteria, yeast and humans.
(Adapted from Peltomaki, 2001)
1.3.2.2 Microsatellite Instability (MSI)
Defects in the mismatch repair mechanisms resulting from MMR gene germline
mutations lead to MSI, serving as the ‘mutator phenotype’ marker of HNPCC
(Peltomaki, 1997; Soreide etal., 2006). In humans, germline mutations in any of the
five MMR genes (AMSH2, hMLH1, hMSH6, hPMS2 and hPMS1), can cause
HNPCC (Buermeyeret al., 1999; Lynch and de la Chapelle, 2003; Peltomaki,
2001b) (Table 1.3). Notably, alterations of hMSH2 and hMLH1 genes have been
suggested to cause early onset of colorectal cancer patients (Montera et al., 2000).
Mutations of these two genes also account for approximately 85%-90% of all MMR
germline mutations (Hisamuddin and Yang, 2004; Soreide et al., 2006).
Furthermore, mutation rates in cell lines from tumour cells of HNPCC are 100-1000
fold as compared with normal cells (Eshleman and Markowitz, 1995; Narayan and
Roy, 2003; Peltomaki, 2001b). The important consequence of mutations in MMR
genes is that the lack of MMRproteins leads to failure of correction of nucleotide
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mismatches and promotes mutations in other genes as the downstream target of MSI
(Soreideet al., 2006; Takayamaet al., 2006) (Table3).
 
Gene
TGFARII
BAX
IGFIIR
hMSH6
hMSH3
PTEN
E2F-4
DNArepetitive
sequence(nucleitides)
(A)io (709-718)
(G)s (114-121)
(G)s (4089-4096)
(C)s (3049-3056)
(A)s (1141-1148)
(A)(795-800)
(CAG);3 (918-956)
Incidence of mutations (%)
 
Sporadic MSI
HNPCC positive tumour
75-83 80-90
50-55 11-50
13 i)
33 25-36
50-58 35-46
— 18.8
71 42-57
Function of the gene
products
Inhibition of cell growth
Induction of apoptosis
Growth promotion
Mismatch repair enzyme
Mismatch repair enzyme
Inhibition of cell growth
Progressionofcell-cycle
 
Table 1. 3 Target genes of MSI in colorectal cancer. (Adapted from Takayamaetal., 2006)
In the MSI positive tumours, frequent frameshift mutations have been identified in
TSGs (TGFBRI, IGFUR, BAX, PTEN), DNA MMRgenes (MSH6 and hMSH3)
and cell-cycle-regulatory gene (E2F-4) (Bertholon et al., 2006; Buermeyeretal.,
1999; Narayan and Roy, 2003; Takayamaet al., 2006). Interestingly, loss of MMR
also appears to accelerate tumourigenesis in an APC deficient background (Huanget
al., 1996; Prolla et al., 1996).
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1.4 Sporadic Colorectal Cancer
Mutations in both APC and MMRgenesare the cause of a large numberof sporadic
CRC (Narayan and Roy, 2003). Inactivating somatic mutations of APC have been
reported to occur in about 70-80% of sporadic colorectal cancers (Fearnheadetal.,
2001; Grady and Markowitz, 2002; Luchtenborget al., 2004), the majority of which
occur in the mutation cluster region (MCR) region (Luchtenborg et al., 2004).
However, the frequency of MMRdeficiency caused MSI in sporadic colorectal
cancers is uncommon, about 10-15%, which is not as high as in HNPCC cases
(Benito and Diaz-Rubio, 2006; Saletti et al., 2001). Taken together, genetic
instability is a critical stage in human colorectal cancer initiation, promotion and
progression in either familial or non-familial form (Grady and Markowitz, 2002),
which providesthe possibility to investigate the molecular mechanism of colorectal
cancer pathogenesis.
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1.5 APC and Wntsignalling pathway
Inactivation of both alleles ofAPC gene marksoneoftheearliest events in colorectal
tumorigenesis (Gryfe et al., 1997), which has developed into the concept ofAPC as a
‘cellular gatekeeper’ protecting against tumorigenesis in the colon (Clarke, 2005).
The APC plays multiple intracellular roles with different functional domains in the
processes of cell adhesion and migration, signal transduction, microtubule assembly
and chromosomesegregation (Fodde, 2002; Fodde et al., 2001) (Figure 1.4). The
human APC gene (NM_000038) locates within 5q21-22 in the length of 10719 bp
spanning 21 exons (Ashton-Rickardt et al., 1989; Thliveris et al., 1996), which
encodes the APC tumour suppressor protein of 2843 amino acids (Nathke, 2004;
Watson, 2006).
Nuclear export signals (NESs)
 
B-catenin binding
B-catenin binding and downregulation Microtubule
Armadilla (1020-1169 aa) (1342-2075 aa) binding site hDLG-
Oligomerization repeat 15aa repeats 20 aa repeats Basic binding
 domain domain am I I domain site
ASE LIX A A
MCR AXIN-binding sites
(1286-1514)
 
     
binding
site
Figure 1. 4 Structure features of APC protein. (Adapted from Narayan
and Roy, 2003)
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The N-terminus and middle region of APC are the most highly conserved regions in
the sequences of APC proteins from different species (Nathke, 2004). At the N-
terminal site, the APC protein contains an oligomerization domain, which allows
APC to form homodimers (Su et al., 1993) and Armadillo repeats domain, which
binds to APC-stimulated guaninenucleotide exchange factor (ASEF) for Rho family
proteins to regulate the actin cytoskeletal network (Kawasakiet al., 2000; Narayan
and Roy, 2003; Nathke, 2004). The N-terminal region also contains nuclear export
signals (NES) that are required for shuttling of APC between the nucleus and
cytoplasm (Henderson and Fagotto, 2002). APC is capable of binding B-catenin
through its 15 amino acid repeats domain.In the central region of APC, seven motifs
of 20 amino acids were identified, which not only bind B-catenin but also down-
regulate -catenin by phosphorylation through interacting with axin and
GSK3B (glycogen synthase kinase 38), which are, apart from APC, the other two
essential components in the Wntsignalling pathway (Rubinfeld et al., 1996; Yost et
al., 1996). The first 20 amino acid repeats overlap with the 5’ end of MCR, which
presents a majority of APC mutation in severe polyposis (Nagase et al., 1992;
Narayan and Roy, 2003). At the C-terminal site, APC contains motifs that mediate
interactions with a number ofstructural proteins (Nathke, 2004), including the
microtubule binding domain and tumour suppressor protein DLG binding domain
(Narayan and Roy, 2003).
25
1.5.1 APC mutations
Mutations in APC gene are not only responsible for familial adenomatous polyposis
(FAP), but also play a rate-limiting role in the majority of sporadic colorectal cancers
and adenomas, 60% to 80% (Fodde, 2002; Narayan and Roy, 2003). Widely
recognised as the initial event in the step-wise CRC development, once APCgeneis
mutated, the truncated APC protein has been demonstrated to be able to trigger
abnormal mitosis by losing the ability to bind the microtubules and maintain the
attachment of microtubules at kinetochores, resulting in the defect of segregation of
chromosomes (Fodde et al., 2001; Kaplan et al., 2001; Narayan and Roy, 2003).
However, the mechanism by which CIN generated in colon cancercells is still not
completely clear.
Almostall mutations in APC genetruncate the protein to take the form ofallelic loss
(loss of heterozygosity, LOH) (Sieber et al., 2006). Both truncating germline and
somatic mutations occur in FAP andalso in most of the sporadic colorectal cancers
(Lamlum etal., 1999; Miyakiet al., 1995). Truncating germline mutations have been
found to be responsible for 70-90% of FAP cases and families (Lipton and
Tomlinson, 2006). The majority of mutations in patients result in truncations of the
APC gene due to frameshifts (68%), nonsense (30%) and large deletion (2%)
(Beroud and Soussi, 1996; Powell et al., 1993).
26
The two most frequent germline mutated ‘hotspots’ are at positions of codons 1061
and 1309 (Beroud and Soussi, 1996; Fearnheadet al., 2001). Inactivation mutations
in APC havealso been reported in 60-70% of sporadic colorectal cancerpatients, the
majority of which occur in the MCR, which spans from codons 1286 to 1513
(Luchtenborget al., 2004; Nakamura, 1993).
In the case of human colorectal cancer, the mutations in APC gene are extremely
complicated and might not result in simple loss of protein function (Lamlum etal.,
1999; Rowan et al., 2000). According to the two-hit model, the position of the
germline mutation in APC gene mightaffect the position or type of the secondhit in
FAP polyps (Lamlum etal., 1999). Several studies of colorectal adenomas from FAP
patients have shownthat somatic APC mutations are dependenton the position of the
germline APC mutation (Crabtree et al., 2003; Lamlum et al., 1999; Sieber et al.,
2006). The second mutation in APC generepresents the rate-limiting step for tumour
initiation (Rowan et al., 2000). FAP patients with germline mutation in APC gene
within a small region (codons 1194-1392) mainly showallelic loss in their colorectal
adenomas and other FAP patients the ‘second hit’ tend to occur by truncating
mutation in the MCR region (Lamlumet al., 1999). Moreover, mutations near codon
1300 are associated with LOH of the wild-type allele with particular severe disease
and other tumours tend to have two protein truncating mutations (Crabtree et al.,
2003; Debinski et al., 1996; Miyoshi et al., 1992; Nugent et al., 1994). However,
when the first mutation does not hit the MCR region, the second event will be a
ad
further mutation in MCR (Bodmer, 2006; Fearnhead et al., 2001). In fact, CRC
patients with mutations outside of the MCR region have a milder phenotype
(Narayan and Roy, 2003). The interdependentrelationshipoffirst hit and second hit
of the APC gene mutation in a selective wayis ableto play its roles in B-catenin
regulation through Wnt signalling pathway or some other Wnt-independentroles in
the cellular regulations of cell adhesion and apoptosis (Nathke, 2004; Rubinfeld etal.,
1996; Sieberet al., 2006).
1.5.2 APC regulates B-catenin via Wntsignalling pathway
The Wntsignalling pathwayis important in organ development, cellular proliferation,
morphology and motility (Cadigan and Nusse, 1997; Miller and Moon, 1996). Over
90% of colorectal cancers have a mutation that activates this pathway (Doucaset al.,
2005).
Wnt was termed by the contraction of the Drosophila segment polarity gene
Wingless and murine proto-oncogene /nt-/, which were shown to share a common
origin (Clevers, 2004; Pinto and Clevers, 2005b; Rijsewijk et al., 1987). Wnt genes
encode 19 cysteine-rich glycoproteins with a highly conversed domain throughout
metazoans (Giles et al., 2003; Gregorieff and Clevers, 2005; Nelson and Nusse,
2004; Watson, 2006). These Wntproteins have also been implicated in the growth of
the gastrointestinal tract (Nelson and Nusse, 2004; Watson, 2006).
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The canonical Wntsignalling pathway is B-catenin-dependant, which is different
from the non-canonical signalling pathway (Logan and Nusse, 2004; Reya and
Clevers, 2005) (Figure 1.5). In the absence of Wnt signals, B-catenin binds the
multiprotein degradation complex, in which Axin acts as the scaffold of the complex
consisting of APC, GSK-3B and B-catenin in the cytosol (Giles et al., 2003; Pinto
and Clevers, 2005a). B-catenin is then phosphorylated at the N-terminus of Ser-45,
LRP
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 Wnt target genes OFF
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the conversed amino-terminal serine and threonine residues, by serine/threonine
kinases, casein kinases and GSK-3f resulting in ubiquitination and proteasomal
degradation (Bienz and Clevers, 2000; Haucket al., 2005; Pinto and Clevers, 2005b;
Watson, 2006).
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When the Wntsignalling pathwayis stimulated, the co-receptor, which consists of
seven-span transmembrane protein Frizzled (Fzd) (Dale, 1998; Giles et al., 2003)
and the single-span transmembrane protein LRP5/6 that belong to the low-density
lipoprotein receptor-related protein family (Heet al., 2004; Wehrli et al., 2000), is
activated by Wntligands. Associated with Dishevelled (Dsh), this complex causes
the recruitment of Axin to the membrane, causing the inhibition of APC degradation
complex activity in cytosol (Gregorieff and Clevers, 2005). B-catenin is then
released from the inhibited degradation complex without phosphorylation (Giles et
al., 2003). Consequently, the accumulated B-catenin in a non-phosphorylated form
translocates from cytosol into the nucleus, which targets the T-cell factor/lymphoid
enhancing factor (TCF/LEF)-driven gene transcription (Figure.1.3) (Bienz and
Clevers, 2000; Sansom et al., 2004; Watson, 2006). Therefore, APC regulates the
level of B-catenin and targets downstream gene expression via the Wntsignalling
pathway (Narayan and Roy, 2003).
1.5.3 Nuclear B—catenin mirrors the status of Wntsignalling pathway
The dynamic transformation of B-catenin between membrane-boundjunction pools
(connects E-cadherin with B-catenin to actin cytoskeleton) and free cytosolic pools
(Wnt signalling pathway) balance the adhesion and transcription in cells as a dual
functional protein (Bienz and Clevers, 2000; Doucas et al., 2005) (Figure 1.6).
Translocation of accumulated stabilized B-catenin from cytosol into the nucleus is
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independent of nuclear import machinery (Behrens, 2005; Yokoya et al., 1999). In
the nucleus, in the absence of Wntsignalling, TCF/LEF complex, which belongs to
high mobility group (HMG)proteins, acts as the transcriptional repressor by binding
of negative regulators (Bienz and Clevers, 2000).
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Figure 1.6 Diagram of dualrole of B-catenin in the cadherin-catenin
adhesion complex and within the Wnt signaling pathway.Seetext for details.
http://zlp.charite.de/typo3temp/pics/15f06ee641.gif, accessed in August 2009.
B-catenin has at least two separate transcriptional activation domains (TADs) with
the lack of a DNA binding domain, however, TCF/LEF factors provide the DNA
binding specificity (Doucaset al., 2005; Fearnheadet al., 2001). The TATA-binding
protein (Pontin52) is thought to mediate the contact between B-catenin and TCF/LEF
complex and the basal transcription machinery (Baueret al., 1998; Kolligs et al.,
2002). Once in the nucleus, B-catenin binds to the TCF/LEF complex and serves as
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a co-activator to trigger transcription of Wnt target genes (Behrens et al., 1996;
Bienz and Clevers, 2000).
The importance of B-catenin in tumorigenesis has been shownin both animal models
(azoxymethane stimulation and oligonucleotides inhibition) and human studies
(Doucaset al., 2005; Green et al., 2001; Yamadaet al., 2001). In humancolorectal
tumours, over 70 B-catenin mutations have been reported, most of which are mis-
sense mutations (Doucaset al., 2005). Moreover, APC and B-catenin mutations are
mutually exclusive (Behrens, 2005; Sparks et al., 1998) and both result in the
stabilization and accumulation of nuclear B-catenin, which is detectable in even
smallest neoplastic lesion of the colonic adenoma-carcinoma sequence (Haoetal.,
2001; Pinto and Clevers, 2005b). However, small adenomas with f-catenin
mutations do not appearto be as likely to progress to larger adenomas and invasive
carcinomasas observed for APC mutations (Pinto and Clevers, 2005b). Also, about
75% of human colorectal cancer tumours have increased nuclear expression of B-
catenin (Doucaset al., 2005) and the cells at the invasive front rather than those in
the tumourcentre tend to show high levels of nuclear B-catenin (Bienz and Clevers,
2000; Brabletz et al., 1998). Therefore, translocation of B-catenin into nucleus plays
a critical role in colorectal cancer progression andis able to mirror the status of Wnt
signalling pathway.
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1.5.4 Identified B-catenin/TCF pathway target genes
The overactive status of the Wnt signalling pathway resulting from either the
presence of Wntsignals or the mutations of any componentsofthis pathwaytriggers
the inappropriate transcription of downstream target genes (Doucaset al., 2005),c-
Myc, Cyclin D1, Axin2 and CD44 are some of the knowntarget genes (Choet al.,
2006).
Both c-Myc and Cyclin D1 promoters contain TCF/LEF-binding sites and increased
nuclear B-catenin is followed by constitutively increased protein expression levels of
both c-Myc and Cyclin D1 (Bondiet al., 2004; Morin, 1999), which is believed to
enhance the tumorigenesis by their effect on cell-cycle progression (Behrens, 2005;
Bondiet al., 2004). c-Myc, encoded by the corresponding proto-oncogene, has been
knownto be overexpressed in colorectal cancers (Kolligs et al., 2002; Pinto et al.,
2003; Watson, 2006), which is able to prevent apoptosis and contributes to
tumorigenesis by deregulation of cell growth and proliferation (Barker et al., 2006;
Bondi et al., 2004; Doucas et al., 2005). Cyclin D1 regulates the G1/S transition
phase ofthe cell cycle with cyclin-dependent kinases (Cdk4 and Cdk6) andlinksthis
pathway to colorectal carcinogenesis (Kolligs et al., 2002; Shtutman et al., 1999;
Tetsu and McCormick, 1999). Up-regulation is more important for tumour
progression than initiation (Sansomet al., 2005).
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Axin2 has been identified as a B-catenin/TCF-regulated gene, which negatively
regulates the signalling (Kolligs et al., 2002). High levels of Axin2 gene expression
have been detected in most humancolon cancercell lines (Salahshor and Woodgett,
2005) and observed in the APC deficient Min mice (Lustig et al., 2002). In response
to increased -catenin concentrations in cells and subsequent increased cell
proliferation and carcinogenesis, Axin2 is upregulated and thus serves to limit the
duration and intensity of the Wnt signals (Yanet al., 2001). Therefore, up-regulation
of Axin2 may constitute a negative feedback loop that controls Wntsignalling
activity with a role in tumour suppression (Hughes and Brady, 2006).
As downstream target of the f-catenin/TCF signalling pathway, CD44
overexpression is an early event in the colorectal adenoma-carcinoma sequence
(Wielenga et al., 1999). CD44 is a cell-surface glycoprotein encoded by a single
gene with alterative splicing and extensive post-translational modifications (Kuncova
et al., 2005; Yamada et al., 2003), and plays a crucial role in cell migration,
inflammation and immune responses (Mishra et al., 2005). The CD44 high
molecular weight splice variants have been found to be over-expressed in colorectal
cancercell lines and carcinomas (Fernandezet al., 2004; Yasudaet al., 2002), which
mayplay a role in the generation and turnover of epithelial cells (Kim et al., 1994;
Wielengaet al., 1993; Wielengaet al., 1999).
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1.6 Smads and TGF-8 signalling pathway
TGF-B (Transforming growth factor B type I) is a ubiquitous cytokine and was
originally termed by its ability of transforming normal fibroblasts in culture
(Bachman and Park, 2005). The TGF-B/Smadsignalling pathway is composed of the
type I TGF-B receptor (TGFBR1), type II TGF-B receptor (TGFBR2) and Smad
proteins (Takayamaet al., 2006). The TGF-f family include 3 isoforms of TGFBI,
TGFB2 and TGFB3 in mammals (Bachman and Park 2005) and TGFB1 is the most
abundant and ubiquitously expressed isoform (Xu and Pasche, 2007).
TGF-B signalling pathway is activated by TGF-f signals binding to TGFBR2
(Chung, 2000). TGFBR2 then recruitt TGFBR1, which is activated by
phosphorylation on specific serine and threonine residues to stimulate the kinase
activity of TGFBR1 (Chung, 2000; Xu and Pasche, 2007). Activated TGFBR1
phosphorylates downstream transcriptional factors Smad2/3 which then bind to
Smad4 (Chung, 2000; Xu and Pasche, 2007). The Smad complexestranslocate into
the nucleus andinteract with other transcriptional factors in a cell-specific manner to
regulate the transcriptional induction or repression of a diverse programmeof genes
(Elliott and Blobe, 2005; Xu and Pasche, 2007) (Figure 1.7).
35
w
r
o
t
e
r
e
e
XN \
1 t ' ' 1 i) i) i) 1 1 t 1 1 1 ' ' 1 1 1 1 ' 1 ' 1 1 1 ' ' { ! 1 1
N
i
1 1 ' ! / 4
om
e
em
me
w
e
e
ew
e
ew
Figurel.7 TGF-B signalling pathway (Adapted from Xu and Pasche, 2007).
See text for details.
TGF-f signals initiate not only the Smads-mediated signalling transduction but also
other pathways, including mitogen activated protein kinases (MAPKs),
phosphoinositide 3’ kinase (PI3K), small GTPases of the Ras superfamily
(Moustakas and Heldin, 2005; Pardali and Moustakas, 2007). However, these
pathways often regulate Smad-mediated responses and also induce Smad-
independent responses (Derynck and Zhang, 2003; Xu and Pasche, 2007).
The TGF-B signalling pathway plays a central but paradoxical role in the initiation
and progression of colorectal cancer development (Bachman and Park, 2005; Xu and
Pasche, 2007). TGF-B receptors (TGFBR1 and TGFBR2) and Smad protein have
been demonstrated to function as tumour suppressors by the finding of somatic
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mutation ofthese genesin certain gastrointestinal cancers (Bachman and Park, 2005),
however Smad4 is more frequently mutated in colorectal cancer than Smad2 and
Smad3 (Kawabata et al., 1999; Xu and Pasche, 2007). Some of the downstream
targets of TGF-B signalling are the cell-cycle checkpoint genes, including p21
(CDKNIA), p27 (CDKNIB) and p15 (CDKN2B), and their activation leads to the
cellular growth arrest (Massagueet al., 2000). Inactivation of TGFBR2, Smad3 and
Smad4 in the in vivo models has been reported to induce intestinal tumourigenesis
(Munoz et al., 2006; Sodir et al., 2006; Takaku et al., 1998). Therefore, TGF-f
pathway acts as a tumour suppressor in the normal intestinal epithelium and early
tumours, including colonic adenomas (Massagueet al., 2000; Munoz et al., 2006;
Siegelet al., 2003a; Sodir et al., 2006; Takakuet al., 1998). However, duringthe late
stages of colorectal carcinogenesis, many colorectal cancers escape the tumour-
suppressor effect of TGF-fB and are resistant to TGF-B-induced growth inhibitor
(Bachman and Park, 2005; Xu and Pasche, 2007). Therefore, TGF-B pathway also
acts as a tumour promoter enhancing metastatic behaviour, immune evasion and
angiogenesis (Bierie and Moses, 2006; Takahashiet al., 2000; Thomasetal., 2005).
It is noticing that a body of studies on mouse models suggests that TGF-B and Wnt
pathways can cooperate to regulate differentiation by controlling gene expression
pattern to promote colorectal tumourigenesis (Attisano and Labbe, 2004; Xu and
Pasche, 2007).
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1.7 K-Ras
K-Ras is mutated in approximately 50% of human colorectal cancers (Malumbres and
Barbacid, 2003). The majority of K-Ras mutations occur as an activating point
mutation in codons of 12 and 13 (exon2) and 61 (exon3) (Capella et al., 1991;
Takayamaet al., 2006; Toyookaetal., 2003).
Mutant K-Ras canact as an initiator of tumorigenesis (Smakmanet al., 2005) andit
also associates with tumour progression and metastasis (Oudejans et al., 1999).
Mutation of K-Ras on its ownis not sufficient to induce metastasis in the intestinal
epithelium (Janssen et al., 2002; Smakman et al., 2005; Tuveson et al., 2004);
however, K-Ras mediated signalling pathways may contribute to the potential
metastasis of tumour cells (Campbell and Der, 2004; Smakmanet al., 2005). The
effector pathways activated by K-Ras include RAF/MAPK, JNK (Jun N-terminal
kinase), and PI3K, which can lead to promoted cell growth (Campbell and Der, 2004;
Smakmanet al., 2005); (Takayama et al., 2006). K-Ras mutations are associated
with up-regulations of its downstream targets, such as DNA methyltranferase
(MGMT)and vascular endothelial growth factor (VEGF) (Chung, 2000; Okadaetal.,
1998; Patra, 2008; Takayamaetal., 2006).
K-Ras also cooperates with TGF-f signalling to induce de-differentiation and
potential metastasis formation in carcinoma cells (Smakmanetal., 2005), which was
found in the study of using murine C26 colorectal carcinomacell line with interfered
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mutant K-Ras or a negative TGF-B receptor (Oft et al., 1998; Oliveira et al., 2007).
An in vivo study showed that conditional expressed mutant K-Rasallele does not
alter the intestinal homeostasis or the immediate phenotypes associated with Apc
deficiency (Sansom et al. 2006). However, the effect of this K-Ras mutation in the
intestine can only be observed over the long term with accelerated tumourigenesis
followed by invasion (Sansom et al., 2006). A more recent study investigated the K-
Ras splice variants in the adenomas of Apc Min mouse (K-Ras 4A and 4B), which
showsthat K-Ras 4A deficiency does not affect Min mouse survival, tumour burden
and histopathology and the level K-Ras 4B increased in the adenomas with no
activating K-Ras mutation (Patek et al., 2008).
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1.8 TP53 (p53)
TP53 is the most commonly mutated tumour suppressor gene in various kinds of
malignant tumours (Takayamaet al., 2006). 7P53 mutations are also identified in
more than 50% of colorectal tumours (Chung, 2000; Takayamaet al., 2006), with
higher frequencies in distal colon and rectal tumours and lower frequencies in
proximal tumours (Iacopetta, 2003). Most mutations occur in highly conserved areas
of exons 5-8 (Chung, 2000; Iacopetta, 2003). Approximately 80% of 7P53 mutations
are missense mutations (GC to AT), which occur mainly in 5 hot spots codons (175,
245, 248, 273 and 282) (Beroud and Soussi, 1996; Takayamaet al., 2006). 7P53
mutations are generally considered to occur at the time of the transition from
adenomato cancer as a late event (Fearon and Vogelstein, 1990; Takayamaet al.,
2006) and typically accompanied by deletions of the remaining wild type allele on
chromosome17q (Chung, 2000).
The 7P53 tumour suppressor gene encoded protein p53 is a sequence-specific
transcriptional activator that plays diverse and complexroles in the regulation ofcell
cycle progression and apoptosis (Chung, 2000; Ko and Prives, 1996; Prives, 1998).
p53 protein normally induces G1 cell-cycle arrest to facilitate DNA repair during
replication, or induce apoptosis (Chung, 2000). p53 is also postulated to be involved
as a critical negative regulator of the Wnt signalling pathway, suggesting that p53
should also have a role in the tumourinitiation process (Clarke, 2007; Reed et al.,
2008). However, p53 deficient Apc Min mice havevariably been reported to have no
40
effect on or to modify adenoma formation (Clarke, 2007; Clarke et al., 1995:
Halberget al., 2000). A more recent in vivo study investigated the consequences of
p53 deficiency on the phenotypes observed immediately following Apc loss (Reedet
al., 2008). It was found that p53 modulates the Wnt transcriptome in the mouse
intestine; however, this activity is not sufficient to modulate the immediate
phenotype of Apc loss (Reed et al., 2008). This study supported the association of
p53 mutation with only the later stages of colorectal disease (Kinzler and Vogelstein,
1996; Reedetal., 2008).
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1.9 C-Myce
The role ofMyc gene family (including C-Myc, L-Myc, N-Myc, B-Myc and S-Myc) in
the biology of normal and cancer cells has been intensively studied (Eilers and
Eisenman, 2008; Ignatenkoet al., 2006). The C-Myc oncogeneis over-expressed in
many types of humancancer, including colorectal cancer (Ignatenko etal., 2006). C-
Myc has been found to be over-expressed in both adenomas of FAP andin sporadic
colorectal cancers (D'Orazio et al., 2002; Ignatenkoet al., 2006; Smith et al., 1993).
In colorectal cancer, C-Myctranscription is activated by the B-catenin/TCF complex
andis inhibited by APC (Heet al., 1998; Ignatenkoetal., 2006).
The proto-oncogene c-Myc encodesa transcription factor that is widely expressed in
proliferation embryonic and mature cells and possesses a potent transforming and
trans-activation ability (Ignatenkoet al., 2006; Xuet al., 1993). Mycis a basic helix-
loop-helix zipper (bHLHZ)protein (Ayer and Eisenman, 1993; Eilers and Eisenman,
2008). Myc participates with the DNA binding proteins MAX (MYCassociated
factor X) and MAD (MAX dimerization protein 1) to regulate specific gene
transcription and predominantly associated with gene activations (Eilers and
Eisenman, 2008; Grandori et al., 2000). Myc heterodimerizes with the small bHLHZ
protein MAX and binds the E-box (enhancer box) sequence CACGTG (Eilers and
Eisenman, 2008; Ignatenko et al., 2006). Myc has also been associated with
transcriptional repression (Eilers and Eisenman, 2008). Heterodimerization of MAX
and MADandits binding to E-boxes block most functions of the Myc-MAX dimers
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(Ayer et al., 1993; Ignatenko et al., 2006). Another mechanism involves with
specific binding and inhibition of the transcriptional activator MIZ-1 (Myc-
interacting zinc finger protein-1) (Eilers and Eisenman, 2008; Kleine-Kohlbrecheret
al., 2006).
Myc has been shownto beessential for intestinal crypt formation and Mycdeletion
induces rapid loss of intestinal crypts (Bettess et al., 2005; Muncan et al., 2006;
Wilkins and Sansom, 2008). Myc has also been demonstrated to be a Wnt pathway
downstream target in the mouse small intestine from an in vivo study with inducible
Apc homozygous knock out (Sansom et al., 2004). Additionally, Myc is a critical
mediator of the phenotypes of Apc loss in the intestine in both genomic and
functional roles (Sansom et al., 2007; Wilkins and Sansom, 2008). An independent
study using Apc Min mouse model showedthat inactivation of Myc suppresses Apc-
dependentintestinal tumourigenesis in adult Min mice, although not having apparent
effect on normal intestinal mucosa (Ignatenkoet al., 2006). Therefore, Myc plays
very importantroles in both initiation of tumourigenesis and tumour formation in the
intestine.
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1.10 Colorectal cancer mouse models
1.10.1 Carcinogen induced Model
Spontaneous formation of colorectal cancer in mice occurs with an extremely low
incidence, which makes it impossible to perform experimental studies on CRC
development using a natured population (Corpet and Pierre, 2005). In order to
increase the incidence of CRC, mice models were developed using carcinogens
(Takahashi and Wakabayashi, 2004). Carcinogen-induced CRC developmentin mice
is largely dose, duration and frequency, routing and timing dependent (Heijstek etal.,
2005). The most frequently used carcinogens are dimethylhydrazine (DMH)andits
metabolite azoxymethane (AOM), causing onset of aberrant crypt foci (ACF) with
DNApoint mutation from G to A on codon 12 of K-Ras (Takahashi et al., 2000;
Zaidi et al., 1995). Intrarectal administration of DMH induces mild hyperplasia and
prenoeplastic lesions in the colon after 34 weeks and repeated intramuscular
injections ofAOM resulted in 80% incidence of CRC after 12 weeks (Heijsteket al.,
2005). B-catenin gene mutations and altered protein cellular localization are
frequently observed in colon tumours of AOM-induced mice,indicating the essential
role of the activated Wnt signalling in the mechanism of AOM-induced colon
tumours in mice as in human (Takahashiet al., 2000). K-Ras mutationsare relatively
frequent (Vivona et al., 1993), but p53 is rarely observed (Takahashi and
Wakabayashi, 2004). The reduced expression of APC protein in AOM-induced mice
tumours has also been reported (Maltzmanet al., 1997).
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1.10.2 Ape Truncated Mouse Models
The Ape“germline mutation in mice, similar to that in patients with FAP and
sporadic cancers, was found with multiple intestinal neoplasia (Moseret al., 1990),
carrying the truncated mutation of a prematuretranslational stop codon at amino acid
850 in the APC protein (Su et al., 1992). The Min mouse model mimics the rapid
development of adenomatous polyps that affect FAP patients (Corpet and Pierre,
716 :476 contains2005). Several APC constructed mutations were also generated, Apc
truncating mutation at codon 716 (Oshimaet al., 1997); Age and Apc'®*" at
codon 1638 (Fodde et al., 1994; Smits et al., 1999). Mice carrying the Apc'®*!
mutation can survive to adulthood without developing tumours, but this mutation is
sufficient to induce B-catenin signalling (Smits et al. 1999). Like in humans, Wnt/B-
catenin pathwayalso plays an importantrole in carcinogenesis in these mutant mice
(Corpet and Pierre, 2005). However, most of the Apc” mutant mice develop polyps,
but mainly in the small intestine and only a few polyps formed in the colon (Foddeet
al., 1994; Heijstek et al. 2005; Taketo, 2006a). Moreover, ACF and
adenocarcinomasare seldom observed in these models (Corpet and Pierre, 2005) and
they do not progress into invasive or metastatic adenocarcinomasat a significant
frequency (Taketo, 2006b).
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1.10.3 Genetically targeted mutations, the Cre-/oxP System
Conditional mouse models have been generated, in which the expression of the gene
of interest can be regulated in a spatial and temporal specific manner by using
genetically engineered constructs (Heijstek et al., 2005). The Cre-/oxP system is one
of the most widely used conditional knock-out control systems (Kuhn andTorres,
2002) (Figure 1.8). Whencells that have /oxP sites in their genomeand also express
Cre, the protein springs into action, catalyzing the reciprocal recombination event
between the /oxP sites (Ghosh and Van Duyne, 2002). The double stranded DNAis
cut at both /oxP sites by the Cre protein and then ligated back together (Ghosh and
Van Duyne, 2002). As a result, any piece of DNA or the gene in between the /oxP
sites is excised and subsequently ‘floxed’out and therefore the Cre-/oxP system
provide a method to produce a mouse model that no longer has a target gene (Utomo
et al., 1999).
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Figure1l.8 Cre-LoxP system.http://www.scq.ubc.ca/targeting-your-dna-with-the-
    
 
crelox-system/ accessed in August 2009.
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In the animal model, mice containing a transgenic construct in which the gene of
interest in flanked by two /oxP sites are crossed with mice carrying a Cre
recombinase gene under the control of a tissue-specific or inducible promotor
element (Maddison and Clarke, 2005). Once the Cre recombinase is activated, the
loxP sites recombine and excise the gene of interest (Maddison and Clarke, 2005).
1.10.3.1 Ape and B-catenin K/O Mouse Model
Although a body of studies has investigated a range of Apc heterozygous mutants,
the primary consequences ofAPCloss in the gut are unknown, because homozygous
loss ofAPC is embryonically lethal. Sansom generated an Ape”" mice model using a
novel inducible Ahcre transgenic line in conjunction with a /oxP-flanked Apcallele
at codon 580 (Sansom et al., 2004; Shibataet al., 1997) (Figure 1.9). In this study, to
investigate the phenotype of conditional deletion of Apc, mice bearing a /ox-flanked
Apc allele were crossed onto a novel inducible Cre transgenic background, which
uses the CyplAl (cytochrome P4501A1) promoter to deliver inducible Cre
expression in the intestine, resulting in virtually 100% recombination within the
intestinal epithelium (Sansom et al., 2004). Loss of APC activates Wnt signalling
pathway through the nuclear accumulation of B-catenin with the coincidentalteration
of differentiation, migration, proliferation and apoptosis and this study firstly
confirmeda series of Wnttargets in an in vivo setting (Sansomet al., 2004).
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Figure 1.9 Inducible Cre-LoxP-Apc K/O mouse model
(Kindly provided by Prof A. Clarke). See text for details.
The central mediator of Wntsignalling, specific deletion of B-catenin was also
shown to be induced, showing its requirement for maintenance ofintestinal cell
proliferation and the implication in gobletcell differentiation (Irelandet al., 2004).
1.10.3.2 Myce K/O Mouse Model
It was known that Myc was involved in the CRC process and the Clarke group
demonstrated that Myc is an immediately activated Wnt target in mouse intestine.
Because c-Myc inactivation is lethal in homozygotes between 9.5 and 10.5 days of
gestation (Davis et al., 1993; Ignatenkoet al., 2006), the Cre-/oxP inducible system
was employed. It has been surprisingly shownthat the loss of c-Myc, following loss of
APC, completely rescues the phenotypes of altered differentiation, migration,
proliferation and apoptosis, demonstrating that c-Myc is the critical mediator for the
majority of Wnt pathway targeted genes and activates following loss of APC (Sansom
et al., 2007). The role of c-Myc (c-Myc mutant) has also been studied in the mouse
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intestine as both a single and double (with APC) conditional mutation (Sansom etal.,
2007). In APC and c-Myc double K/O mice, loss of c-Myc rescued the perturbed
phenotypes which occur upon deletion ofAPC (Sansometal., 2007). Interestingly, this
rescue occurred despite high levels of nuclear 6-catenin (Sansom etal., 2007). To study
the role of the genes behind the phenotypes observed, expression array studies were
carried out on both the single (c-Myc or Apc) and double (c-Myc and Apc) mutants,
which identified a set of genes (59%, 24/46) whose expression reverted to the normal,
non-mutated levels and a set whose expression wasstill altered in the double (c-Myc
and Apc) mutant (Sansom etal., 2007). The former set (c-Myc dependent) tends to be
more important in imposing Apc-dependent phenotype in the mouse model and the
later (c-Myc independent) with non-specific gene expression may not be involved with
the phenotypic changes from the immediate loss of Apc (Sansom et al., 2007).
Therefore, these genes (c-Myc dependent) are responsible for the phenotype of Apcloss
in mice.
1.10.3.3 K-Ras K/O Model
K-Ras is mutated in about 50% of human colorectal cancers (Malumbres and Barbacid,
2003). Ras proteins are activated by binding GTP andregulate cell cycle progression,
apoptosis, and cell migration and are capable of transforming cells (Malumbres and
Barbacid, 2003). After deleting APC, K-Ras was not identified to be over-expressed in
mouse intestine accompanied with the immediate phenotypic changes (Sansom etal.,
2004). The Clarke group has used a conditional transgenic knock in strategy to switch
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on the oncogenic K-Ras”” allele in the intestine of mice (Guerra et al., 2003;
Johnson etal., 2001). It has been shown that K-Ras“!* expression does not impose a
‘crypt progenitor’ phenotype, importantly that nor does it perturb the Wntsignalling
pathway (Sansom etal., 2006). However, K-Ras accelerates tumour formation when
expressed in the context of APC heterozygosity (Sansom et al., 2006). 81% of the
animals were systematic for the disease, in double mutants, at day 165 as compared
to 10% for the single APC mutation, with a Chi-Square p value of 0.0001 (Sansom et
al., 2006).
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1.11 Cited1
Cited] is one of the genes identified to be a Myc-dependent Wnt signalling
downstream target (Sansom et al., 2007). Cited! (CBP/p300-interacting
transactivators with glutamic acid [E]/aspartic acid [D]-rich carboxyl-terminal
domain 1) wasoriginally identified as melanocyte-specific nuclear protein from a
murine melanoma cell line (Shioda et al., 1996). Formerly known as Msg/
(melanocyte-specific gene 1), Cited] locates on X-chromosome(Fenneret al., 1998).
Cited1 is the founding member of family of transcriptional cofactors, which also
contains another 3 members: Cited2 (formerly Mrgl, Msgl-related gene 1), Cited3
(not present in mammals) and Cited4 (formerly Mrg2, Msg1-related gene 2) (Plisov
et al., 2005; Rodriguez et al., 2004). The Cited encoded proteins have approximately
200 amino acid residues and share a conserved carboxy-teminal transcription
activation domain (CR2 domain of approximately 50 amino acids) (Plisov et al.,
2005; Shiodaet al., 1997).
Cited] is a non-DNA binding transcriptional co-factor having 2 known functional
domains SID (Smad4 Interacting Domain) and CR2 (Conserved Region 2) (Lovvorn
et al., 2007a) and the bi-function of activating or repressing transcription is
dependant on cellular context (Plisov et al., 2005). It has been shown to activate
estrogen and TGF-6 dependenttranscription in vitro, and is able to bind to 6-catenin
to inhibit Wnt-induced transcription and axis formation during Xenopus development
(Heasman, 1997; Plisov et al., 2005; Yahata et al., 2000). Both activation and
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inhibition of transcription are dependent on the CBP/p300 binding domain CR2
(Freedmanetal., 2003; Yahataet al., 2000).
During vertebrate development Cited] is expressed in progenitors of the heart, limb,
axial skeleton, kidney, and placenta (Rodriguezet al., 2004). It is implicated as a key
co-ordinator during renal epithelial morphogenesis, regulating cellular responses to
TGF-6 and Wntsignalling (Plisov et al., 2005). In adults, Cited] is expressed in the
mammary gland and heart, as well as melanocytes, melanomacells, and papillary
thyroid carcinoma(Liet al., 1998; Nair et al., 2001; Scognamiglio et al., 2006).
Little is known about the role of Citedl in cancers but it has been implicated in
several types of cancers. Increased expression has been observed in melanoma,
thyroid, breast cancers (Li et al., 1998; McBryan et al., 2007; Prasad et al., 2004).
Over-expression of Cited] in a human Wilms tumourcell line led to a significant
increase in proliferation, whereas mutation of the CR2 domain of Cited1 resulted in a
reduction of proliferation (Lovvorn et al., 2007a). Jn vivo injection of CR2 mutant
Cited] Wilms tumourcells into immuno deficient mice also led to a reduction in
proliferation and tumourigenesis (Lovvorn et al., 2007a). Citedl has also been
linked to mammary cancer, as it is up-regulated in mammary tumours and associates
with EGR2 (early growth response 2) to regulate expression of the oncogene ErbB2
(v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma
derived oncogene homolog(avian)) (Dillon et al., 2007).
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1.12 Objectives
The microarray gene analysis on the Cre-/oxP-Apc mutant and Apc Myc double
mutant mouse models have identified a large number of Wnt regulated gene
alterations, for the majority of which, there has beenlittle previous association with
neoplasia. We proposed to apply these findings from the mouse models to the human
disease to determine the prevalence of altered gene expression in human colorectal
cancer through mRNAanalysis of the match paired samples from CRC patients. In
the human study, C/TED/ wasidentified as a previously unrecognised Wnttarget.
Wewereinterested in the underlying mechanisms of C/TED/, which maygive us an
insight into colorectal carcinogenesis.
1.13 Aims
1 — To validate the observed genearray alterations in Cre-/oxP-Apc mouse model
using human colorectal cancers and to identify the novel Wnttarget genes (from the
early stage mouse model) involved with colorectal carcinogenesis.
2 — Toinvestigate the effects of reduced CITED] mRNA expression on colorectal
carcinogenesis and the alterations of Wnt signalling activity using siRNA treatment
of colon cancercell lines (cell survival and proliferation).
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3 — Toinvestigate the role of Cited/ loss in the intestinal tumourigenesis using the
Min mouse modeland to investigate the underlying molecular mechanism of Cited
in regulation of Wntsignalling and in other involved pathways (e.g. TGF-B).
4 — To investigate the early effects of loss of Cited] in the intestine using Cited
K/O and Cre-/oxP-Apc mouse models and to investigate the underlying molecular
mechanism of Cited1 in Wnt signalling pathway regulation.
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Chapter 2 Materials and Methods
2.1 Patient tissue collections and genetic material extraction
Patient tissue samples were obtained from Cancer Tissue Bank Research Centre,
which weresurgically removedtissue for the research with informed patient consent.
Total RNA, genomic DNA and protein samples were extracted from colorectal
cancer tissues and adjacent uninvolved colonic mucosa from the random numbered
patients. Uninvolved colonic mucosa was generally 5-10cm away from the
malignant tissue, depending on the availability of non-malignant tissues (size and
type of specimen).
2.2 Animal work
All experiments were performed according to UK Home Office regulations. The
procedures involved with animal breeding, drug injection and tissue collection &
preparation were performed by Dr Phesse and Dr Meniel in Cardiff. Tissue sections
for histology staining and immuno-histochemistry were prepared by Derek
Scarborough.
2.2.1 Transgenic mousestrains
The animals were housed at the experimental animal facility under a 12 hour
light:dark cycle with standard rodent chow and water in the University of Cardiff.
Mice breeding were carried out by Dr Phesse and Dr Meniel in the University of
Cardiff.
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Min Mice
Min micecarrying the heterozygous Apc werebred routinely in the animal housein
the University of Cardiff (Moseret al., 1990).
ApcFlox Mice
Conditional Ape knock-out mice were generated in Prof Clarke’s group, bearing
inducible AhCre transgenic line with /oxP-flanked Apc allele. Injections of B-
napthoflavone at 8-10 weeks age (see details 2.2.3) induced the conditional gene
targeting Cre-/oxP system resulted in virtually 100% intestinal recombination
(Sansom et al., 2004).
Cited] K/O Min Mice
Cited] null mutant mice were obtained from Dr. Dunwoodie, University of New
South Wales, Australia (Rodriguez et al., 2004). Cited] null mutant mice had
previously been backcrossed for 6 generations onto a C57BI/6 background andthese
“~* mice on the same C57BI/6 background toanimals were crossed with Apc
produce three cohorts, Ape" Cited1**, Ape”* Cited1*” and Apc™””* Cited1””.
Mice were aged and culled upon signs of intestinal neoplasia (white feet, rectal
bleeding andlack ofactivity).
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Cited] K/O ApcFlox Mice
Ape" Cited1” were then used to cross onto AhCre Apcflox background to
produce Citedl*’* Apc”*, CitedI”’* Ape", Cited1” Ape™" and Cited1”” Apc”
cohorts. Mice from all four cohorts carry the Cre promoter to be comparable controls.
Cre-/oxP was inducedas previously stated for ApcFlox mice.
2.2.2 Genotyping
Genotyping work wascarried out by Mark Bishop in University of Cardiff. A small
(3-5mm) section of mousetail tip was taken from the new born pups. 500uIofcell
lysis solution (Gentra) and 10ul of proteinase K 20mg/ml (Roche) were added to
each tube containing mousetail and tubes were shaked overnight at 37°C. The tubes
were allowed to cool to room temp before adding 200ul of protein precipitation
solution (Gentra) to each tube. The tubes were inverted and then spun in micro-
centrifuge at 10,000 g for 10 minutes. The supernatant was removedinto clean tubes
containing 500 ul of isopropanol. The tubes were inverted and spun again at 10,000
g for 15 minutes. The supernatant was poured off and the tubes were left upside
downto dry for 1 hour. 5001 of nuclease-free water was added to each sample. 21
of the resulting DNA suspension was used in the following genotyping PCR
protocols. The Genotyping protocols were provided by Mark Bishop.
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APC Min mouse
Apc Min mutation was characterised by PCR reactions on genomic DNA extracted
from mousetail. The following primers were used: minl 5’-TCT CGT TCT GAG
AAA GAC AGA AGC T-3’, min2 5’-TGA TAC TTC TTC CAA AGC TTT GGC
TAT-3’. PCRs were performed to the following conditions: 1 cycle at 94°C for 2
minutes; 30 cycles at 94°C for 1 minute, 60°C for 1 minute, 72°C for 1 minute; 1
cycle at 72°C for 5 minutes. 20 ul PCR product were then digested with 2.5uls of
buffer E (Promega) and 1.5uls of HIND III (10 Unit/ul) (Promega) for 2 hours at
37°C, then run on 4% gel. The fragment size generated were ~300bp for wild type
and ~330bp for min.
Cre-loxP flanked Apc mutation detection
Frame-shift mutation of Apc gene were characterised by PCR reactions on genomic
DNAextracted from mousetail. The following primers were used: P3 5’-GTT CTG
TAT CAT GGA AAG ATA GGT GGTC-3’, P4 5’-CAC TCA AAA CGC TTT TGA GGG
TTG ATT C-3’, PS 5°GAG TAC GGG GTC TCT GTC TCA GTG AA-3’. PCRs were
performed to the following conditions: 1 cycle at 95°C for 3 minutes; 30 cycles at
95°C for 30 seconds, 60°C for 30 seconds; 72°C for 1 minute; 1 cycle at 72°C for 5
minutes using Pic Taq polymerase. Amplification products were run out on 2%
agarose gels. P3 and P4 were used to amplify the wild type or the mutant Apc, for which
mutant allele gave product at the size of 314 bp and 226bp for wild type allele. P3
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and P5 were used to detect the recombined Apcallele after inducing Cre-/oxP, which
gave productat size of 250bp.
Cre recombination reporter assay
Cre and Cre-mediated recombination reporter Laz were genotyped. The following
primers were used: for Cre FWD 5’-TGA CCG TAC ACC AAAATT TG-3’; REV
5’-ATT GCC CCT GTT TCA CTA TC-3’: for LacZ, FWD 5’-CTG GCG TTA CCC
AAC TTA AT-3’; REV 5’-ATA ACT GCC GTC ACT CCA AC-3’. PCRs were
performed to the following conditions: 1 cycle at 95°C for 3 minutes; 30 cycles at
95°C for 30 seconds, 55°C for 30 seconds, 72°C for 1 minute; 1 cycle at 72°C for 5
minutes by using Go Taq polymerase. Amplification products were run out on 2%
agarosegels.
Cited1 K/O genotyping
Cited] global knock-out mice on both Apc Min and Apcflox background were
genotyped. The PCRprimers used to distinguish between the wild type Cited/ allele
and Cited1neo alleles were FWD 5’-TTA CTT GCA GAC CAA CAG GC-3’; REV
5’-TGC TTC TTT GAC CCA TTT CC-3’ and GFP-REV 5’-TGT TGC ATC ACC
TTC ACC CT-3’. PCRswere performedto the following conditions: 1 cycle at 94°C
for 2.5 minutes; 35 cycles at 94°C for 30 seconds, 60°C for 30 seconds, 72°C for
Iminute; 1 cycle at 72°C for 5 minutes by using Go Taq polymerase. Amplification
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products were run out on 2% agarose gels. The fragment sizes generated were 367
bp for the wild type Cited/ allele and 206 bp for the Cited/ neo-allele.
2.2.3 Animal treatment
Injections of B-napthoflavone and bromodeoxyuridine werecarried out by Dr Meniel
in the University of Cardiff.
Cre recombination induction
ApcFlox mice and CitedlApcFlox mice were given 4 daily intraperitoneal (IP)
injections of 6-napthoflavone at 80 mg/kg to induced Cre recombination, and
harvested 4 days later. If we assume mouse is with the weight of 25g, 0.2 ml of
10mg/mlB-napthoflavone wasinjected into one mouseto give final concentration.
Bromodeoxyuridine (BrdU)in vivo labelling
4 days after first injection of B-napthoflavone, 2 hours before the cull, mice were
given an intraperitoneal (IP) injection of BrdU (Amersham Biosciences) at 1 ml per
100g body weight.
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2.2.4 Tissue Retrieval
2.2.4.1 Sample preparation for RNA and protein extraction
Mousetissue sample preparation was carried out by Dr Phesse and Dr Meniel in the
University of Cardiff. The small intestine was removed up to the appendix (pulling
on the stomach so the intestine would not be damaged) and flushed through with
water (through placement of a syringe in one end). The large intestine was then
removedto the anus and also flushed.
Cited1 null/Apc Min
Three cm of the small intestine located 7 cm from the stomach was placed in
RNAlater (after removing any mesentery and ensuring that no Peyer’s patches were
present). The tissue was then homogenized in Trizol reagent and RNA extracted
using standard phenol-chloroform methodologies (Chomezynski, 1993)
Epithelial cell harvesting from Cited] null/Apc flox mice
Seven-10 cm of the small intestine located 10 cm from the stomach was removed
from the culled mouse for epithelial extraction. The section was flushed with water
and then flushed once with PBS. Oneend of the section wastied off using suture.
The intestine was then inverted over the curved end ofa glass spiral, starting at the
tied end. The straight end of the spiral was inserted into a vibrator. The inverted
intestine on the glass spiral was placed into a tube containing HBSS (Hank’s
buffered salt solution)/EDTA (ethylene diaminetetraacetic acid) (2 ml 0.5M EDTA
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pH8.0 per 100ml HBSS (Gibco), pre-warmed in water bath at 37°C), leaving the
tube in water bath. After 15 minutes incubation (with vibration) in HBSS/EDTA,the
intestine was taken out of the tube and transferred into another tube of pre-warmed
HBSS/EDTAfor further 15 minutes incubation with vibration. Tubes (0-15 minutes
and 15-30 minutes fractions) were then spun down at 1,000 g for 15 minutes. The
pellets were washed once with 10ml of PBS and then spun down again. For RNA
extraction, pellet was resuspended in Iml Trizol and stored at -80°C for following
standard phenol-chloroform procedures. For protein, pellet was resuspended in 5 ml
of PBS and spun downagain at 1,000 g for 15 minutes. Pellets were then snap frozen
in liquid nitrogen andstored at -80°C for following protein extraction procedures.
2.2.4.2 Preparation of samples for paraffin embedding
Tissue preparation and fixation were carried out by Dr Phesse and Dr Menielin the
University of Cardiff. Prepared tissue embedding in paraffin was carried out by
Derek Scarborough in the University of Cardiff.
Gutrolls:
Theintestine was placed onto one piece of Whatman 3MMfilter paper and openedt
up with the villi facing upwards. Samples were then woundinto ‘swiss rolls’ (picked
up with forceps at one end and then wound aroundanda needle placed through).
 
 
    
Opened up gut Seeson 3MM e
Stomach end anus end
Gutparcels:
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Murine intestine was removed and flushed with water, then cut into 3 x 1.5cm
pieces. The 3 sections were arranged in a pyramid shape on 3M surgical tape and
rolled into a bundle. The surgical tape prevented the gut from falling apart.
Surgical tape 9C) \ Windsurgical
SI pieces (end on) aN Tape round gut
Tissue fixation
Openedupintestine wasfixed for at least 3 hours to overnight in methacarn (4 parts
methanol, 2 parts chloroform, | part acetic acid) in a glass dish before rolling up. Gut
rolls were then stored in 70% ethanol or formalin prior to staining. For antibodies
working better in formalin, gut rolls and parcels were fixed in ice cold 10% formalin
(4% formaldehyde) for 12-24 hours and then embeddedin paraffin as normal.
2.2.5 Histology staining
Histology staining was carried out by Derek Scarborough in the University of
Cardiff. For all procedures, used sections were obtained from formalin-fixed,
paraffin-embedded samplesat a thickness of 5-10um. Sections must not be allowed
to dry out at any point in the procedure. Xylene and ethanol rehydration/ dehydration
steps were carried out in a fume hood. Incubationsare carried out in a humidified
slide box, at room temperature unless otherwise stated. Standard steps of rehydration,
dehydration, clearing and mounting are as below.
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Rehydration
Washslides 2 x 10 minutes in xylene
Wash 2 x 5 minutes in 100% ethanol
Wash 1 x 5 minutes in 95% ethanol
Wash | x 5 minutes in 75% ethanol
Washin tap water 1x 2 minutes.
Dehydration
Washslides 1 x 5 minutes in 75% ethanol
Wash | x 5 minutes in 95% ethanol
Wash 2 x 5 minutes in 100% ethanol
Wash 2 x 10 minutes in xylene
Mounting
Stained slides were mounted in DPX (distreneplasticiser and xylene) (Sigma). Place
the coverslip on flat surface and apply a small amount of DPX, making sure there
are no bubbles. Slides were picked up and gently placed section side down onto a
coated coverslip. the assembly was turned over and gently pressed down onto the
coverslip with a blunt pencil until the DPX spread out to cover the whole section and
the whole of the underneath of the coverslip. Slides were left on a level surface to
dry for 48 hours.
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Haematoxylin and Eosin staining
Slides were rehydrated as normal and then immersed in haematoxylin for 1 minute.
Slides were rinsed in tap water with a continuous flow-through for 5 minutes and
then immersed in eosin for 30 seconds. Slides were rinsed again in tap water for 5
minutes. Stained slides were then dehydrated, cleared and mounted as normal.
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2.3 Tissue Culture
2.3.1 Maintenanceofcell lines
The human colon adenocarcinoma cell line HT29 was provided by Dr. B. J.
Campbell in Henry Wellcome Laboratory, Liverpool and HCT116 was obtained
from John Hopkins Medical Institute, MD, USA. Cell lines were grown as
monolayers (37°C in 5% CO2) in DMEM (HT29) and McCoy’s 5A media
(HCT116) supplemented with fcetal calf serum (FCS) (10% v/v) (Gibco),
penicillin/streptomycin (SOU/SOug per ml, Sigma), and L-glutamine (2 mM final
conc., Sigma). Media were all supplied by Sigma. The cells were maintained by
sub-culturing at 70-80% confluence using trypsin (50 ug/ml) (Sigma). HT29 carries
mutant APC with wild type B-catenin and HCT116 carries wild type APC with
mutant B-catenin (Dinetal., 2004).
2.3.2 SulforhodamineB cell growth assay
Cells from each treatment were seeded at a density of 1,000-3,000 cells per well
(2,000 for HT29 cells and 1,000 for HCT116) in 96 well flat-bottomed plates and
allowed to adhere overnight. Plates were then fixed from day 1 to day 7 post seeding.
In the hood, cells were fixed with 100 ul per well of 3:1 methanol:glacial acetic acid
for 5 minutes and washed gently with ddH20. Move out of hood, cells were then
stained with 0.4% (w/v) sulforhodamine B (SRB) in 1% (v/v) glacial acetic acid for
30 minutes (100 ul per well), washed 3 times gently with 1% (v/v) glacial acetic acid
and left to air dry for overnight. The dye was then solubilised by the addition of
100ul per well of 10 mM Tris-HCl pH 10.5, left for 5 minutes and the plates gently
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agitated to disperse the dye. Plates were subsequently read at A570 nm (absorbanceat
570 nm) using a Tecan Sunrise absorbance microplate reader (Tecan, Reading,UK)
and data analysed using XReadPlus v4.30 software.
2.3.3 Clonogenic cell survival assay
Cells from each treatment were seededat a density of 1,000 cells (HCT116) per well
or 2,000 cells (HT29) per well of 6-well plate in 2ml complete media. The cells were
grown in complete media and incubated at 37°C for 10 days (HCT116) or 11 days
(HT29). The media wasdiscarded and the colonies fixed with 70% methanol (1ml)
at room temperature for 5 minutes. The fixative was discarded and the cells stained
with crystal violet solution (0.2%w/v in 70% methanol) (Sigma) for 5 minutes. The
stain was removed by pipetting and the colonies washed gently (to avoid colony
loss), by pipette, with tap water. The plates were air-dried overnight before colony
counting (a colony was classed as ‘a plaque of 50 or morecells). Colony counting
was carried out independently by the author of this thesis and by another person
(blinded to the experiment) to avoid experimenter/observerbias.
2.3.4 Harvesting cells for RNA extraction
The media was removed from the cultured cells, and the cells were washed once
with PBS. The cells were trypsinized for 5-10 minutes in the incubator. Sufficient
volume of media (5 ml for T25 flask, 2 ml for 6-well plate, 1 ml for 12-well plate)
was then added into suspendedcells and transferred to a 15 ml centrifuge tubes. The
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cells were pelleted at 1,000 rpm for 5 minutes at 4°C using a IEC Multi-RF
centrifuge (Thermo Electron Corporation). The supernatant media was removed by
pipetting. 10ml of PBS was then used to wash the cell pellet and removed by
centrifugation. Cell pellet were resuspended in lysis buffer (RLT buffer) provided in
the RNeasy Kit (Qiagen) (2.6.1). The samples were stored at -80°C until processed
for RNAextraction.
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2.4 RNA work on human samples from tissue bank
2.4.1 RNAprecipitation in sodium acetate
Ten pg of total RNA samples were supplied in 40 ul of ethanol at -80°C. One tenth
volume (41) of 3M sodium acetate (Sigma), pH5.2, which is made up with DEPC
(diethypyrocarbonate) treated water, was added into the total RNA samples, which
were then incubated overnight at -80°C. On the following day, the incubated
samples were centrifuged at 11,000 g at 4°C for 10 minutes. Ethanol was removed
and RNA pellets were resuspended in 20ul of DEPC treated water at the
concentration of 0.5ug/ul.
2.4.2 DNase digestion on humantissue total RNA samples
Since these total RNA samples provided by Cancer Tissue Bank Research Centre
were not treated with DNase, DNase digestions were required to eliminate the
genomic DNA contamination when the Taqman probe is designed from the 3’
coding end rather than going through the exon/intron boundary of the nucleotide
sequences of candidate genes, which is possible to amplify the contaminated
genomic DNA in the RNA samples. DNase digestion on the patient RNA samples
were performed by using TURBO DNA-free™ kit (Ambion). 2.5ug of total RNA
sample (Sul of each aliquote) was treated with DNase in the reaction size of 25ul.
lul of TURBO DNase (2U/u1), 2.5u1 of 1OX TURBO DNase buffer and 16.5ul of
Nuclease-free water were added into the digestion reaction together with 5ul of total
RNA,which was mixed gently and incubated at 37°C for 30 minutes. Then 2.51 of
DNase inactivation reagent was added into the above digestion reaction system.
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After being incubated at room temperature for 2 minutes with occasionally mixing,
the digestion reaction system was centrifuged at 10,000 g for 1.5 minutes. The
supernatant that contains RNA wastransferred into fresh tubes, which werestored at
-20°C and ready to be used for 5 reactions of the following first strand cDNA
synthesis.
2.4.3 First strand cDNA synthesis (Reverse iT ™. ABgene)
RNA with or without DNase digestion, which depends on the way of probe
designing, was used to synthesize the first strand cDNA by using Reverse-iT’™1st
Strand Synthesis Kit (ABgene). For each 20 ul reverse transcription reaction, the
following components were mixedfirstly:
1 ul of RNA template (0.5 pg/pl)
1 pl of anchored oligo dT (500 ng/ul)
10 ul of RNase free water to makethe reaction up to 12 ul
This 12 ul reaction system washeated at 70°C for 5 minutes and then placed onice.
Other components were added in when the reaction mixture was cooled downonice.
4 ul of 5X first strand synthesis buffer
1 pl of DTT (100 mM)
2 ul of dNTPs (5 mM each)
1 wl of Reverse-iT™ RTase Blend (50 U/ul)
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The final reaction system was incubated at 47°C for 50 minutes and 75°C for 10
minutes. The synthesised cDNA can be used to perform the real-time PCR
amplification or stored at -20°C.
2.5 RNA work on mouse samples
2.5.1 RNA extraction in Trizol
Frozen mouse tissue samples in Trizol were defrosted on ice and then transferred
into Lysing Matrix D tubes containing ceramic beads (MP Biomedicals). Samples
were homogenised for 20 seconds each time (twice) on the homogenizer (Precellys
24). The homogenized samples were incubated on ice for 5 minutes to permit the
complete dissociation of nucleoprotein complexes. Tubes were then spun at 10,000 g
for 10 minutes at 4 °C and supernatant wastransferred into clean tubes. 200 ul of
chloroform was added into each tube and shaken vigorously for 15 seconds and
incubated on ice for 10 minutes. Tubes were spun again for 15 minutes at 4 °C. The
top clear aqueous phase (RNA) wascarefully transferred into clean tubes (making
sure no interphase material is transferred). RNA sample in each tube was then
precipitated by mixing with 600 ul of isopropanol. Mixture was incubated from 2-3
hours to overnight at 4°C. Tubes were spun at 10,000 g for 15 minutes at 4°C.
Supernatant was then carefully removed without touching the pellet. Pellet was
washed with 500 ul of cold 75% ethanol. Supernatant was removed and pellet was
air-dried for 5-10 minutes. 100 pl of RNase-free water was used to dissolve pellet by
10 minutes incubation at 65°C on heating block. 2-5 yl of RNA was run on 2% w/v
Al
agarose gel to check sample quality. RNA samples were then quantified using
nanodrop spectrophotometer.
2.5.2 RNA quantification (Nanodrop)
With the sampling arm open, 2 ul of RNA sample (or RNase free water as the
reference) was added onto the lower measurementpedestal. The sampling arm was
then closed and the operating software was used to initiate a spectral measurement.
Sample concentrations were then calculated by the software.
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http://www.molcardiology.com/index.php?option=com_content&view=article
&id=55:working-with-nanodropr-nd-1000-
spectrophotometer&catid=46:micrornas-extraction&Itemid=56
2.5.3 DNase Digestion (Promega)
For 50 ul reaction system, 5 ul of RQ1 buffer and 10 ul of RQ] enzyme were added
onto 10 ug of total RNA in required volume of RNase-free water to make up to be
50 ul. The mixture was heated at 30°C for 30 minutes on heating block. Afterwards,
5 ul of stop solution was added into the 50 ul reaction and heated at 65 °C for 10
minutes. The DNased RNA samples were ready to be used in following
experimentations.
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2.5.4 First strand cDNAsynthesis (Invitrogen)
For 25 ul reverse transcription reaction
4 ul of 100 ng/ul Random Hexamers
4 ul of 5X First-Strand Buffer
2 wl of 0.1M DTT
0.8 ul of25mM dNTP
7.5 ul of DNase treated RNA template
5.7 ul of ddH20
Mixture washeated in water bath at 65°C for 5 minutes then put back on ice. ll of
SSII (superscript II reverse transcriptase) was then added into the mixture. Tubes
were heated on PCR machine, 25°C for 10 minutes; 42°C for 1 hour; 70°C for 15
minutes and hold at 4°C. 200 ul of ddH20 was addedinto 25 pl of cDNA to makeit
to be at working concentration.
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2.6 RNA work on humancell samples
2.6.1 RNAextraction with DNase treatment (QIAgen)
Cells were harvested as a cell pellet and lysed in 350 wl of RLT buffer (2.3.4).
Lysate was homogenized using QlAshredder spin column by full speed
centrifugation for 2 minutes at 4°C. One volume of ethanol was added into the
homogenized lysate and mixed well. Mixture was then spun down in RNeasy spin
columnat 10,000 g for 15 seconds at 4°C to let total RNA bind onto the spin column.
Spin column was washed twice with 350 ul of RW1 buffer by centrifugation at
10,000 g for 15 seconds at 4°C. Genomic DNA contamination waseliminated using
RNase-Free DNase Set. Total RNA binding on the spin column wastreated with 10
ul of DNase I stock solution by 25 minutes incubation at room temperature in
between the two RW1 washes. Total RNA on spin column was then washed with
500 ul of RPE buffer (at 10,000 g for 15 seconds at 4°C). A long centrifugation (at
10,000 g for 2 minutes at 4°C) was used to dry the spin column membraneto ensure
no residual ethanol remains. Total RNA samples were then eluted in 30ul of RNase-
free water by centrifugation at 10,000 g 1 minute at 4°C. DNase treated total RNA
samples from humancells were then stored at -80°C for following experimentations.
2.6.2 RNA quantification (Spectrophotometer)
RNA (5 ul) was added to RNase-free water (995 pl) and the sample analysed at
A260nm and Azgonm using the UV/VIS Spectrophotometer (UVP). RNase-free water
alone was used as the reference. An absorbance of 1 is equal to 40 ug of RNA,
therefore the concentration wascalculated using the following formula:
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RNAconc.(ug/ml) = A26onm X 40 x dilution factor
The purity of RNA wascalculated by the absorbanceratio Az¢onm/A2gonm; Where pure
RNAexhibits a ratio of 1.9-2.1.
2.6.3 First strand cDNAsynthesis (Verso '™, ABgene)
Quantified DNase treated total RNA was used to synthesize the first strand cDNA
using Verso!” cDNAKit (ABgene). For each 20 ul reverse transcription reaction,
the following components were mixed:
4 ul of SX cDNAsynthesis buffer
2 wl of dNTP mix (5 mM each)
1 wl of anchored oligo dT (500 ng/l)
1 pl of Verso™reverse transcriptase
1 pl of RNA template (0.5 pg/pl)
11 pl of RNase free water to makethe reaction up to 20 pl
Reactions were performed to the following conditions: 1 cycle at 42°C for 30
minutes and 1 cycle at 95°C for 2 minutes. The synthesised cDNA canbestoredat -
20°C for the real-time PCR amplification.
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2.7 Real-time quantitative PCR
2.7.1 Taqmanreal-time quantitative PCR
2.7.1.1 Taqman Reaction Principle
Polymerization
Taqman Probe
5’ = - = - > ‘
Boundary
 
et
REV Primer
Strand Displacement
FWD Primer
qm - - - - - - - - - - - -
 
Cleavage
FWD Primer 3
 
 
REV Primer
In the Taqman real-time PCR reaction, the 3’ end of the Taqman probe is always
blocked, so it is not extended during the PCR reaction. When both dyes are attached
to the probe, reporter dye emission is quenched due to fluorescence energy transfer
from the reporter (FAM) to the quencher (TAMRA). During each extension cycle,
the probe is displaced at the 5’ end by the DNA polymerase. The 5’ exonuclease
activity of the polymerase cleaves the probe, releasing the reporter dye from the
probe. Once separated from the quencher, the reporter dye emits its characteristic
fluorescence. The whole processrepeats in every cycle. The fluorescenceintensity of
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the reporter dye, as a result increases. The amount of fluorescence measured is
proportional to the amount of PCR product made.
2.7.1.2 Primers and Taqmanprobe designing
Taqman primers and probes were designed by using the Primer Express program
(Applied Biosystems), which should be specific to the candidate genes on NCBI
Nucleotide-BLAST search. When the primers and probes being designed, the G/C
content should be between 30% and 80%, which can be done automatically by the
Primer Express program whenthe item of ‘limit G/C content’ is chosen. In all the
designing of primers and probes, Tm (melting temperature) of the primersets should
be 10°C lower than the Tm of the probe that should be 70 °C.
2.7.1.3 Primers and probe optimisation
Before performing the Taqmanreal-time PCR assays on the RNA samples of human
colon cancer tissues from Cancer Tissue Bank Research Centre, the designed and
synthesised primers and probes (Eurogentec) were required to be optimised on the
RNA samples of colon cancer cell lines. HCT116 colon cancer cell RNA samples
were provided by Dr. Andrea Davies, which was used to optimise the sets of primers
and probes.
The Taqman real-time PCR reactions were set up by using the qPCR Core Kit
(Eurogentec), which componentswill be listed in the following part of Taqmanreal-
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time PCR amplification. The ABI PRISM 7700 real-time PCR machine wasused to
run and record the reactions, and to analysis the data of qPCR reactions. The
optimisation protocol was provided by Applied Biosystems. For the primer
optimisation, probes were firstly used at the concentration of 200nM for all
combinations of primersat the final concentrations in nM.
 50 FWD /50 REV 50 FWD / 300 REV 50 FWD / 900 REV
300 FWD / 50 REV 300 FWD / 300 REV 300 FWD / 900 REV
900 FWD / 50 REV 900 FWD / 300 REV 900 FWD / 900 REV    
Secondly, probes were optimised with the above optimised primers at the final
concentration in nM.
25 50 75 100 125 150 175 200 225
          
For all the optimisation experiments, each reaction wasset up in triplicate, and the
combination which gives the both lowest Ct (threshold cycle) value and highest Rn
(normalized reporter signal) value was chosen to precede the following
experimentation. All the sets of primers and probes of candidate genes in the
optimised concentrations (in nM) were tested by using a series of increasing cDNA
concentrations. A serial dilution of cDNA template of 0.25 ul, 0.5 ul and 1 pl were
used to assess the efficiencies of both the target gene and reference gene
amplifications being approximately equal.
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2.7.1.4 PCR Amplification reaction
The expression levels of candidate genes were determined by performing Taqman
real-time PCR amplification on the first strand cDNA template from the DNase
treated or untreated total RNA samples of patients. Each reaction was set up in
triplicate.
For each 25 ul real-time PCRreaction, the components are listed below:
2.5 ul of 10X reaction buffer
2.5 ul of 5|0mM MgCl,
1 ul of SmM dNTP Mix
0.5 ul of optimised primers
0.5 ul of optimised probe
0.5 ul of CDNA template from reverse transcription
0.125 ul of HotGoldStar PCR enzyme (5U/ul)
17.325 ul of molecular water (Sigma)
The thermal amplification conditions are as below:
1 cycle at 50°C for 2 minutes (enzyme activation); 1 cycle at 95°C for 10 minutes
(cDNAandprimers denaturation); 40 cycles at 95°C for 15 seconds and at 60°C for
1 minute (amplification).
Primers and probe optimisations of candidate genes on HCT116 colon cancercell
line and genomic DNAcontrol test after DNase digestions were also performed by
applying the same amplification reaction system.
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2.7.2 SYBR Greenreal-time quantitative PCR
2.7.2.1 SYBR Green Reaction Principle
The SYBR Green I dye binds onto double-stranded DNA. During the extension
phase, the dye binds to the newly synthesized DNA and exhibits enhanced
fluorescence which increases proportionally to the amount of the amplicon (the
target mRNA)present. The products detected by SYBR Green I can be analysed by a
dissociation curve (or melting curve). As the reaction being heated, the point at
which the double stranded DNA denatures (or melts) is observed as a drop in
fluorescence as the SYBR Green I dissociates. Different length products and
products of different sequences will melt at different temperature and be observed as
distinct peaks.
2.7.2.2 Primers design (Primer3)
Primers for SYBR Green real-time qPCR were designed and optimised by Dr T.
Phesse using Primer3 programme and manufactured in Sigma. Primers for detecting
recombined Apc werekindly provided by DrK. Reed.
mMye Fwd 5’-TGA GCC CCT AGT GCT GCA T-3’
Rev 5’°-AGC CCG ACT CCG ACC TCTT-3’
m Axin2 Fwd 5’-GCT CCA GAA GAT CAC AAA GAG C-3’
Rev 5’-AGC TTT GAG CCT TCA GCA TC-3’
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mCD44_ Fwd 5’-GGC AGA AGA AAA AGC TGG TG-3’
Rev 5’-TCT GGG GTC TCT GAT GGTTC-3’
mHer2 Fwd 5’-AAT GCC AGC CTC TCA TTC CT-3’
Rev 5’-CCA GGG CAT ACT TGT CCT CA-3’
mEGR2_ Fwd 5’- GGG AGA TGG CAT GAT CAA CA-3’
Rev 5’-TGG AGA ATT TGC CCA TGT AA-3?’
m BActin Fwd 5’-ACA GCT TCT TTG CAG CTC CTT-3’
Rev 5’-TGG TAA CAA TGC CAT GTT CAAT-3’
m ApcRec Fwd 5’-TTG ATG GAA TGT GCT TTG GAA-3’
Rev 5’-CAC AAG GCT TCC TGG TCT TT-3’
2.7.2.3 SYBR Green PCR Amplification - I
The SYBRreal-time PCR reactions were set up by using the FINNZYMESmaster
mix. The MJ Research Chromo4 real-time PCR machine wasused to run and record
the reactions, and to analysis the data of qPCR reactions by Opticon Monitor 3
Software.
For each 28ul of SYBR green PCRreaction, the components are listed as below:
12.5 ul of SYBR Master Mix
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6 ul of cDNA template from reverse transcription
2.5 ul of paired primers (10uM of each)
7 ul of ddH20
The thermal amplification conditions are as below:
1 cycle at 95°C for 15 minutes; 40 cycles at 95°C for 30 seconds, 60°C for 30
seconds, 72°C for 30 seconds; 1 cycle from 53°C to 95°C for dissociation curve
generation.
2.7.2.4 SYBR Green PCR Amplification- II
The SYBR Green real-time PCR reactions were set up by using the Eurogentec
qPCR Core Kit for SYBR Green I, which components will be listed in the following
part of real-time PCR amplification. The ABI PRISM 7700 real-time PCR machine
was usedto run and recordthe reactions, and to analysis the data of qPCRreactions.
For each 25 ul real-time PCR reaction, the componentsare listed below:
2.5 ul of 10x Buffer
1.75 pl of S0mM MgCl2
1 pl of SmM dNTP
0.125 ul of HotGoldStar polymerase (5U/l)
0.75 ul of SYBR Green I
0.5 ul of template cDNA template from reverse transcription
0.5 ul of Paired Primers (10uM for each)
17.875 ul of ddH2O
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The thermal amplification conditions are as below:
1 cycle at 95°C for 10 minutes; 40 cycles at 95°C forl5 seconds and 60°C for 1
minute.
Dissociation curve were generated separately on ABI PRISM 7700 real-time PCR
machine: 1 cycle at 95 °C for 15 seconds; 1 cycle at 60 °C for 20 seconds; 1 cycle
from 60 °C to 95 °C for 20 minutes; 1 cycle at 95 °C for 15 seconds.
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2.8 Semi-quantitative PCR
2.8.1 PCR amplification
The PCR amplification cycles of the mouse B-actin gene were used to standardize
the concentration of cDNA samples. When the amounts of the B-actin PCR products
of all the samples were equal, cDNA concentration was halved and doubled in order
to confirm that the chosen amplification cycles were within the exponential phase.
The normalised volume of cDNA for each sample wasthen used to amplify Cited/,
whose exponential amplification curve was also evaluated. Amplification products
were run out on 2% w/v agarose gels. The density of each band was measured by
densitometry and the tumour samples were normalised to the non-adenomatous
tissue from the same mouseresulting in arbitrary density units for each tumour
sample. The primers used were as below. The sequences of mouse B-actin primers
were kindly provided by Dr T. Phesse and the mouse Cited] primers were obtained
from the published work of S. Boyle (Boyleet al., 2007).
mouse B-actin FWD 5’-ACA GCT TCT TTG CAG CTC CTT-3’
REV 5’-TGG TAA CAA TGC CAT GTT CAAT-3’
mouse Citedl1 FWD 5’-GCA CTT GAT GTC AAG GGTGG-3’,
REV 5’-GAG AGA CAG ATC CCG GAG AC-3’.
For each 50 ul B-actin PCRreaction, the componentsare listed below:
5 ul of 10X Buffer
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5 ul of 25 mM MgCl
0.4 ul of 25 mM dNTP
0.1 pl of 10 uM Forward Primer
0.1 pl of 10 uM Reverse Primer
0.4 ul of Go Taq Polymerase (5 U/l)
1 pl of cDNA template from reverse transcription
38 ul of H20
The thermal amplification conditions ofmouse f-actin are as below:
1 cycle at 94°C for 2.5 minutes; 30 cycles at 94°C for 30 seconds, 60°C for 30
seconds, 72°C for 1 minute; 1 cycle of 72°C for 5 minutes; Hold at 4°C.
For each 20 yl Cited7 PCRreaction, the componentsare listed below:
4 ul of 5X Phusion HF Buffer
0.4 ul of 10 mM dNTP
1 ul of 10 uM Forward Primer
1 ul of 10 uM Reverse Primer
1 ul of cDNA template from reverse transcription
0.2ul of Phusion Taq Polymerase (2 U /ul)
12.4 ul of H20
The thermal amplification conditionsare as below:
1 cycle at 98°C for 1 minute; 28 cycles at 98°C for 10 seconds, 60°C for 30 seconds,
72°C for 30 seconds; 1 cycle at 72°C for 5 minutes; Hold at 4°C.
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2.8.2 DNA agarosegel electrophoresis
PCR products were detected by performing DNA agarose gel electrophoresis. 2%
Agarose gel was made up with 2 g of agarose (Sigma) in 100 ml of 1X TAE buffer
(SOX TAE buffer: 242g of Tris base (Sigma); 57.1 ml of acetic acid (Fisher
Scientific) and 18.6g of EDTA (Sigma) in 1L of dH2O, pH 8.5). 5ul of ethidium
bromide (10 mg/ml) was added into the gel to stain the DNA samples. Five ul of
Hyper Ladder IV (Bioline) and 10 ul of DNA sample (2 pl of 5X loading buffer and
8 ul of PCR product) were loaded onto the gel, which was running for 50 minutesat
100 volts. Samples in the gel were visualised by employing Quantity One’ program
(BioRad) on FX scanner.
2.8.3 Densitometry
The density of bands from western blotting assay and agarose gel electrophoresis
assay were measured using Quantity One'™ software. The area of each band from
the assays was measured individually. Band density of each sample was then
normalised to the correspondinginternal control(e.g. B-actin).
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2.9 RNAinterference (RNAi)
2.9.1 Principle of lipid-mediated siRNA transfection
Cationic lipid mediated transfection is one of the most common delivery methods
and cationic lipid-based transfection reagents are suitable for transfecting into
dividing cell cultures (De Paula et al., 2007; Gilmoreet al., 2004). In cationic lipid
mediated transfection, siRNA interact with the cell membrane in the form of an
siRNA:lipid complex, a partly hydrophobic, partly hydrophilic, detergent-like
structure held together by electrostatic forces between the positive chargeslipids and
negatively charged siRNAs (De Paula et al., 2007; Gilmoreet al., 2004). Although
the mechanistic details of this form of transfection are poorly understood, current
models suggest that siRNA:lipid complexes enter cells by way of enhanced
adsorptive endocytosis and allow escape of the nucleic acid from
endosomal/lysosomal vesicles by membrane destabilisation (De Paula et al., 2007;
Gilmoreet al., 2004).
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RNAinterference
RNA interference technologies provide the possibility of a more rapid genetic
manipulation in vitro and in vivo at the level of gene transcription and consequent
protein translation (Kumar and Clarke, 2007; Martin and Caplen, 2007). RNA
interference (RNAi) is a gene-silencing mechanism induced by double-stranded
RNA (dsRNA) and can silence gene expression at both a transcriptional and post-
transcriptional level, which involves in cellular antiviral responses, transposon
expansion and post-transcriptional regulation of endogenous gene expression
(Hannon, 2002; Martin and Caplen, 2007; McManusand Sharp, 2002; Tuschl, 2001;
Zamore, 2001). The mechanism of gene silencing wasfirst noted in plants in 1990
(Napoli et al., 1990). The major understandings of the mechanisms underlying RNAi
were identified in C. elegans by dsRNA injection (Fire et al., 1998; Kumar and
Clarke, 2007) and subsequently found to explain previous observations in plants and
fungi (Martin and Caplen, 2007; Nakayashikiet al., 2006; Vaucheret, 2006).
The appearance of these dsRNAs (>30-S50bp) induces a cascade of events involving
the initial recognition of cytoplasmic RNase III-like protein Dicer (Kumar and
Clarke, 2007; Martin and Caplen, 2007). Dicer is responsible for cleaving double-
stranded molecules into small inhibitory or interfering RNA duplexes (siRNA) of
21-23 base pairs with characteristic 3’ overhangs of 2nt (dinucleotide) (Bernstein et
al., 2001; Elbashir et al., 2001; Martin and Caplen, 2007). Processed siRNA is then
incorporated into RISC (RNA Induced Silencing Complex) in cytosol (De Paula et
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al., 2007; Gilmore et al., 2004). Dicer is also involved in the early steps of RISC
formation and maybe required for siRNA entry into RISC (De Paula et al., 2007;
Lee et al., 2004). The antisense RNAstrand is then guided by RISC complex to the
complementary sequence in target mRNA (Gilmoreet al., 2004). In mammalian
cells, the protein Argonaute 2 (Ago2) is the catalytic component of RISC that
cleaves target mRNAs(DePaulaet al., 2007; Liu et al., 2004; Meisteret al., 2004).
The RISC can undergo numerous cycles of mRNA cleavage that comprise the high
efficiency of RNAi (De Paulaet al., 2007; Elbashir et al., 2001; Meister and Tuschl,
2004). The target gene expressionis then inhibited that subsequently reducethe level
of the encoded protein translation. Therefore, RNA interference can be a powerful
tool for investigating the gene-specific functions (Martin and Caplen, 2007).
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Schematic diagram of the mechanism of RNAinterference. Adapted from
RNAinterference: Technical reference & Application guide. See text for details.
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2.9.2 siRNAtransfection optimisation
2.9.2.1 siRNA transfection optimisation in HCT116cellline
The transfection protocol (DharmaFect 1) of HCT116 cells was optimised using the
siT7OX transfection control. siTOX is a cytotoxic, RNA-based reagent and triggers an
apoptotic response within 24-72 hours once entering the cells. Matrices of
siRNA:lipid concentrations and cell densities for use in 96-well plate format were
employed for optimisation. HCT116 cells were seeded in 96-well plates. On the
following day, si7OX (or non-target siRNA) were mixed with transfection lipid in a
series of siRNA:lipid ratio, according to the manufacturers suggested guidelines.
After an additional 24 or 48 hours incubation,cell surviving transfection with siTOX
(or non-target siRNA) were then quantified for all cultures using AlamarBlue™ dye
(BioSource,Inc.).
AlamarBlue™assay incorporates an oxidation-reduction (REDOX)indicator based
on detection of metabolic activity. The colour of the dye changed in response to
chemical reduction of growth medium, resulting from cell growth. Plates were
subsequently read at As7onm (absorbance at 570nm) and Asosnm (absorbance at 595nm)
using a Tecan Sunrise absorbance microplate reader (Tecan) and data analysed using
XRead Plus v4.30 software.
91
To determinethe percentreduction of AlamarBlue™ dye:
YoReduced = Crep Test Well / Cox Negative Control Well
= [(€0x) do Ahy - (€ox) A, Add / (ERED) M1 A’- (ERED) do A’hy] x 100
The lowest concentration of the experimental siRNA that includes the greatest
amountof silencing with the least amountof cell death is the desired concentration.
Optimisation of the conditions for inhibitory siRNA transfection of HCT116 cell
line
It is important to optimise experimental conditions of lipid-mediated siRNA
transfection to achieve effective silencing while minimizing toxicity. In this
procedure, the viables are: transfection reagent (lipid) type, siRNA type,
concentration, siRNA:lipid ratio, cell density, transfection incubation time for
different cell lines. HCT116 cell line is not amongthe previously validated protocols
from Dharmacon and there is no detailed protocol available in the literature.
Therefore, a thorough optimisation of CITED1 siRNA transfection in HCT116 cell
line was required. Due to the time limit, some of the siRNA knock-down
optimisation wastested onceas the preliminary experiment.
Selection of siRNA andtransfection reagent(lipid)
A number of companies provide the pre-designed siRNA to known genes in human
genome. Weselected siRNA together with transfection reagent from Dharmacon.
Human CITED1 siGENOME SMARTpool siRNAis a pool of 4 siRNA duplexes.
a2
The standard negative control of siGENOME Non-Targeting siRNA Pool #2 was
used in parallel. In addition, the transfection efficiency control si7OX wasalso used
in the optimisation procedure. si7OX is a cytotoxic, RNA-based reagent andtriggers
an apoptotic response within 24-72 hours of entering the cells. It therefore is well
suited for monitoring siRNA delivery and uptake. The precise mechanism of siTOX
activity is not well understood, although it is thought to participate in a variety of
pathwaysthat likely converge to induce global cell death (company information).
Dueto the cell type characteristics, different types of lipid (transfection reagent) may
induce greater or less cell viability and transfection efficiencies. Whilst there is no
detailed literature concerning which transfection reagent, a number mention that they
have been successful using DharmaFECT1. Therefore, DharmaFECT1 was chosen
to be the first choice in termsofthe transfection reagent type.
Optimisation of siRNA:lipid ratio of siRNA transfection in HCT116cell line in
96-well plate format by AlamarBlue assay
The ratio of siRNA: lipid wasfirstly optimised. Several possible cell densities and
incubation time wereincluded in the design, in order to ensure the best siRNA:lipid
ratio can be detected in the provided conditions. The results of siRNA treatment of
cultured cells in multi-well plate may differ from format to format, however the 96-
well plate wasinitially used in the optimisation, becauseit allows siRNA:lipid ratio,
cell density and transfection incubation time all to be tested on one plate. The
resultant AlamarBlue™ dye provided a measure of metabolic activity. The rate of
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loss of colour in the medium is proportional to the metabolic activity, when added
into culture medium. Therefore, AlamarBlue™ assay was used to detect cell
viability.
Experimental design of the matrices of siRNA:lipid ratio in 96-well format
Several conditions were included therefore an explanation of the 96-well matrix is
required. The layout of the experimental design on the 96-well plate format is shown
as below (Figure 2.1 A).
The siRNA transfection controls and the AlamarBlue™ assay controls were both
considered. Al, A2 and A3 are the wells with 100 ul of culture medium but with no
cells, which is used as the negative control for the AlamarBlue™ assay (Figure 2.1
A). A4, AS and A6are the blank wells that are used to zero the plate reader when the
absorbanceofthe AlamarBlue’™™ dye was measured (Figure 2.1 A).
siRNA transfection in all the wells was performed in the same way using
DharmaFECT1. One hundred nM of siRNA wasused with a series of lipid volumes.
In this optimisation, there are 3 groups of siRNA treatment: no siRNA (water)
(Figure 2.1B), si7OX positive control (Figure 4.5C) and non-target siRNA negative
control (Figure 2.1D). In each group, the tested lipid volumes are 0.1 pl, 0.2 ul, 0.4
ul and 0.8 ul per 100 pl culture medium to cover the routine range of lipid dose in
96-well plate (Figure 2.1 B-D). Different cell densities are SK, 10K, and 25Kcells
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per well, in duplicate. Two separate plates were used for 24 hours and 48 hours
incubation time.
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No siRNA (water) and seriesof lipid volumes
 
     
B Nolipid 5K 5K 10K 10K 25K 25K
0.1 ul 5K 5K 10K 10K 25K 25K
0.2ul 5K 5K__| 10K 10K 25K 25K
0.4ul 5K 5K 10K 10K 25K 25K
0.8ul 5K 5K 10K 10K 25K 25K  
siTOX — single concentration with a series of lipid volumes
Nolipid
0.2ul
0.4ul
0.8ul
 
siGENOME Non-target siRNA-single concentration with a series of lipid
volumes
D Nolipid
0.1 ul
0.2ul
0.4ul
0.8
Figure 2.1 The experimental design of siRNA:lipid ratio optimisation using
AlamarBlue™ assay in HCT116cells on the 96-well cell culture plate. Three
different siRNA treatments were tested with a series of transfection lipid volumes. The
area in green on the pate indicates the no siRNAcontrol (B). The area in blue indicates
the si7OXtransfection efficiency control (C). The area in yellow indicates the
siGENOMEnon-target siRNA control (D) Three cell densities of SK, 10K and 25K
were seededinto wells in duplicate, together with the controls of blank wells (A4-A6)
and no cell wells (A1-A3).
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Establishment of siRNA:|lipid ratio
The criteria for this optimisation are to identify the lowest cell viability in siTOX
treatment with minimal reduction of cell viability in the no siRNA control (water)
and siGENOMEnon-target siRNA control. AlamarBlue™assay detects the colour
loss of the dye in medium, whichin turn reflects the percentageofviable cells.
The absorbance of the dye was measured after 24 hours and 48 hours transfection
incubation. Standard curve for each time point was generated from cells with no
treatment on the plate in order to verify the incubation time for the validity of the
assay. At each time point, the measurement of each well is normalised to the no
treatment control.
At 24 hour time point, the assay is not sensitive at 5K cell density, because the
standard curve does not show much colour loss of the dye after being added into
medium (figure 2.2A). The valid dye incubation time is 75 minutes, when the dye
colour loss was the quickest for both 10K and 25Kcells. In figure 2.2C, transfection
with 0.1.1 of lipid induces the lowest level of cell viability in siTOX treatment and
the much higher level of both no siRNA and non target siRNA controls. The
difference between si7OX and the other 2 controls is the largest for 10K cells.
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The 48-hour transfection incubation results in a higher cell confluence at the end
point than 24 hours, although cells were originally seeded at the same densities in 2
separate 96-well plates. At 48hour time point, the valid dye incubation time is 60
minutes considering all 3 cell densities. The cell viability differenceis still large
between si7OX and non-target siRNA control when beingtransfected with 0.1 ul of
lipid in 10K cells. However, the lipid only control induced a highertoxicity to cells,
which must merely result from the exploration to transfection lipid for a longer time.
Although there was limitation of AlamarBlue™ assay on cell numbers, I conclude
from these experiments that the optimum lipid concentration is 0.1 pl per 100 ul
transfection medium. This condition was used for all the following experiments of
siRNAtransfection in HCT116 cell line.
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Optimisation of cell density and incubation time of siRNA transfection in
HCT116cell line in 6-well plate format
In order to obtain sufficient material for detecting the gene silencing effect at mRNA
level, siRNAtransfection in HCT116 cells needed to be scaled up from 96-well to 6-
well format. The established siRNA:lipid ratio was also scaled up based on the
volume of transfection medium in 6-well format. For siRNA transfection, cell
density and incubation time needed to be determined and therefore a 2 by 2
combination of experiments were performedin this format.
siRNA inhibitory effect was measured by qPCR. Clonogenic and SRB assays were
then used to detect the cell growth post siRNA transfection. In these two assays,cell
numbershavealready been determinedin the laboratory protocols.
Experimental design of optimisation of cell density and incubation time
Cell densities were scaled up based on the space of the well surface. The transfection
conditions mayvary overthis transformation, because the parameters were scaled up
based on volume or well space. Compared with the range from 5K to 10K,there is a
greater cell density gap between 10K to 25K in 96-well format optimisation. Cell
density of 15K needs to be considered to be a closer density to 10K in the following
tests.
In the 6-well plate, cell densities were scaled up to 200K (equivalent to 10K in 96-
well plate) and 300K (equivalent to 15K in 96-well plate) per well. Incubation time
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of 24 hour and 48 hour was tested with the HCT116 cells. Therefore, 4 sets of
experiments were performed in termsof different parameter combinations.
In each set of experiment, blank control (no treatment to cells), lipid only control (no
siRNA), nontarget siRNA control and si7OX control were performed together with
the target CITED1 siRNAtest. For clonogenic and SRB assays, treatment conditions
are as described above, 200K, 300K;it is important to note that from these different
treatment populations only 1,000 cells per well were used.
Establishmentof cell density and incubation time by CITED1 siRNAinhibitory
effect on MRNA
The normalised CITED/ mRNAexpression levels were all dramatically reduced by
CITED1 target siRNA treatmentin 4 sets of experiments (figure 2.4 A-D). However,
CITEDI mRNAexpressions were also reduced in the lipid only control and non-
target control in 2 sets of 24 hour transfection experiments (figure 2.4 A-B). In 48
hour siRNAtransfection, lipid only control increased the CJTED/ level for about
60%, although the non-target control is similar to the blank control in 200K cell
density (figure 2.4 C). In figure 4.7 D, CITED] mRNAexpressionlevel in lipid only
control and non-target siRNA control were both similar to the blank control and the
dramatic inhibition of CITED] mRNA cellular expression by target siRNA.
Therefore, the optimal siRNA transfection conditions in HCT116 cell line are 48
hour siRNA transfection in 300K cell density determined by mRNA expression
inhibition.
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Figure 2.4 Effect of siRNA transfection on CITED] mRNA abundancein the
preliminary tests on HCT116cells in 6-well plate. Cell densities of 200K (A, C) and
300K (B, D) and incubation time of 24 (A, B) and 48 hours (C, D) weretested.
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Confirmation of established cell density and incubation time by siRNA
inhibitory effect on cell growth
The cell growth assays were used to confirm the established cell density and
incubation time of siRNA transfection for HCT116 cell line. In SRB proliferation
assay, the si7OX control showed a more prolonged low level of proliferation over 7
days after 48 hour transfection, which indicates a higher functional transfection
efficiency (figure 2.5 C-D). After 48 hour transfection, the proliferation curve of
target siRNA treatment in 300K cell density is slightly lower than 200K cell density
(figure 2.5 C-D). Similarly, in clonogenic assay, si7OX induced a lowerlevel ofcell
survival after 48 hour transfection by counting the colony forming units (2.5 C-D).
Cell colonies of non-target control are slightly less in 200K cell density compared
with the non-target control in 300K cell density after 48 hour transfection (figure 2.5
C-D). Therefore, 48 hour siRNA transfection in 300K cell density is confirmed to be
the optimal conditions for HCT116 cell line.
Due to the time limitation, optimisation experiments were only performed once.
Taken qPCR, SRB and clonogenic assay together, data consistently showed that
300K cells per well in 6-well plate and 48 hours transfection incubation were the
best conditions for siRNA transfection in HCT116 cell line. So far, siRNA:lipid
ratio, cell density and incubation time of this siRNA transfection experiment have
been optimised.
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Off target effect of non-target siRNA control
Knowing that CITED]is a co-activatorof transcriptional complex, it was interesting
to detect whether knocking down CITED] in HCT116 cells has an effect on
expression of target gene transcriptions regulated by Wntsignalling. Axin2 (c-Myc
dependent) and CD44 (c-Myc independent) have been identified as Wnt downstream
targets.
When CITED] mRNA expression was inhibited, Axin2 was dramatically over-
expressed and CD44 expression level wasslightly increased. However, in the non-
target siRNA control, Axin2 mRNAexpression was decreased at 70% compared with
the lipid only control, which indicates a strong off-target effect of this non-target
siRNA on Axin2 (Figure 4.11 A). This off-target effect was also observed in the
other 3 sets of experiments (Figure 4.11 B-D). Therefore, this is not dependent on
cell density or incubation time overthe transfection.
Althoughthere is no off target effect of non-target siRNA control on CITED/ gene,
in a perfect condition, the non-target siRNA will not have any effect on known
genes. However, I found that non-target siRNA have an off target effect on one of
the identified Wnt targets. Therefore this needed to be eliminated before we carried
on the actual experiments on CITED inhibition.
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Figure 2.7 Off-target effect of iGENOMEnon-target siRNA control on Axin2 in
HCT116cell line.
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Resolving off-target effect issues
Axin2 is a component of the Wnt signalling pathway in cytoplasm and closely
related to the Wnt regulated nuclear transcription. The reduction of Axin2 in the
siGENOME non-target control may result in an unexpected alteration of this
pathway, which could be phenotype related. Therefore the siGENOMEnon-target
control needs to be replaced with another siRNA product.
In order to reduce off-target effects and therefore to enhance siRNA specificity, I
then selected ON-TARGETplus siRNA from Dharmacon. The new pair of siRNA
has the only modification pattern that addresses off-target effects caused by both
strands (Jackson et al., 2006). Sense strand is modified to prevent interaction with
RISC and favors antisense strand uptake. Additional modification is applied on the
antisense strand seed region to minimize seed-related off-targeting (personal
communication with Dharmacon company).
The pair of ON-TARGETplusnon-target and target siRNA was used instead of the
siGENOMEduplexes in the optimised conditions in HCT116 cells. qPCR data
showed the inhibition of C/TED] mRNA expression in target siRNA with no
obviousoff-target effect in non-target siRNA control (figure 4.12). Up to this step,
the thorough optimisation of CITED/ siRNA transfection in HCT116 cell line was
accomplished. The optimised transfection conditions were then used in all the
following cell assays in HCT116 cell line.
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2.9.2.2 siRNA transfection conditions in HT29 cell line
The optimised protocol (DharmaFect 2) of siRNAtransfection in HT29 colon cancer
cells was provided in a 96-well plate format from Dharmacon. In my experiments,
96-well plate was converted to 12-well plate format in the larger scale experiment.
2.9.3 Lipid-mediated siRNA delivery into cultured cells
Cultured colon cancer cells were used at low passage number. Lipid-mediated
siRNAtransfection was performed following the recommendedprocedurefrom. Cell
density, type of lipid and siRNA, siRNA:lipid ratio, transfection incubation time
differ among several colon cancercell lines. = hay Memes
Taking HT29 cells as an example, cells were grown in
   . Dilute, : : Day1: Plat HI e .T75 flask until 70-80% confluence in complete media. 2shouspriert | Reagent
transfection
Twenty four hours prior to transfection, cells were ABER
Day2: Overlay transfection
complexes onto cellstrypsinized, counted and seeded in antibiotic-free media,
at the density of 50,000 cells per well in 12-well plate. The following day, Sul of
20uUM siRNA wasdiluted in 95ul of antibiotic-free and serum-free media (Tubel)
and 4ul of Dharmafect 4 transfection reagent was diluted in 96u1 of antibiotic-free
and serum-free media (Tube2). Both tubes were incubated for 5 minutes at room
temperature by pipetting carefully up and down. Tubel and Tube2 were then
combined and incubated for a further 20 minutes at room temperature. Media in
cultured cells were removed and replaced with 800u1 of fresh antibiotic-free media
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whilst siRNA lipid complex was being incubated. When the siRNAtransfection lipid
complex wasready, the mixture was added into the freshly changed medium.Cells
were then incubated for 48 hours at 37°C with 5% CO,until being harvested.
 
       
Multi-well plate Lipid siRNA Incubation
Cell line Cell Density Typeoflipid
Format Volume Volume Volume
HT29 12-well plate 50K per well DharmaFect4 4ul Sul 1000ul
HCT116_ 6-well plate 300K per well DharmaFect 1 41 10ul 2000ul
Blank (no-treatment), transfection reagent only (lipid only) and non-target siRNA
controls were also performed in parallel. Lipid only control was used to detect the
siRNA delivery into cells efficiently with minimal disruption of cellular function.
Non-target siRNA control was a duplex whichlacks sufficient homology with any
known gene. Genesilencing effect on the target mRNA was detected by Taqman
quantitative PCR.
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2.10 Protein Analysis
2.10.1 Western Blotting
Protein Extraction from mousetissue
Mousetissues were harvested, snap frozen in liquid nitrogen and stored at -80 °C
(2.2.4). 200ul of RIPA lysis buffer (for 100ml stock: 50mM Tris-HCl pH 7.5,
150mM sodium chloride, 1% Nonidet P40, 0.5% sodium deoxycholate and 0.1%
SDSin ultrapure water; protease and phosphotaseinhibitors were addedjust prior to
use) was added to each tissue sample and then left in buffer to defrost. Once
defrosted, sample tubes were transferred on ice. Tissue was homogenised on ice
using Eppendorf homogenizer for 10 minutes and then the mixture of tissue and
buffer was sheared by passing through 21G or 23G needle for 20 times. Tubes were
spun down at 10,000 g for 10 minutes at 4°C. The supernatant of cell lysates was
then quantified.
Protein Estimation and Sample Preparation:
Total protein estimations were performed using the Bradford Assay technique
(Bradford 1976). 1 ul of lysate was mixed with ddH2O (159 wl) and Bradford Assay
Solution (BioRad) (40 ul) and loaded (final volume of 200 pl) into a 96-well plate.
The plate was read at Asosnm absorbance using the Tecan Sunrise microplate reader
(Tecan). Data was analysed using the XRead Plus v4.30 software. The absorbance
readings of the unknown protein concentrations were interpolated against a BSA
(bovine serum albumin) standard curve: - 0, 1, 2, 3, 5, 8 and 10 pl of BSA stock
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solution (1 mg/ml). The protein samples were adjusted to a concentration of 10 pg
protein/yl using RIPA Buffer.
Tewnty five pg total protein of sample lysate was mixed with 5X sample loading
buffer (2% w/v SDS, 0.125M Tris-base HCl pH6.8, 0.001% w/v bromophenolblue,
10% v/v glycerol) with 6-mercaptoethanol (one fourth volume of loading buffer),
vortexed briefly, and heated at 95°C for 5 minutes. The samples were brought to
room temperature and spun downbriefly prior to gel loading.
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE):
The denatured protein samples (prepared as above) were separated by SDS-PAGE
(western blotting) using the MINI PROTEAN™ (BioRad) gel casts. A 12%
resolving gel (10ml final volume) was prepared by combining ddH2O (3.35 ml),
1.5M Tris-base HCI pH8.8 (2.5ml), 10% w/v SDS(100 pl), 30% acrylamide (4.0 ml)
(Sigma), 10% w/v APS (ammonium persulphate) (50 yl) and TEMED (5 pl)
(Sigma). The gel components were mixed thoroughly by inverting and poured
immediately into the vertical gel cast. Saturated butanol (1:9 parts ddH2O:butanol)
(~500 ul) was overlaid (to prevent a meniscus forming) and allowed to set for ~45
minutes. The butanol was washed off thoroughly with water, and the excess water
removed with blotting paper. A 4% stacking gel (10 ml final volume) was prepared
by combining ddH20 (6.1 ml), 0.5M Tris-base pH6.8 (2.5 ml), 10% w/v SDS (100
Ll), 30% acrylamide (1.33 ml) (Sigma), 10% w/v APS (ammonium persulphate) (50
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ul) and TEMED (10 ul) (Sigma). The gel components were mixed thoroughly by
inverting and poured immediately over the resolving gel. The comb wasinserted
carefully avoiding trapping any bubblesat the bottom ofthe teeth. The stacking gel
wasallowedto set for 30 minutes. The comb was removed and the protein samples
loaded into the wells and run at constant voltage (100 V) in Running Buffer (14.4 g
glycine, 3.03 g Tris-base, 10 ml 10% w/v SDS, and makeit up to 1 litre with
ddH30).
Western Blotting:
The SDS-PAGE separated proteins were transferred to a Protran® nitrocellulose
membrane(Shneiller & Shneider) using Transfer Buffer (14.4 g glycine, 3.03 g Tris-
base, 200 ml MeOH and makeit up with 1 litre of ddH2O) for 1 hour at constant
voltage (100 V). The membranes were stained with Ponceau S solution (5% w/v in
glacial acetic acid) (Sigma) to verify success of protein transfer. The PonceauS stain
was washed off with either PBS or TBS buffer depending on the recommended
antibody probing buffer. Membranes were blocked (5% w/v non-fat dried milk
powderin either 0.1% TBS- or PBS-Tween 20 for 1 hour with constantagitation, to
reduce background non-specific binding, prior to antibody probing.
Western Blot Analysis:
Primary antibodies were added to the membranes (p-mad,1:1000 in 0.1% TBS-
Tween; B-actin, 1:2000 in PBS- Tween) and incubated with constant agitation for
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either 1 hour at room temperature (B-actin), or overnight at 4°C (p-smad2). The
membranes were washed three times (5 minutes each wash) with constant agitation
using the appropriate wash buffer (PBS or TBS). The HRP-conjugated secondary
antibody was incubated at room temperature for 1 hour with constant agitation. The
membranes were washedthree times (5 minutes each wash) with constant agitation
using the appropriate wash buffer prior to developing.
The abovedescribed blots were developed using SuperSignal® West Dura Extended
Duration Substrate (Pierce) and the images captured on the Fluor-S Multilmager
System (BioRad) using the QuantityOne™software (BioRad).
2.10.2 Immuno-histochemistry
Tissue sections for immuno-histochemistry were prepared as described in histology
staining (2.2.5). Xylene and ethanol rehydration/ dehydration steps were carried out
in the same way (2.2.5). Sections were all counterstained with haematoxylin.
Immuno-histochemistry procedures for the following antigens differ between the
rehydration and dehydrationsteps.
B-catenin (BD transduction Laboratories)
Endogenous peroxidase activity was blocked in peroxidase buffer with 1.5%
hydrogen peroxide (83.2 g ofcitric acid, 215.2 g of disodium hydrogen phosphate 2-
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hydrate, 20 g of sodium azidein 20 litres stock) for 30 minutes. Sections were then
boiled in Tris EDTA buffer pH 8.0 (242 g Tris and 18.6 g EDTAin litre stock) for
50 minutes. Once boiled, sections were slowly cooled downin solution. Sections
were then blocked in 1% w/v BSA in PBSfor 30 minutes and stained with 1:50 anti-
B-catenin primary antibody (BD transduction Laboratories) in 1% w/v BSA in PBS
at 4°C overnight. After washing 3 times in PBS, mouse HRP-labelled polymer
(Envision plus Dako) was applied on sections for 1 hour. After washing another 3
times in PBS,peroxidase was then developed with DAB (Dako).
Phosphorylated Smad2 (Cell Signaling Technology)
Antigen wasretrieved in 10 mMcitric acid buffer pH 6.0 (Sigma) for 15 minutes (5
minutes each time, 3 times) in microwave. Sections were then allowed to cool for 30
minutes in solution. Endogenous peroxidase was blocked in 3% hydrogen peroxide
solution (Sigma) in water for 20 minutes. After washing twice in water and once in
TBS-Tween, sections were blocked in 5% v/v normal goat serum in 0.1% TBS-
Tween for 40 minutes. 1:500 anti-p smad2 primary antibody in 5% v/v goat serum in
0.1% TBS-Tween wasapplied on sections overnight at 4°C. After washing 3 times in
TBS-Tween, 1:200 HRP-conjugated goat anti-rabbit secondary antibody (Dako) in
5% v/v goat serum in 0.1% TBS-Tween was applied on sections for 1 hour followed
by washing 3 times in TBS-Tween. ABC complex (Vector Labs) was applied on
sections for 30 minutes. After washing twice in TBS-Tween, sections were then
stained with DAB (0.07% w/v plus 0.3% hydrogen peroxide) (Sigma) for 5 minutes.
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BrdU (BDtransduction Laboratories)
Antigen was retrieved in 1X citrate buffer (Labvision 10X stock) in preheated
solution at 99°C in water bath for 20 minutes. Sections were then cooled down in
solution for 30 minutes. Endogenous peroxidase activity was then blocked in
hydrogen peroxide solution (Envision plus, Dako) for 20 minutes. After washing 3
times in PBS, sections were blocked in 1% w/v BSA in PBS for 30 minutes and
stained with 1:150 of anti-BrdU (BD transduction Laboratories) primary antibody in
1% BSA in PBS overnight at 4°C. After washing 3 times in PBS, sections were
incubated with mouse HRP-labelled polymer (Envision plus, Dako) for 1 hour
followed by washing 3 times in PBS. ABC complex (Vector Labs) solution was then
applied on sections for 7 minutes. After washing 3 times in PBS, peroxidase was
then developed with DAB (Dako).
Active caspase3 (R&D Systems)
Endogenousperoxidase activity was blocked in 0.3% hydrogen peroxide (Sigma) in
methanol for 45 seconds with constant agitation in between 100% and 90% ethanol
rehydration steps. After washing once in distilled water and twice in PBS, antigen
was retrieved in 10 mM citric acid buffer, pH 6.0 (Sigma) for 20 minutes in
microwave. Sections were left in the microwave heated solution for 10 minutes and
then slowly rinsed in running tap water. After washing twice in PBS, sections were
blocked with 10% v/v normal goat serum in 0.5% TBS-Tween for 45 minutes. The
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solution was removed andsections were then incubated with 1:750 active caspase-3
(R&D Systems) in 10% v/v goat serum in 0.5% TBS-Tween overnight at 4 °C. After
washing twice in TBS-Tween, sections were incubated with 1:200 biotin-labelled
goat anti-rabbit secondary antibody (Dako) in 5% v/v goat serum in 0.5% TBS-
Tween for 45 minutes. After washing twice more in TBS-Tween, ABC complex
(Vector Labs) was applied on sections for 20 minutes followed by another twice
washing in TBS-Tween. Sections were then briefly rinsed in PBS and stained with
DAB (Dako) for 5 minutes.
2.11 Mouse small intestine crypt scoring
The effect of insults on the intestine was assessed by distribution of apoptotic and
mitotic bodies in the crypt on histological sections. The Potten laboratory generated
a computer model called “WinCrypts” (Merritt et a/., 1996). Here the cells were
counted sequentially from the bottom of the crypt (cell position 1) towards the neck
and along the villus. Each cell was assigned as BrdU negative (value “1”), BrdU
positive (value “2”). The data was used to generate a graphical representation of the
percentage population of apoptotic or mitotic cells (y-axis) versus their crypt
location (x-axis).
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2.12 Statistical Analysis
Comparison between the median of a single column of data against a hypothetical
median was performed onrelative fold changes of candidate gene expressions in
human colorectal tumours using Wilcoxon Signed Rank Test (GraphPad PRISM for
Windowsv4). Pairwise comparison of treatment meansofdelta Ct, the cell survival
and the proliferation data following siRNA treatment of human colon cancercell
lines were performed post Kruskal-Wallis non-parametric analysis of variancet
(ANOVA)(StatsDirect v2.6.8). In the in vivo Cited] knock out studies, comparison
of medians of delta Ct data sets and tumour burden between mouse cohorts were
performed using Mann-Whitney U test (MiniTab for Windows v15). Comparison of
median life span of murine cohorts was performed on survival percentage using
Kaplan Meier method and analysed by Chi-square test (GraphPad PRISM for
Windows v4). Comparison of maximum vertical distance of cell proliferation was
performed on cumulative frequency between mouse cohorts using the Kolmogorov-
Smirnov test (Sokal and Rohl, 1981). P values, where applicable, were assigned to
indicate statistical significance (P<0.05 = * ; P<0.01 = ** ; P<0.001 = ***). Error
bars indicate standard error of the mean (SEM).
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Chapter 3 Gene validation from early colorectal cancer mouse
models to the human disease
3.1 Introduction
Loss of APC in the Cre-/ox regulated APC floxed mice model (4PC™") activated
Wntsignalling pathway through the nuclear accumulation of B-catenin with the
coincident alteration of crypt-villus architecture, differentiation, migration,
proliferation and apoptosis (Sansometal., 2004). In order to test whether the nuclear
translocation of B-catenin following loss ofAPC activated the transcription of known
and unknown Wnt target genes, microarray analysis were performed using the
Affymetrix chips (Sansom et al., 2004). From these results of microarray analysis, a
subset of dysregulated genes were also validated and confirmed by performing
immunohistochemistry in the Apc-deficient tissue (Sansom et al., 2004). In this
project, we aimed to determine whether genes that have previously been identified as
dysreglated following deletion of Apc in mice, also showed altered expression in
humancolorectal cancers.
Top dysregulated target genes from the Apc conditional K/O mouse model
Following the preliminary work on the Cre-/oxP Apc mice model in Clarke’s group,
we validated a subset of 21 candidate genes that were significantly up-regulated
following loss of Apc in mice. These top 21 genes were the highest up-regulated as
seen from the DNA microarray analysis, the majority of which were over-expressed
at least 4-fold after losing Apc in mice. In murinetissues, these 21 genes had already
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been validated by quantitative PCR and immuno-histochemistry to confirm the
findings from the arrays. For some candidates on this list, their roles in intestinal
tumourigenesis were already being studied by Clark’s group in Cardiff. The table
below showsthe list of top 21 candidate genes that were significantly upregulated
overlapping between day 4 and day 5 (Table 3.1).
Table 3.1 List of the top 21 up-regulated genes in Cre-/oxP APC mouse model.
 
 
 
 
 
Gene Name_| Accession ID Number (Mouse)
TROY NM_013869
Fem1b AF064448
Tiam1 U05245
Fzd6 NM_008056
CyclinD2 NM_009829
CD44 X66084
Axin2 NM_015732
Musashi NM 008629
EphB2 AV221401
EphB3 BC014822
EphB4 NM_010144
Semac3 X85994
Sox17 AK004781
Fn14 NM_013749
HtrA1 NM_019564
Sox4 NM_009238
Mash2 NM_008554
MBD4 NM_010774
SPARC-Like NM_010097
CITED1 NM_007709
MTAP NM_024433    
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3.2 Bioinformatics: Gene list from mouse to human
In order to test whether these genes are also up-regulated in human colorectal cancer
samples, the corresponding orthologue human geneswereidentified from the mouse
gene, using the public databases (NCBI, ExPASy, MGI) (Table 3.2).
Taking Cited1 as an example, NM_007709 is the GenBank Accession ID number in
Mus musculus as providedin the list of genes which were identified in Cre-/oxP Apc
mouse model. Mouse GenBank Accesion ID numberwasfirstly being searched on
MGI(Mouse Genome Informatics) database. The item of ‘mammalian orthology’ in
MGIwasthen selected for obtaining the accession numberof the orthologue genes
in Homo sapiens. The corresponding human gene wasthen linked with the NCBI
database through this human GenBank Accession number. The sequence of mRNA
and the encoded protein in human was shown in the Evidence Viewer of NCBI. To
ensure the accuracy of the orthologue human GenBank Accession number, human
Cited1 protein was also searched in ExPaSy proteomics database. If the identical
amino acid sequences were found in both UniProtKB from ExPaSy and Evidence
Viewer from NCBI, this orthologue human GenBank Accesion number was assumed
to be correct. The mRNAsequence shownin the Evidence Viewer of NCBI wasthen
used to design the primers and probes for Taqmanreal-time PCR assay.
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3.2.2 Array analysis on c-Myc and APC double conditional K/O mouse model
In APC and c-Myc double K/O mice, loss of c-Myc rescued the perturbed phenotypes
which occur on deletion of APC (Sansom et al., 2007). Interestingly, this rescue
occurred despite high level of nuclear 6-catenin (Sansom et al., 2007). The c-Myc
dependent genes overlapping with the top 21 genes werelabelled in yellow boxesin the
list (Table 3.3).
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 mouse genes.Table 3.2 Orthologue human genes from thelist of top 21 upregulated
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Genesin yellow boxes are c-Myc dependent downstream Wnttarget genes.
Table 3.3 List of genes from APC c-Myc double K/O mouse model.
3.3 Taqman qPCRprimers and probes designing and optimisation
Taqman qPCR technique was chosen to measure gene level alteration in human
colorectal cancer samples, which provides the advantages of giving accurate gene
expression levels from limited amount of patient cancer tissue samples. To the gene
of interest, there are more specific signals released from the qPCR reactions with
additional Taqman probesthan simply adding SYBR GreenI dyein the reactions.
The designing of primers and probes wascarried out before the data from the double
K/O (APC and c-Myc) mice were available. Wnt signalling pathway downstream
targets, which were either c-Myc dependentor independent, were designed following
the list of 21 genes. The Primer Express program (Applied Biosystems) was
employed to design the primers and probes.
3.3.1 Taqman qPCR primers and probe designings
The criteria for a good qPCR primerset is that forward and reverse primers should
bind to neighbouring exons respectively and Taqman probe should cross the
intron/exon boundary to avoid false positive results arising from amplification of
contaminating genomic DNA(intron) in the RNA samples. Figure below showed an
example (human Cited1) of primers and probes designing in the ‘intron spanning
approach’(figure 3.1).
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ATGCCAACAA CGTCGAGGCC TGCACTTGAT GTCAAGGGTG GCACCTCACC.
Exon4 Exon5
IGCGAAGGAG |GATGCCAACC AAGAGATGAG CTCCGTGGCC TACTCCAACC
TTGCGGTGAA AGATCGCAAA
Figure 3.1 Diagram of an example of ‘intron spanning approach’ for primer and
probe designing. The nucleotide sequence was the neighbouring sequences of exon4
and exon5 from human gene Cited/. The sequence was obtained from NCBIdatabase.
The underlined blueletters indicates the location of designed forward or reverse
primers and the underlinedredletters indicates the location of designed Taqman
probe.
However, notall the sets of primers and probes for these 21 candidate genes can be
designed via the ‘intron spanning boundary’ approach, especially when there was
only one exonexisting in the nucleotide sequenceofthe gene. In these cases, the sets
of primers and probes were designed via another approach, from the 3’ coding end of
the nucleotide sequence. This also requires the DNase treatment to remove the
possible existence of contaminating genomic DNA in the RNA samples. Figure
below showed an example of the primers and probe designing (human FEM/B) in
the ‘3’ coding end approach’ (figure 3.2).
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CTCAAGTGCC TGGCTGCCCG AGCAGTTCGG GCTAATGACA TITAACTACCA
AGACCAGATC CCCAGAACTC TTGAAGAGTT TGTTGGATTT CATTAAGTGA
CTGGATATGT AAAGTCGTTT
3’coding end
Figure 3.2 Diagram of an exampleof ‘3’ coding end approach’ for primer and probe
designing. Nucleotide sequence was the sequenceofthe close end of 3’ coding from
human gene FEM/B. The sequence was obtained from NCBIdatabase. The underlined
blue letters indicates the location of forward or reverse primers and the underlined red
letters indicates the location of Taqmanprobe.
When the ‘3’ coding end’ primers and probes were being used, the genomic DNA
control set of primers and probeare required to test the effectiveness of the DNase
digestion on the RNA samples, giving no or, in most cases, acceptable low levels of
signals from the genomic DNA.For this genomic DNA control set of primers and
probe, primers should bind to the neighbouring intron and exon, respectively. This
probe should be comprised of part of the exon and part of the intron, which would
pick up the signals from the contaminating genomic DNA (intron) in the RNA
samples. The nucleotide sequence of any known gene could be used to design the
genomic DNA control set. Figure below showed the designing of genomic control
primers and probe on humangene Axin2 (figure 3.3).
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ACCCCACCCA ACACGCTGGC TCAGCTGGAG GAGGCCTGTC GCAGGCTAGC
a Intron9
TGAGGTGTCG AAGCCCCCAA AGCAGCGGTG AGTGGAAGTG AAGGGTCCTA
GGTTGAGGCA GGGATTGGGT TTGGGTGGAG ACCTGGTCTG
Figure 3.3 Diagram of the genomic DNAcontrol for primer and probe designing.
Nucleotide sequence wasthe neighbouring sequence of Exon9/Intron9 from the human
gene Axin2. The sequence wasobtained from Ensembl database. The underlined blue
letters indicates the location of forward or reverse primers and the underlinedredletters
indicates the location of Taqman probe.
Forall the primers and probes designed to the genes on the list using any approach,
the primers and probes echuerities were searched using the online database
Nucleotide BLAST to ensure the specificity of the nucleotide sequence to the gene
of interest. The primers and probes sequences that could possibly result in unspecific
amplifications were redesigned until the possible unspecificity was eliminated.
3.3.2 Taqman qPCRprimers and probe optimisations
The primers and probes needed to be optimised prior to performing Taqman qPCR
reactions on human colorectal tumour samples (2.7.1.3). In order to preserve the
precious humantissue samples, humancell line (HCT116) RNA was employed to
optimize the primers and probes workingconditions.
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Various ratios of primers were used to establish the conditions. Taking CITED1 as
the example, we are looking for the best ratio to produce an amplicon of
approximately 100bp. The gel below showsthe specific PCR products of the correct
amplicon size (102bp) according to the designing (figure 3.4).
PrimerSet Dilutions
 
Figure 3.4 Human Cited/ gene primers optimisation test on 2% w/v
agarose gel.
Five lanes on the left hand side were the specific products of human Cited/
PCRreactions showing the specific amplifications. The lane on the right
hand side was the DNA marker (HyperLadderIV) to show the size of PCR
products.
A similar process was repeated with additional Taqman probeto access the required
concentrations of primers and probe. For both primers and probe, the relative low
concentrations of primers and probe giving the relative high level of qPCR products
with more steep exponential amplification curves were chosen to be the working
concentrations.
After the primers and probe optimisation, a series of dilutions of cDNAs were used
to ensure the efficiencies of both the target gene and reference gene. Again, taking
the human gene C/TED/ as an example, doubling amount of cDNA sample were
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analysed to ensure the values observed fall within the linear range of the exponential
amplification. The data showed that two lines respectively indicating target gene
CITEDI and reference gene 6-actin were approximately parallel (figure 3.5).
Therefore, amplification efficiencies were equal for both target gene and reference
gene. This set of primers together with its Taqman probe were then used on human
colorectal tumours.
 
40 +
zl. a—-30 —a— —_»
®2© + ooS 20 , . -
eed
O —?— beta-actin
10 + —m— Cited1
0 t + | 
0.25 0.5 1
cDNAvolume(microlitre)
Figure 3.5 Equal amplification efficiencies of human Cited] and humanbeta-
actin genes. 2 paralleled straight lines of Ct values showed the equal
amplification of target gene (C/TED/) and reference gene (G-actin) along with the
increased cDNA amount.
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3.3.3 Optimised Taqman qPCRprimersand probes
The optimised primers and probes of gene ofinterest are listed as below (Table 3.4).
Genes in group I were designed using ‘intron spanning approach’. Genesin groupII
were designed in ‘3’ coding end approach’. G-AX/N2 in group III was designed for
detecting the level of genomic DNA in RNA samples when primers and probes from
group II were being used.
Top II and GPR49 genes were used as the positive controls. Top II is a known
proliferation marker indicating the level of cell mitosis and proliferation (Barkeret
al., 2006). GPR 49 has been shownto be a small intestine and colon stem cell marker
in mice (Barkeret al., 2007). They were both designed using the intron spanning
approach. f-ACTIN was used as the internal reference gene to standardize the
amount of the cDNA samples. Primers and probe for human gene {-ACTIN were
kindly provided by Dr. A. Davies.
Table 3.4 List of Designed primers and probe. Sequenceswereall written from 5’ to 3’.
 h B-ACTIN HQ TCA AGA TCA TTG CTC CTC CTA GCG C
FWD GGC ACC CAG CAC AAT GAA G  REV GCC GAT CCA CAC GGA GTA CT  
GroupI
h TopIl HQ TTC GAA AGC AGT CAC AAG CAA GAA ATC CAA
FWD TGA TTC TGA CTC TAA TTT TGA GAA AAT TG
REV GGA GCC ACA GCT GAG TCA AAG   
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h GPR49
h AXIN2
h CD44
h CITED1
h EPHB2
h EPHB3
h EPHB4
h Fnl4
 
 
          
HQ TTC CCC AGG CCC CTT CAA ACC C
FWD AGA CCT GAA AGC CCT TCA TTC A
REV GGT CCA CAC TCC AAT TCT GAT CA
HO CAG CAA AAA GGG AAA TTA TAG GTA TTA CTT CAA AAA
AGC A
FWD TGA CCC TGG GCC ACT TTA AA
REV ACC GCT CCA CAG GCA AC T
HQ TTC CAG AAT GGC TGA TCA TCT TGG CAT
FWD AAC ACA ACC TCT GGT CCT ATA AGG A
REV AAT CAA AGC CAA GGC CAA GA
HQ CTG CGA AGG AGG ATG CCA ACC AA
FWD AAC GTC GAG GCC TGC ACT T
REV TTC ACC GCA AGG TTG GAG TAG
HQ ACG TCG TGT CTC AGA TGA TGA TGG AGG A
FWD GCC GGC TTC ACC TCC TTT
REV GAC CCC AAC CCG GAG AAT
HQ TCC TTC CTC CGG CTC AAC GAT GG
FWD CCT CAC TGA GTT CAT GGA AAA CTG
REV GCA ATG CCC CGC AAC A
HQ AGA TCT CTG CTG AGG ACC TGC TCC GAA
FWD TGG CTT TGG CTC CTT CGA
REV GGT GTC CCG CCA GAG TGA
HQ CGC AGG AGA GAG AAG TTC ACC ACC CC
FWD GCT GCT TTC TGG CTT TTT GG
REV TCT CCG CCG GTC TCC TCT AT 
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h ASCL2
h SOX4
h SOX17
h HTRAI
h SPARCLI1
h CCND2
Group II
G-AXIN2
 
          
 
HQ ACC TGG ACC CCT GCC CCC ACT ATC T
FWD GCT GGC AAA CGG AGA CCT ATT
REV TTG GCC AGC ATG GAA AAC TC
HQ TTA AAA TTC AAG GCC ACA AAA ACA ATG TTT GGG
FWD CCT GTG CAA TAT GCC GTG TAG A
REV ACT TGA CAT GAT TAG CTG GCA TGA
HQ CTG ATC CGC CCC AGC CTG CA
FWD TTA CTG CAA CTA TCC TGA CGT GTG A
REV CTC CAG GAA GTG TGT AAC ACT GCT T
HQ CAG AGA CCC CGG GTG GGT GAG C
FWD AGT CAG CAC CCA AAG GTC AAT G
REV CAA CTT CGG CCG TTT GAG AA
HQ TCC AGC ATC CTC CTC TGT TCT AAC CAC TTC A
FWD TTG TIT TGA ACG AAG ATT TTA AAG AAC TC
REV AAT ATA AAT CTA CAA GTA TCA CAG CTG CAT ATA TTT
HQ TGG CAA AAA TGT TGT ATT GGC TAT GAT GGT G
FWD TGA TCA GTG TAT GCG AAA AGG TTT
REV CTC TTA AAA GGC AGC TGA CTA TAT CAT G
HQ CCA AAG CAG CGG TGA GTG GAA GTG AA
FWD CAG GCT AGC TGA GGT GTC GAA
REV AAC CCA ATC CCT GCC TCA AC 
Dueto the time limitation and sample availability, MSI1, FEM1B, TROY, ASCL2,
SOX4, SOX17, HTRA1, SPARCLI, CCND2 were not analysed in the human
colorectal tissue samples.
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3.4 Real time quantitative PCR data
This section describes how the data from the real-time PCR experiments was
analysed. Reference: User Bulletin #2 of ABI PRISM 7700 Sequence Detection
System (Dec. 1997). C; value is the first significant increase in the amount of PCR
product. It is inversely correlated to the logarithm of the initial amountof target
template.
Normalisation of the target Ct to the internal reference Ct value:
ACt = target Ct - reference Ct
Relative comparison to normaltissue Ct:
AACt = tumourtissue Ct — normaltissue Ct
Therelative fold change = 2°“
In normal and tumourtissue samples, Ct values of the target gene are normalised to
the reference gene used as the internal control, which gives the delta Ct. On the
graph, delta Ct represents the distances from the curve of reference gene to the curve
of target gene, respectively (Figure 3.6). Then the normalised Ct in tumour was
compared to the normalised Ct in normaltissue, which gives the delta delta Ct value.
This represents the distance difference in between the normal and in tumour samples.
Finally, the relative fold change wascalculated as 2 to the power of minusdelta delta
Ct, which showstherelative amount ofmRNA message in tumour sample.
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Figure 3.6 Example of an up-regulated gene in tumourtissue.
3.5 Candidate gene expressions in humancolorectal cancer
To determine whether the changes observed in mouse model also alter in human
colorectal cancer, the patient tissue samples for this project were obtained from
Cancer Tissue Bank Research Centre (with informed patient consent). Match paired
Total RNA samples were extracted from colorectal cancer tissues with adjacent
uninvolved colonic mucosa. Taqmanreal-time PCR was used to amplify candidate
gene expression in human colorectal tumours. The sample size calculations were
performed by Dr. A. Jorgensen, giving a guide for the minimal patient number
(n=10) needed to showstatistical significance. The fold change for each gene was
calculated separately for each pair of patient samples. The minimum required patient
number (n=10) wasinitially used for each gene of interest. The candidate gene
expression levels in fold change from patients are non-parametric data, the median
value (rather than mean value) was used to carry out the data analysis for each
candidate gene.
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For the Taqmanassay, a fold change of lower than 2 is considered to be no change.
Therefore, after the first round of 10 pairs of patient samples, the genes that showed
less than 2-fold (plus or minus) in tumour tissues were no longer considered to be
candidate genes. These 4 human genes were MTAP (1.97-fold, n=10), MBD4 (1.35
fold, n=10), SEMA3C (-1.31-fold, n=10) and TI4M1 (-1.40-fold, n=10).
Data from the Taqmanassay showedthat 8 orthologous human candidate genes were
over-expressed (figure 3.7). These genes were: AX/N2 (4.55-fold, n=43), CD44
(4.81-fold, n=16), EPHB2 (2.31-fold, n=29), EPHB3 (2.48-fold, n=26), EPHB4
(2.22-fold, n=29), FZD6 (2.42-fold, n=16), Fn/4 (5.48-fold, n=20) and CITED]
(2.74-fold, n=40). For each group of data, the candidate gene (non-parametric data),
the Wilcoxon Signed Rank Test was used to determinethestatistical significance.
Overexpression of all 8 genes observed showedstatistical significance at P<0.001.
In addition, 6 (in the yellow boxes) out of those 8 homologous human candidate
genes were c-Myc dependent, as identified in the APC and c-Myc double K/O mouse
model. The tumour sample positive controls, Top II (3.92-fold, n=10) and GPR49
(5.83-fold, n=23) were also significantly over-expressed at P<0.01.
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Figure 3.7 Candidate gene expression in human colorectal cancer. Data for
altered gene expression levels in tumourtissues were presented asthe fold changesrelative to
normal, which were shownin the graph as column of box-and whiskers plot showing the median
values with the interquartile ranges and whiskers. In each column ofthe graph, the horizontal line
across each box showed the median ofthat group of data for this candidate gene. Each box
extends from 25" and 75"percentiles. Whiskers extend downto the lowest value andup to the
highest. n= ‘number’ beneath each columnindicated the patient number being employed for that
group of data. ‘NC’ above each columnindicated no changeas altered by the Taqmanassay. ‘**’
above each column indicated the significance (P<0.01) from thestatistical analysis. Genes
covered by yellow boxes were c-Myc dependent Downstream Wnttarget genes.
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3.6 Discussion
3.6.1 Wnt signalling status in human colorectal tissues
The Wntsignalling pathway is switched on following loss of Apc in the Cre-/lox
mouse model. To validate these observations, it was necessary to clarify the Wnt
signalling status in human colorectal tumours. One of the initial thoughts was
detecting the mutations of APC in human colorectal tumours by employing the
method of DNA sequencing. APC is a very large gene with a MCR (mutation
clustered region) site in which the majority of APC mutations occur. Therefore we
decided to sequence this specific site ofAPC gene. However, it was not easy to use
this strategy to analyse APC mutations in patient samples and APC protein would
also be truncated during the post-translational process.It is not possible to clarify the
Wntstatus by sequencing of the APC gene in human colorectal tumourtissues.
It has been reported that mutations in the APC tumoursuppressor gene are present in
approximately 85% of colorectal tumours (Anderson et al., 2002). Over 90% of
colorectal cancer have a mutation from any components of Wntsignalling, which are
able to activate this pathway (Doucas et al., 2005). APC and (-catenin are two
central components of this pathway, their mutations have been reported to be
mutually exclusive (Behrens, 2005; Sparkset al., 1998). Mutations in both APC and
G-catenin result in the accumulation of nuclear 6-catenin whichis detectable in even
the smallest neoplastic lesion of the colonic adenoma(Haoet al., 2001; Pinto and
Clevers, 2005b). Therefore, we assume that the large majority of the human
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colorectal tumour tissues obtained from our Cancer Tissue Bank Research Centre
maintained the activated Wntsignalling.
3.6.2 Validation of the mouse modelstrategy
Data from Taqmanreal-time PCR analysis showed that 8 out of 12 detected genes
from the mouse model were over-expressed in human colorectal tumours, which
were also over-expressed from qPCR data in the Cre-/ox-Apc mouse model. These
observations demonstrated how transferable the candidate genes identified in the
mouse model are to the study of human colorectal cancer. Six out of these eight
over-expressed orthologue human genes have already been knownto be Wnttargets.
Elevated AXIN2 and CD44 geneas well as EPHB2, EPHB3, EPHB4 and FZD6 gene
expressions and corresponding gene encoded protein functions have been well
studied, which again validates the process in humancolorectal cancer.
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3.6.3 Previously known Wnt downstreamtarget in colorectal cancer
Below is a summary of the previously known Wnt downstream targets weidentified
as up-regulated in both the mouse model and humancolorectal samples.
AXIN2 waselevated in human colorectal tumours as reported previously (Yanetal.,
2001) and is cMyc dependent Wnttarget from the Sansom study (Sansom etal.,
2007). Being a scaffold protein molecule in the APC degradation complex, AXIN2
promotes the phosphorylation and degradation of B-catenin (Jhoet al., 2002). In the
case of mutant APC, TCF binding sites in the AX7N2 promoterplay a keyrole in the
ability of B-catenin to activate AX7N2 transcription (Leung et al., 2002). AXIN2
functions as a tumour suppressor and has been reported to be one of the negative
effectors in the Wnt signalling pathway by inhibiting B-catenin abundance and
functions (Leung et al., 2002; Salahshor and Woodgett, 2005). Over-expressed
AXIN2 also constitutes a negative feedback loop of Wnt signalling activity in
colorectal cancer (Lustig et al., 2002).
CD44 is a family of cell-surface glycoproteins encoded by a single gene with
alterative splicing and extensive posttranslational modifications (Kuncova et al.,
2005; Yamadaetal., 2003), and plays a crucial role in cell migration, inflammation
and immuneresponses (Mishra et al., 2005). An early study reported that CD44 is
downstream target of the Wnt signalling pathway, which was over-expressed in the
adenomas of the Min mice and in human FAP (Wielenga et al., 1999). Over-
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expression of CD44, both CD44s and CD44v forms, is an early event in the
colorectal adenoma-carcinoma sequence and plays a role in the generation and
turnover of epithelial cells (Wielenga et al., 1999). Another more recent study
reported that deletion of CD44 in Min mice attenuated the intestinal tumourigenesis
in Min mice with 50% reduction in numberofintestinal adenomas(Zeilstra etal.,
2008). However, in Clarke’s early stage Cre-/ox transgenic mice models, although
elevated in intestinal epithelium was observed 4-5 days after losing APC (Sansom et
al., 2004), it was unaffected by the additional loss of c-Myc within the same time
frame (Sansom et al., 2007). Data from CD44 expression from this double K/O
mouse model showedthat CD44is still altered in the rescued intestinal epithelium
after losing both Apc and c-Myc, which demonstrated the insufficient role of CD44
in imposing the phenotype associated with Apc loss. Data of the Taqman assays
showed the over-expression of CD44 at mRNA level in human colorectal cancer
tissues, which was consistent with other previous studies, although it may not
associate with the onset of colorectal carcinogenesis from Cre-/ox mice studies.
EphB receptors have been reported to control intestinal epithelial architecture
through repulsive interactions with EphrinB ligands, which was inversely mediated
by B-catenin and TCF (Batlle et al., 2005; Batlle et al., 2002; Sansom etal., 2004).
Reduction of EphB activity accelerates tumorigenesis in the colon and rectum in Min
mice, which demonstrated that EphB receptors suppress colorectal cancer
progression (Batlle et al., 2005; Clevers and Batlle, 2006). Our human qPCR data
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showedthe elevated transcription of EphB receptors in the colorectal tumours as
observed in Apc deficient intestinal epithelium. Essentially, EphB2 and EphB3are c-
Myc-dependent Wnttargets and their normaltranscription levels are consistent with
the normal localization of paneth cells in the double mutants (Sansometal., 2007).
FZD6 hasbeen reported to act as a negative regulator of the Wnt signalling cascade
in colon cancercell lines (Golan et al., 2004). Being c-Myc dependent downstream
Wnttarget, our data showed that FZD6 was elevated in human colorectal tumours as
observed in Apc deficient mouseintestinal epithelium.
3.6.3 Previously undiscovered Wnt targets in humancolorectal cancer
The over-expression of Fu14 and CITEDI gene have not previously been detected
as Wnt pathway targets in human colorectal cancer and therefore are the potential
novel candidates for future investigation.
A member of TNF receptor superfamily, Fn14 is a small cell surface receptor of
TWEAK (tumour necrosis factor-like weak inducer of apoptosis) (Wiley and
Winkles, 2003). TWEAK binding to Fn14 receptor plays an important role in the
ability of Fnl4 to activate NF-kB pathway, which involves with a number of
immune and inflammatory processes, as well as oncogenesis (Winkleset al., 2007).
Fn14 has already been reported to be expressedat relative high levels in certain types
of human tumours (Winkleset al., 2006; Winkles et al., 2007). A more recent study
demonstrated a non-redundant role of Fn14/TWEAKin intestinal damage in mice
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through a TWEAK/intestinalepithelial cell axis (Dohietal., 2009).It firstly reported
the role of Fn14/TWEAKinthe intestine, which elucidated the potential contribution
of this pathway to the maintenance ofthe intestinal homeostasis (Dohiet al., 2009).
However, it has not been shown to be part of the Wnt signalling pathway in
colorectal carcinogenesis.
CITED1 is involved in regulating a wide variety of CBP/p300-dependent
transcriptional responses (Shi et al., 2006). CITED1 is over-expressed in renal
development andacts as a bifunctional regulator of transcription, activating TGF-B
family signals while repressing Wnt-B-catenin-dependent responses (Plisov et al.,
2005; Shi et al., 2006). However, CITED1 has not been shownbeing regulated by
the Wnt pathwayin colorectal carcinogenesis.
In this project, we were establishing the importance of these Wnt target gene
alterations in intestinal tumourigenesis using animal models. In the literature, there
are Fn14 and Cited] K/O mice available (Zhao et a/l., 2007; Rodriguez et al., 2004),
which provided us the opportunities to investigate their roles in vivo. The role of
Fn14 in intestinal tumourigenesis had been taken by another research group for
further investigations. Therefore, we set out to investigate the role of CITED] in
intestinal tumourigenesis.
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Chapter 4 Effects of CITED1 deficiency (siRNA knock down) on
humancolon cancercell lines
4.1 Introduction
Cited] wasoriginally identified in murine melanomacell line, which has been found
to be associated with pigmentation (Shiodaet al., 1996). It has been characterized as
a non-DNAbinding transcriptional co-regulator which is able to activate or repress
transcription in association with other transcriptional factors depending on the
cellular context (Labbe et al., 2007; Plisov et al., 2005). It is implicated in
embryogenesis, in vertebrate development and carcinogenesis in breast, thyroid and
Wilms’ cancers (Dillon et al., 2007; Lovvorn et al., 2007b; Prasad et al., 2004).
However,its role in colorectal carcinogenesis is still unknown.
From our previous data, Cited] was found to be one of the genes which wereover-
expressed in the inducible mouseintestinal epithelium specific Apc knock-out model
(Sansom etal., 2004). In the Ape and c-Myc double knock-out mouse model, Cited]
was identified as a c-Myc dependent Wnttarget, which identifies it as a candidate in
the pathwayresulting in the phenotype of Apc loss (Sansom et al., 2007). We also
found CITEDto be over-expressed in human colorectal cancer tissues compared
with adjacent uninvolved colonic mucosa (See figure 3.7, Chapter 3). Therefore, we
hypothesized that CITED]is involved in colorectal carcinogenesis andits deficiency
would inhibit the growth of colorectal cancer.
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Before progressing to transgenic mouse models, we used human colon cancercell
lines to establish a potential role for CITED1 as part of the mechanism of
precancerous phenotype.
4.2 Selection of human colon cancercell lines
In order to establish the in vitro model for investigating the functional role of
CITED1 in colonic carcinogenesis, suitable human colon cancer cell lines were
selected. Due to the involvement of CITED] mRNAtranscription in the Wnt
pathway, the major criteria for the cell line selection is a maintained activated Wnt
signalling. HCT116 and HT29 are two widely used human colon cancercell lines.
HCT116 carries the mutant B-catenin with wild-type APC and HT29 carries the
mutant APC with wild-type B-catenin (Din et al., 2004), both maintain an activated
Wntsignalling pathway resulting from the mutations of the central components of
this pathway.
One of the mostefficient approaches of generating a reduced expression of a specific
protein in cultured cell lines is RNA interference (RNAi) gene silencing technique.
Thetransient transfection of small interference RNA (siRNA) duplexes induces the
degradation of the mRNA and consequently loss of protein over a period of time
(Wuet al., 2004). siRNA induced genesilencing is primarily an mRNAlevel event,
therefore Taqman gPCR waschosento detect the siRNA genesilencing effect.
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Prior to the siRNA experimentation, the basal cellular expression levels of C/TED/
mRNA weredetected by Taqman qPCR in HCT116 and HT29cell lines. For both
cell lines, mRNA samples were extracted from the cells which were randomly
harvested 4 times. As shownin the figure 4.1, CITED] mRNAis detectable and
expressed stably in both cell lines as normalised to the reference gene beta-Actin.
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Figure 4.1 Basal expression levels of CITED1 in the
studied humancolon cancerlines. Grey bars show the
normalised delta Ct values of CITED] to beta-actin in
HCT116 and HT29cell lines. The error bars stand for the
standard error of the mean (SEM) of the Ct value for each
cell line (n=4).
Ideally, both mRNA and protein levels should be analysed whenever possible to
detect the siRNA knock down effect. Unfortunately, there is no suitable CITED1
antibody for western blotting assay in this project.
148
A commercial CITED] antibody from Genetex wasfirstly used on HepG2 whole
cell lysate positive control. The predicted molecular mass for CITED1 is
approximately 23 kDa (Shiodaet al., 1996); however, Genetex CITED1 antibody
showeda band of a much larger size than 41 kDa, which was unlikely to be CITED1
(figure 4.2). Therefore, this antibody cannot be used to detect CITED] protein.
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Figure 4.2 Western blotting of HepG2 wholecell lysate
probed by Genetex CITED1antibody. This antibody did
not detect CITED1 antigen in samples. Pan-actin was used
as an equal loading control.
Another antibody was then found in literature, which is not commercially available
but has been reported to be good for western blotting (Howlin et al., 2006; Lovvorn
et al., 2007b). We used this antibody on western blotting assay of HT29, HCT116
whole cell lysate samples and Min mouse small intestine tissue protein samples,
together with HepG2 whole cell lysate positive control. The blotting band of
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CITED1 was observed on the Min mouse smallintestine tissue sample and it was of
the correct molecular size (Figure 4.3). Unfortunately, this antibody was not able to
visualise CITED1 antigen in any of these human cell lines samples (including
HepG2 positive control) in our western blotting assay. Therefore, data is only
available at mRNAlevel for siRNA inhibition experiments on human colon cancer
cell lines, which is measured by qPCR.
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Figure 4.3 Western blotting of studied humancell line lysate and
Min mouse small intestine protein using CITED1 antibody
provided by Dr. Shioda. CITED1 antigen was only detected in Min
mouse small intestine sample using this antibody. Beta-actin was used
as an equal loading control. Thisis the representative data of 3
repeats.
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4.3 siRNA inhibition of CITED] mRNA expression in human colon cancercell
lines
CITED1 down regulation is demonstrated by qPCR. Cellular expression of CITED1
mRNA was reduced by siRNA transfection in HCT116 and HT29 human colon
cancer cell lines, as detected by qPCR. All pairwise comparisons were analysed
following Kruskal-Wallis non-parametric analysis of variance (ANOVA) and data
showed statistically significant reduction of CITED]in both cell lines (Figure 4.4).
In HCT116 cells, C/TED/ expression was significantly reduced by 95% in target
siRNA compared with the non-target siRNA control (P<0.01, Kruskal-Wallis)
(figure 4.4 A). This reduction was 80% in HT29 cells (P<0.05, Kruskal-Wallis)
(figure 4.4 B). siRNA transfection experiments were all performed at the optimised
conditions (as outlined above) to obtain the highest reduction in the mRNA of our
gene of interest. The difference of knocking downeffect in the HCT116 and HT29
cells may be result of the different cellular context.
For both cell lines, CITED] mRNAexpression in the lipid only control and non-
target siRNA control stay at similar level to the blank control. This indicates that
there is no off-target effect from either cellular toxicity of the transfection lipid or the
non-target control siRNA.This is the final step in validating the down regulation of
CITED1 mRNA in the two cell types. Therefore, the siRNA transfection
experiments in HCT116 and HT29 humancolon cancercell lines have been proven
to be valid for the following phenotypicstudies.
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4.4 Effects of CITED1deficiency on human colon cancercell growth
As mentioned earlier in this chapter, high level of Cited/(CITED1) mRNAare
present in both Apc knock-out mouse intestinal epithelium and human colorectal
tumour tissues, we hypothesized that CITED1 is involved in colorectal
carcinogenesis and its deficiency could possibly inhibit the growth of colorectal
cancer.
4.4.1 Effect of CITED1 deficiency on cell survival
The clonogenic assay was used to measure the ability of the cancer cells to divide
and grow following siRNA treatment. After 48 hours siRNA transfection, cell
numbers for each treatment were counted and the same numberofcells (1000 for
HCT116 and 2000 for HT29) from each treatment were reseeded and re-grown with
no further siRNA treatment until the visible colonies were observed.
For HCT116 cells, there was a small but statistically significant decrease in cell
survival following targeted siRNA treatment compared with the other controls
(P<0.001, Kruskal-Wallis) (figure 4.5 A). Similar results were also observed for
HT29 cells (P<0.01, Kruskal-Wallis test) (figure 4.5 B). Therefore, data
demonstrated a decreasedcell survival following the knock down of CITED1.
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Figure 4.5 Reduction in CITED1 expression reduces clonogenic
survival in HCT116 cell line (A) and HT29cell line (B). Thisis the
representative data from minimum of 3 experiments.
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4.4.2 Effect of CITED1 deficiency on cell proliferation
Thecell survival assay only measured the end point effect of cell growth. Therefore,
weused the SRBassayto accesscell proliferation over several days.
For both HCT116 and HT29 cell lines, cells were reseeded as described above and
collected over 7 days post transfection. For both cell lines, there was a
demonstratable reduction in cell proliferation following siRNA treatment. The
reduction in cell proliferation wasstatistically significant from day 3 to day 5 for
HCT116 cells (P<0.05, Kruskal-Wallis) and the largest reduction being observed on
day 4 (P<0.01, Kruskal-Wallis) (figure 4.6 A). For HT29 cells, the reduction in cell
proliferation was significant from day 2 to day 7 and the largest reduction was
observed on day 5 (P<0.01, Kruskal-Wallis) (figure 4.6 B). One of the reasons for
this cell proliferation difference between two cell lines could possibly be the
different cell growth speed. HT29 cells generally grow slower than HCT116 cells in
culture. Once the cells were reseeded after the 48 hour siRNA treatment, CITED1
deficient HCT116 cells would proliferate at a higher rate than CITED1 deficient
HT29 cells. This could explain the later time point of the largest proliferation
difference between target and non-target siRNA treatment in HT29cellline.
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Figure 4.6 Reduction in CITED1 expression reduces proliferation
(SRB assay) in HCT116 cell line (A) and HT29cell line (B). Thisis
the representative data from minimum of3 experiments.
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4.5 CITED1deficiency does not turn Wntsignalling off
As stated earlier, CITED] has been characterized as a non-DNA binding
transcriptional co-regulator depending on the cellular context (Labbe et al., 2007;
Plisov et al., 2005). Therefore, the question addressed here is whether or not
CITED! acts as a transcriptional co-regulator in this cellular context. Furthermore,
does CITED1 deficiency cause the inhibition of downstream Wntsignalling?
Axin2 and CD44 are known Wnt regulated downstream targets, we used these to
access the effect on the Wnt pathway following down regulation of CITED1. In
HCT116 cells, Axin2 was significantly three-fold over-expressed following siRNA
knock down (p<0.05, Kruskal-Wallis test). However, CD44 did not show much
changes in cellular expression between target and non-target siRNA treatment
(P>0.05, Kruskal-Wallis) (figure 4.7 A). In HT29 cells, Axin2 and CD44 were both
significantly increased (both P<0.05; Kruskal-Wallis), although the changes are not
as muchas the level of Axin2 in HCT116 cells (figure 4.7 B). So far, data showed
that these two Wnt targets were not down-regulated with the deficiency of C/TED/
and therefore CITED/ deficiency does not turn off the Wnt signalling in HCT116
and HT29cell lines.
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4.6 Discussion
4.6.1 Possible mechanism ofcell growth reduction
In our in vitro model, cell survival and cell proliferation were significantly reduced
following CITED1 knock down for both HCT116 and HT29cells. There are several
possible mechanismsbehind the observed cell growth reduction. Unfortunately, no
further mechanism studies werecarried out because of the timelimit.
Firstly, a smaller number of surviving cells following reduction in CITED1
expression are likely to be the result of a greater cell death. An essential step in
clonogenic assay is that the same numberofliving cells was settling down and
attached at the bottom ofthe cell culture wells to grow. The reduced numberofcell
colonies wastherefore initially decided by the numberofsuccessfully attached living
cells. However, the proportion of cells processed to cell death is presumably not
large, because of the minor reduction of cell survival. Additionally, the ability of the
attached cells to divide mayalso contribute to the result of clonogenic assay. Active-
caspase 3 labelling would be an approach for determiningif the cell death was due to
apoptosis.
Whenthe cell proliferation was being tracked by SRB assay on a daily course, the
cell proliferation was obviously reduced following CITED/ knock down (4.6.2). It is
important to note that there was no further siRNA treatment during the SRBassay.
Therefore this assay is measuring the effect of CITED1 deficiency onthe starting
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population of cells. The reduced proliferation may result from either a prolongedcell
cycle or a cell cycle arrest. Cells would be arrested at certain phase of the whole cell
cycle in the later case, which will result in an increased number of cells being
blocked at one phase, and in turn will interfere the rate of cell proliferation. The cell
cycle analysis can be detected by using flowcytometry assay on the cells pulse
labelled with BrdU to track the cells went through the S-phase and propidium iodide
(PI) for the DNA content.
4.6.2 Hypothetical molecular mechanism of CITED1
Following CITED/ knockdown, AXIN2 and CD44 were not down-regulated, which
indicates that CITED1 deficiency does not turn off downstream Wntsignalling.
For both HCT116 and HT29 cell lines, AX7N2 was dramatically up-regulated
following CITED/ knock down.Asidentified in Sansom’s Nature paper (Sansom et
al., 2007), CITED1 and Axin2 are both c-Myc dependent Wnttargets. In the context
of knocking down CITEDin colon cancercells, up-regulation of Axin2 may be one
of the rapid compensatory effects induced by CITED1 efficiency on maintaining the
activity of the downstream of c-Myc, because C/TED/ and Axin2 expression levels
were measuredat the end point of siRNA transfection, whereis the start point of the
SRBcell proliferation assay. However, in function, Axin2 is primarily a repressor of
the Wnt signalling pathway (Lustig et al., 2002), as well as being a target. In a
slightly longer time frame (e.g. days post transfection) after the C/TEDI knock
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down, the negative feedback loop of Axin2 onto the Wnt pathway may induce more
inhibition. Therefore, the hypothetical functional relations between CITED1, Axin2,
c-Myc and Wntare that if CITED1 has a negative effect on Axin2.It then acts in a
negative mannerupstream of Wntsignalling, as shownin figure 4.17.
Due to the complexity of Axin2 being both repressor and target of Wnt signalling
pathway, a series of TOP-FLASHreporter assay is neededto clarify the alterations
of the activities of this pathway at different point from the top to the bottom. If
possible, a comprehensive DNA microarray or PCRsignalling pathway assay would
be able to generate a full map of the related- pathwayalterations following C/TED/
knock downin cell lines.
APC /B-catenin  |-----------.f 4
CD44 c- Myc >
f ™
CITED1 ------- | AXIN2 -----------!
?
Figure 4.8 Hypothetical functional relations between
CITED1, Axin2, c-Myc and the Wnt pathway.
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Chapter 5 Effect of Cited1 loss on intestinal tumourigenesis in the
Min mouse
5.1 Introduction
In chapter 4, the inhibitory effect of CITED1 on human colon cancercell growth was
demonstrated in vitro, although the underlying molecular mechanism waselusive. In
this chapter, we use a transgenic mouse model to demonstrate the potential of
Cited1’s key role in the intestinal tumourigenesis and the underlying in vivo
molecular mechanism.
5.2 Mouse models
Min (multiple intestinal neoplasia) mouse model carries a heterozygous truncating
mutation of Apc and typically develops multiple intestinal polyps in the small
intestine (Taketo and Edelmann, 2009). The min mouse model mimics the rapid
development of adenomatous polyps that affect FAP patients, which is caused by
germline mutation of APC in humans(Corpet and Pierre, 2005). In this project, Min
mice on C57Black/6 background were used and provided a high penetrance of
disease.
Cited] is located on the X chromosome. Cited/ global knock-out mice (also on
C57Black/6 background) are available, which display placental deficiency resulting
in developmental growth retardation from embryonic day 18.5 (E18.5) and a high
death rate immediately during birth or after birth (Rodriguez et al., 2004). Cited/
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null mice also display a mammary ductal outgrowth defect during (Howlin et al.,
2006).
Given that Cited1 is over-expressed in the small intestine after Apc loss and in Min
mouseintestinal adenomas, together with its role in human colon cancercell lines,
we asked whether deficiency of Cited] could inhibit intestinal adenoma formation in
Min mice.
Min/+ Min/*) and wild typeHomozygous (CitedI”” Ape™'*), heterozygous (CitedI"* Apc
(CitedI”* Apc") cohorts were generated by crossing Cited] null mice with Apc
Min mice. The mice used were all homozygous with respect to Pla2g2a
(phopholipase A2) locus for Mom-1 (modifier of Minl), which is C57Black/6
background dependent.
Cited null mice are not born according to Mendelian ratios and pups that are born
are significantly smaller than wild type litter mates. The intestine of Cited]
heterozygous females will be composed of mosaic areas oftissue that are essentially
wild type or null for Cited1, which is due to random X chromosomeinactivation
during development leaving either the wild type or the mutantallele inactive (Figure
5.1). Due to the nature of the X-linked Cited] mutation, the males can only be
homozygous mutants.
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 Figure 5.1 Due to random X chromosomeinactivation,
heterozygous females will have a mosaic expression pattern for
Cited1 with large areas of homozygousand wild typetissue. This
diagram is kindly provided by Dr. Phesse.
5.3 Characterization of Cited1 knock-out mice on Min background
5.3.1 Characterization of Cited1 mRNA expression in small intestine
The Cited] mRNA expression in 3 mice cohorts were analysed by semi-quantitative
PCR and the data of the representative samples is shown in Figure 5.2A. Normal
tissues and tissues of random adenoma polyps were taken from mouse small
intestine of 3 cohorts. PCR products of Cited] and f-actin at exponential phase were
separated on gel. The normal tissue and adenomas from the Cited! homozygousnull
Min/+min mice (CitedI” Apc”) expressed no Cited] as expected and confirmed their
status as genuine Cited/ null animals. Cited] expression was almost undetectable in
Min/+the normal tissue of both Cited1 heterozygous (CitedI*Apc™””*) and wild type
(CitedApc“”*) Min mice, but was up-regulated in adenomas of both cohorts
when compared to normaltissue from the same mouse.
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Figure 5.2 Analysis of Cited1 expression in 3 Min mice cohorts. (A) Representative gel
showing Cited1 mRNAexpression from semi-qPCR.(B) Relative fold changes of Cited]
mRNAin tumoursin heterozygous and homozygousCited1 null Min mice. (C) Cited]
mRNAexpressionlevels in all analysed Min adenomas from heterozygous and homozygous
Cited1 null Min mice. This is the representative data from 2 repeat experiments.
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Similar results were observed in an independent SYBR Green quantitative PCR
assay (Figure 5.2B), which confirmed the semi-quantitative data showing the Cited/
status in the inter-cross-generated Min mice. There were no detectable amplification
curves in the normal and adenomatissues of the homozygous Cited/ null Min mice
showing no detectable Cited] mRNA, therefore the fold changes cannot be
calculated. The fold changes of adenomasin heterozygous and wild type Cited] Min
mice were normalised to the normal tissues taken from the same mouse, which
showed the Cited] mRNA over-expression in Min adenomas in heterozygous
mutants and wild type Cited] Min mice.
Densitometry of the semi-quantitative PCR gel of samples taken from all 9 mice (3
from each cohort) was used to analyse the Cited/ expression levels (Figure 5.2C).
Density data showed large majority of adenomas (12 out of 14) displayed
dramatically up-regulated Cited] mRNAexpression (larger than 5-fold) in Cited]
wild type cohorts, when compared to normal tissue from the same mouse. Highly
expressed Cited] mRNA wasin a smaller proportion (2 out of 6) of adenomas in the
heterozygous mutants.
In Cited] homozygous null mice, adenomas werepresent and these had undetectable
level of Cited! demonstrates that Cited1 is not essential for adenoma formation in
Min mice. However, the adenomasdisplayed significantly up-regulated levels of
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Cited1 in both Cited] heterozygous and Citedl wild type cohorts suggests that
Cited1 plays an importantrole in intestinal tumourigenesis.
5.3.2 Characterization of Cited1 protein expression in small intestine
Western blotting analysis was used to measure protein levels of Cited] expression in
the 3 mouse cohorts. In chapter 4, two different Cited1 antibodies were tested. The
commercial antibody from Genetex failed to show the correct band of Cited]
protein. However, the antibody(a kind gift from Dr. Shioda; in Methods) was able to
detect Cited] antigen in Min mouse samplesat the correct size. This antibody was
then used to characterise the Cited] knock out.
Paired normal and tumour tissue samples from heterozygous and homozygous
Cited] null Min mice were analysed (Figure 5.3). As a point of note, these protein
samples came from the same mice as the mRNA samples for semi-qPCR.In figure
5.3A, on the blot, the lower bands are assumed to be Cited! becauseit is the correct
size. However, what the upper bandsare is unknown.It is observed that there are
weaker bands of normal and tumourtissues from homozygous Cited/ null Min mice
compared with the normal and tumour tissues from the heterozygous cohort.
However, the visible bands of homozygous Cited/ null Min mice from western
blotting conflicts with the semi-qPCR and qPCR data showing no detectable mRNA
in Cited] homozygous KO /Minusing specific primers. Due to the uniqueresult of
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using Cited] primers as confirmed by the Blast nucleotide search, it is highly
probable that this Cited1 antibody lacks specificity to mouse Cited] antigen.
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Figure 5.3 Cited1 protein expression levels detected by antibody
provided by Dr. Shioda. (A) Blot ofintestinal tissues probed by Cited]
antibody. (B) Blot showsthe equal loading control of Beta-actin. N=normal,
T=tumour; Het= heterozygous, Hom= homozygous. Thisis the
representative data from 2 repeats.
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In the Cited1 blotting of figure 5.3, two bands for each sample (both upper and
lower) are very close to the size of light chain (25kD) and heavy chain (50kD) of
mouse IgG immunoglobulin. Since this is an antibody generated from mouse and
probed to a mouse antigen, it is likely that there is unspecific mouse IgG
immunoglobulin in this antibody.
A mouse IgG immunoglobulin sample was then used together with Cited]
heterozygous and homozygous samples, light chain and heavy chain of mouse IgG
are at the same position as the two bands probed by Cited] antibody (FigureS.4).
Again, bands of Cited1 homozygous are weaker than heterozygous, butstill visible
on the blotting (Figure 5.3 and Figure 5.4).
Taken all above data together, it suggests that Cited] antibody provided by Dr.
Shioda does not appear to be absolutely specific to Cited1 (partcularly given that
bands could be detected in the homozygous Cited] animals), with the antibody
potentially only showingCited1 when overexpressed. Data from semi-quantitative
and quantitative PCR are morereliable than western blotting analysis in terms of
characterisation of the Cited] knock out Min mouse model to be genuine Cited1 null
animals.
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Figure 5.4 Test of Cited1 antibody with Mouse IgG
immunoglobulin. Protein samples of mouseintestinal tissues (different
from samples used in figure 5.3) were used with MouseIgG antigen.
Top blotting was probed by Cited! antibody. Bottom blotting showsthe
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carried over from the previous western blotting. Het= heterozygous,
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5.4 Loss of Cited1 increased the life span of Min mice
The 3 cohorts were aged and culled upon signs of intestinal neoplasia. The median
life span of wild type Cited7 Min mice is 284.5 days (n=8). The median life span of
heterozygous Cited] Min mice is 269 days (n=21). However, the median life span
dramatically increased to 515 days for Cited] homozygous null Min mice (n=5)
(Figure 5.7). ‘Wild type’ Cited] Min mice are naturally heterozygous for Cited/
(Min Cited1*’*), as Cited] is located on the X chromosome. Additionally, due to the
high penetrance of disease on C57Black/6 genetic background for the Cited]
deficient induced placental defect, the homozygous mice survived to adulthood were
all males (Min Cited/ay Accordingly, the statistical significance cannot be analysed
as the heterozygous cohort is actually the mixture of ‘wild type’ male (Min
Cited1**) and heterozygous female (Min CitedI”*). Therefore, it is necessary to
separate female and male populations in cohorts for comparison due to the nature of
the X-linked Cited] mutation.
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Figure 5.7 Kaplan Meier plot showing the survival
percentage of 3 mice strains. (Data for this figure is kindly
provided by Dr. Phesse)
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In the female population, the median life span slightly increased from 284.5 daysg
(Min Cited1 **, n=8) to 325 days (Min Cited/ *”, n=13) after losing Cited] on one
allele (Figure 5.8). However, the life span extension wasnotsignificant with P value
of 0.237 (Kaplan-Meier; Chi squared =1.4, DF=1).
P=0.237
1004 —— Min Cited1+/+
= —— Min Cited1+/-
2 754
5
”
= 504
oO2a 254
0  tt tC qv v T v t0 100 200 300 400 500 600 700 800
Days
Figure 5.8 Survival percentages of wild type and heterozygous
Cited1 female Min mice.
In the male population, the median life span of ‘wild type’ Cited7 Min mice cohort
was 230.5 days (Min Cited! *’*, n= 8), which wassignificantly increased to 515 days
(Min Cited] *”, n=5) with a P value of 0.001 (Kaplan-Meier; Chi squared =10.68,
DF=1) (Figure 5.9). Data demonstrated that Cited/ deficiency significantly increase
life span of Min mice in the male rather than the female population.
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Figure 5.9 Survival percentages of heterozygous and
homozygous Cited1 male Min mice. 7
It is interesting that the significant life span extension after losing Cited] only
happened to Min males, although the females theoretically lost Cited] on one X
chromosomein heterozygous mutants. In mammalian females, most genes on one X
chromosomeare silenced by X inactivation through epigenetic system, however,
some ‘escape’ X inactivation and are expressed from both active and ‘inactive’ Xs
(Heard and Disteche, 2006). Due to the potential complication of variable expression
of genes on the X chromosome, therefore the following tumour burden
characterization only focuses on the Min males.
173
5.5 Tumour burden characterization in Cited1 knock-out Min mice
5.5.1 Loss of Cited1 reduced the tumour numberin both small intestine and
large intestine of male Min mice
The tumour numberper mouse wasusedto analyse the initiation of tumourigenesis
in male Min mice. Taking both small and large intestine into consideration, tumour
numbers were significantly reduced in the Cited] homozygousnull mice compared
to the heterozygous mutants (P<0.05, Mann-Whitney) (Figure 5.10). The Cited/
homozygous null mice still developed some adenomasin both the small and large
intestine demonstrating that Cited] is not essential for the formation of adenomasin
the intestine of Min mice. However, the significant reduction of tumour number in
homozygous null suggests that Cited] expression is required for the increased
development of adenomas in Min mouse intestine. In the heterozygous mice,
tumours were predominant in small intestine and only a few in the large intestine. In
homozygous null mice, there are several tumours in the small intestine and only one
in the large intestine. Tumours that developed in the small intestine of homozygous
nulls were less than one third as manyas seen in the heterozygous mice.In the large
intestine, the reduction of tumour number waseven greater.
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Figure 5.10 Tumour numberin small and large intestine in Cited1
deficient Min males. (A) Tumour numbercounted in the smallintestine.
(B) Tumour numbercountedin the large intestine. (Data for this figure is
kindly provided by Dr. Phesse)
5.5.2 Loss of Cited1 increased the tumoursize in both small intestine and large
intestine of male Min mice
The median tumour size (mm) wasalso analysed for heterozygous and homozygous
null mutants. Tumour size was significantly increased in both small intestine
(P<0.001, Mann-Whitney) and large intestine tissues (P<0.05, Mann-Whitney)
(Figure 5.11). This increase is larger in small intestine than large intestine tissue.
Presumably, this increase is because that the Cited] homozygous null mice live the
longest and there was longer time frame to develop adenomasin a largersize.
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Figure 5.11 Tumoursize in small andlarge intestine in Cited1 deficient
Min males. (A) Tumoursize measured in small intestine. (B) Tumoursize
measured in large intestine. (Data for this figure is kindly provided by Dr.
Phesse)
Taken tumour numberand tumoursize data together, the life span of male Min mice
was terminated by the tumour numberrather than the absolute tumour size. Tumour
numberindicates the abundance of tumourigenesis events taking place in the tissues.
Data was collected at the end points for different cohorts. To obtain the best
comparison, the tumour size should be measured at the same time points of
heterozygous and homozygous cohorts of male Min mice, which may provide more
comparable data.
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5.6 Loss of Cited1 does not switch off Wnt signalling status in mouseintestine
5.6.1 Loss of Cited1 does not alter B-catenin translocation in Min adenomas
Nuclear B-catenin translocation is critical for activated Wnt signalling pathway. B-
catenin immuno-histochemistry was performed on small intestinal tissue sections for
3 cohorts of Cited1 deficient Min mice (Figure 5.12). B-catenin translocation from
cytoplasm to nucleus was observed only in adenomatous tissue but from all 3
cohorts. There is no nuclear B-catenin translocation in normal (non-adenomatous)
tissue in any of the 3 cohorts.
Data of immuno-histochemistry suggest that loss of Cited] does not inhibit B-catenin
translocation into the nucleus in Min adenomas. The development of the Min
adenomasoccursin all 3 cohorts, regardless of the Cited! status. It could be inferred
that active Wnt signalling is required for almost all the adenoma development,
however Cited] over-expression is only required for a proportion of adenomas in
heterozygous and wild type Cited] Min mice, but not in homozygous null Min mice.
Presumably, the reduced number of adenoma tumours from ‘wild type’ Cited/ to
Cited] null Min males wasactually dependent on high level of Cited] expression;
therefore fewer adenomas developed when no Cited] was present in the small
intestine of Min males.
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Figure 5.12 Immunohistochemistry of B-catenin of 3 Min cohorts. Images on
the top row were taken undera lower amplification and the bottom row under a
higher amplification. This is the representative data from 3 mice.
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5.6.2 Loss of Cited1 does not switch off downstream Wntsignalling activity in
Min normaltissues
Wnt downstream targets were then used to measurethealteration of Wntsignalling
activity. Cited] deficient Min mice from 3 cohorts were terminated at different time
points, due to signs of neoplasia, therefore using transformed adenomatoustissues
from various development times with different Citedl status will bring
complications to the comparison. However, the normal tissues remain untransformed
among 3 cohorts. Non-adenomasintestinal tissue of Cited] homozygous null Min
mice must be moreresistant to tumourigenesis, since a small number of adenomas
were developed in the intestine of this cohort, in turn, resulted in a longerlife span.
Therefore, normal tissues of 3 cohorts were used to detect the alteration of Wnt
signalling activity.
c-Myc, CD44 and Axin2 were used as reporters of Wnt signalling. Their mRNA
expression levels in normal intestinal tissues of wild type, heterozygous and
homozygous Cited] null Min mice were measured using quantitative PCR. Data
were all normalised to wild type intestinal tissue. In the Cited1 homozygous null
mutants, Myc, CD44 and Axin2 wereall over-expressed compared with heterozygous
Cited] Min mice (Figure 5.13).
Although it was only preliminary data from one mouse of each cohort, data suggests
that the presents of Cited] seems to be able to inhibit downstream Wntsignalling
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activity. When losing Cited1, downstream Wntsignalling is more active on the Min
background, under which condition Min mice survived for another ~250 days
compared with heterozygous Citedl Min. However, no nuclear f-catenin
translocation was observed in the normal intestinal tissues from the 3 cohorts.
Therefore, there must be some unknown molecular events happening, dependent on
Cited1 status, lying between B-catenin and Wnt signalling regulated gene
transcription. In normal tissue, this potential molecular mechanism will modulate
Wntsignalling activity possibly inhibiting B-catenin translocation from cytoplasm
into nucleus; however, downstream Wntsignalling is moreactive.
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Figure 5.13 Wnt targets expression in Min normal
tissues of 3 cohorts. Myc, CD44 and Axin2 wereall
dramatically overexpressed in homozygousCited1 null
min mouse non-transformedintestinal tissues. Due to
the limited amout of sample, this experiment wascarried
out once on one mousefrom each cohort. It is shown as
preliminary data.
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5.7 Is ErbB2 part of the underlying Cited1 mechanism for enhancing tumour
formation?
5.7.1 Cited1 deficiency does not reduce ErbB2 mRNA expression in the Min
mouseintestine
ErbB2 has been demonstrated to be an oncogenein breast cancer (Ross and Fletcher,
1999). The importance of ErbB2 in mammary gland tumour development has been
well demonstrated andit is the target of therapy in this disease (Rosset al., 2009).
Cited1 has been reported to be a co-activator of the EGR2 transcription factor and is
able to associate with EGR2 to activate ErbB2 expression during mammary tumour
progression (Dillon et al., 2007). The research question is that whether Cited/
deficiency is reducing ErbB2 expression levels in Min mouseintestinal tissues and
therefore inducing a longerlife span of the homozygous Cited/ null Min cohort.
Normal intestinal tissues from cohorts were used for the detection of ErbB2 and
EGR2 mRNAexpressions (Figure 5.14). Data from heterozygous and homozygous
Cited] null Min mice were normalised to wild type Cited/ Min. In the Min mouse
intestinal tissues, EGR2 was over-expressed with increased ErbB2 mRNA
expression after losing Citedl. This preliminary data suggests that ErbB2 mRNA
remain expressed at a high level in the Cited] homozygous null Min mice which
lived the longest. Therefore, Cited/ deficiency does not reduce ErbB2 expression in
Min mouseintestine.
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Figure 5.14 ErbB2 and EGR2 mRNAexpression in Min normaltissue
of 3 cohorts. ErbB2 and EGR2 were both over-expressed in homozygous
Cited] null Min mousenormalintestinal tissue. Due to the limited amout of
sample, this experiment wascarried out once on one mouse from each
cohort. It is shownas preliminary data.
5.7.2 No ErbB2 over-expression in the initial stage of tumourigenesis
The involvement of ErbB2in the initial stage of tumourigenesis needsto be clarified
by detecting whether it is altered as one of the Wntsignalling regulated targets in the
early Apc knock-out model. Intestinal epithelium of wild type and knock out Apc
mice were used to detect ErbB2 mRNAexpression levels together with the controls
of another 3 known Wht targets (Axin2, CD44 and cMyc) (Figure 5.15). As
expected, three Wnt targets were all over-expressed. However, the normalised fold
change data showed that ErbB2 mRNAexpression level wasslightly decreased less
than 2-fold in the Apc knock-out mouseintestinal epithelium, which was considered
to be no change. Therefore, ErbB2 mRNAis proposed to be uninvolvedin theinitial
stage of intestinal tumourigenesis.
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Figure 5.15 ErbB2 and Wnttargets
expression in Apc knock outintestinal
epithelial cells. Error bars indicate the
standard error of the mean (SEM). n=3
Taken all together, ErbB2 is not an important target of the intestinal tumour
progression in both Min mouse model and immediate Apc knock-out model.
183
5.8 The possible involvement of TGF-B pathway in the mechanism of the
inhibitory role of Cited1 deficiency in intestinal tumourigenesis
In the TGF-B pathway, the TGF-B ligands bind to transmembrane TGF-f receptors
which phosphorylate SMAD2/3 (Li et al., 2005). Phosphorylated SMAD2/3 then
associates with SMAD4 forming a heterotrimeric complex (Li et al., 2005). This
phosphorylated receptor complex of Smads translocate to the nucleus where it
interacts with transcription factors to control gene expression (Figure 5.16)
(Massagueetal., 2000).
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Figure 5.16 Schematic graph showing TGF-f signalling pathway. (Adapted from Liet
al., 2005) The hypothetical role of Cited1 through CBP/p300 in this pathway was added
by the authorofthis thesis, but not included in the original paper.
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In addition to this canonical pathway TGF-B also interacts with many other pathways
regulating cellular growth, for example, RhoA, Cdc42, Ras, PI3 kinase, which
causes the role of TGF-B in cancer to be both complex and highly dependent on
cellular context (Barrios-Rodiles et al., 2005; Bierie and Moses, 2006). In early
stages of tumourigenesis, including colonic adenomas, TGF-f acts as a tumour
suppressor (Munozetal., 2006; Siegel et al., 2003a; Sodir et al., 2006; Takaku et
al., 1998). In more advanced lesions, TGF-f acts as a tumour promoter enhancing
metastatic behaviour, immune evasion and angiogenesis (Muraoka-Cooketal., 2004;
Thomaset al., 2005).
Non-DNAbindingtranscriptional co-regulator Cited1 has been reported to be able to
bind to the CBP/p300 coactivators and DNA-binding Smad proteins, in turn
enhancing the functional link between Smads and CBP/p300, and the Smad-
mediated transcription (Yahataet al., 2000). The research question is whether Cited]
deficiency is altering the TGF-f signalling activity in Min mouseintestinal tissues
and therefore induced a longerlife span of the homozygous Cited/ null Min cohort.
The phosphorylated Smad2/3 translocation would indicate the TGF-f signalling
pathwayactivation.
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5.8.1 Loss of Cited1 does not prevent nuclear translocation of phosphorylated
Smad2/3
In the images of immuno-histochemistry, phosphorylated Smad2/3 translocates into
nucleus in both Min adenomasand the surrounding normaltissues in all 3 cohorts
(Figure 5.17 top row). The condensed nuclear phosphorylated Smad2/3 were
observedin all the intestinal epithelium cells as shown under higher amplifications
in both tissue types (Figure 5.17, middle and bottom row). Immuno-histochemistry
data suggests that loss of Cited] does not prevent phosphorylated Smad2/3
translocation into nucleus in either normal or adenoma tissues of Min mouse
intestine. Therefore, TGF-f signalling turns out to be active in normal and adenoma
intestinal tissues in all 3 cohorts. The following question is whether Cited]
deficiency alters the degree of TGF-B signalling activity. However, it is difficult to
determine the level of TGF-B signalling activity from immuno-histochemistry data
of phosphorylated Smad2/3.
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Figure 5.17 Immunohistochemistry of phophorylated Smad2/3 of Min mouseintestine in 3
cohorts. Top row showsthe phosphorylated Smad2/3 location in both normal and tumour
intestinal tissues. Middle and bottom row show the phosphorylated Smad2/3 in normal or
tumourtissue under high amplification, respectively. This is the representative data from 3 mice.
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5.8.2 Cited1 is not interacting with TGF-B signalling pathway
In order to clarify the activity of TGF-B signalling and then the involvement of
Cited1 in this pathway in mouseintestinal tissue, levels of phosphorylated Smad2/3
were measured by western blotting and phosphorylated Smad2/3 expression were
analysed by densitometry.
In the western blotting assay (figure 5.18), the top blot shows that the
phosphorylated Smad2/3 protein expression is at a higher level in the tumours than
in the normal tissue taken from the same mouse. However, the bottom blot showsthe
higher density of control beta-actin for the tumour samples in the heterozygous and
homozygous Cited/ null Min intestine. Thus, it is difficult to directly compare the
phosphorylated Smad2/3 from the images ofthe blot. Additionally, the difference of
phosphorylated Smad2/3 between normal and tumour tissues does not reflect the
effect of Cited] deficiency on the mechanism and the life span changes. However,
the comparable samples are normal tissues from wild type, heterozygous and
homozygous Cited] mutants. Therefore, the densitometry was used to measure the
normalised expression level of phosphorylated Smad2/3 in normalintestinaltissues.
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Figure 5.18 Western blotting of phosphorylated Smad2/3 in
3 mice cohorts. Top blotting showsthe phosphorylated protein
expression in intestinal tissues. Bottom blotting showsthe
loading control Beta-actin. N=normal, T=tumour; WT=wild
type, Het= heterozygous, Hom= homozygous. Dueto the
limited amout of sample, this experiment wascarried out
once on one mouse from each cohort. It is shown as
preliminary data.
Data from the densitometry on western blotting shows that the normalised level of
phosphorylated Smad2/3 expression increased in heterozygous and homozygous
Cited] mutants compared to wild type Min cohort (Figure 5.19). However, in the
two Cited/ deficient cohorts, normalised Smad2/3 expression levels are moreor less
the same. This indicates that activation of TGF-@ pathway increased in normal
tissues with both reduced and absent Cited1 which level compared with the normal
tissue with the wild type Cited1.
Taking the data of survival percentages into consideration, the significant extended
life span was only observed in homozygous Cited] null Min cohort rather than
heterozygous mutants, but not between wild type and heterozygous Cited/ cohorts.
Therefore, TGF-f signalling activity, indicated by the levels of phosphorylated
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Smad2/3, does not consistently associate with the extended life span of Cited/
deficient Min mice,as there is no difference in the levels of phosphorylated Smad2/3
expression between heterozygous and homozygous Cited] Min cohorts. Therefore,
data suggests that Cited] is not interacting with TGF-f signalling pathway in the
context ofApc Min mouseintestinal Wnt pathway.
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Figure 5.19 Phosphorylated Smad2/3 expression levels
in Min mouse normalintestinal tissue of 3 cohorts
normalised to B-actin levels.
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5.9 Discussion
Cited1 wasidentified as one of the Apc/c-Myc dependent Wnttargets. When Cited/
null mice were crossed with Apc Min mice, the Min carrying homozygousdeficient
Cited/ have a significantly extended lifespan in the male population. This may be the
result of Cited] being located on X chromosome. The mechanisms of random
inactivation of one allele of X chromosomesand the fine tuning of the possible
escape from the X-inactivation in female mammals made the data from the female
Min mice too complex to interpret.
In the homozygous Cited/ null male Min mice, number of developed adenomas was
reduced in both small and large intestinal tissue, which suggests that Cited1 loss
inhibits the initiation of tumourigenesis in Min mice. However, in the homozygous
Cited1 null Min cohort, sizes of intestinal adenomas in small intestine and large
intestine were much larger, which is probably the result of a longer life span. The
tumour burden for 3 cohorts were all analyzed at the end point, therefore data
demonstrated the last day structure of the intestinal adenomas. If those homozygous
CitedI null male Min mice were culled at the same time point as the ‘wild type’
Cited1 males, the tumoursize could possibly be the same or even smaller. However,
there was no opportunity to perform the experiment for comparing samples collected
at this time point.
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In homozygous Cited] null Min cohort, c-Myc, Axin2, and CD44 are all over-
expressed compared with the heterozygous Cited] Min mice in normal tissues
although we could not detect B-catenin in the nucleus. There may be a problem of
methodology in tissue fixation when performing B-catenin immunohistochemistry.
However, if B-catenin is not present in the nucleus of the normal tissue, whilst
Cited1 deficiency enhanced the level of Wnt pathway regulated genetranscription,
this suggests other pathways may contribute to this attenuated tumourigenesis. It
could be at some point in downstream of B-catenin, but in upstream of gene
transcription regulation (Figure 5.20).
Wetested two hypotheses described above in normal tissues from the cohorts: the
possible role of ErbB2 and TGF-B in the Wnt-Cited1 pathway. Cited1 associates
with EGR2 to activate ErbB2 expression during mammary tumour progression
(Dillon et al., 2007). However, in mouse normalintestinal tissue, ErbB2 and EGR2
mRNA were both up-regulated when no Citedl was expressed. It has also been
demonstrated that ErbB2 is probably not involved in the initial stage of intestinal
tumourigenesis in this model as shown by its mRNA expression in the intestinal
epithelium cells taken from an immediate Apc knock-out model. These data
demonstrate that ErbB2 is not an important target in this model and its expression is
not regulated by Cited] as in the mammary gland (Figure 5.20).
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The TGF-f signalling pathway is the other candidate, as Cited1 interacts with
CBP/p300 and Smadsto activate TGF-B signalling regulated transcription (Yahataet
al., 2000). Phosphorylated Smad2/3 was used as an indicator of TGF-B signalling
activity and did not show obvious changes at protein levels between heterozygous
and homozygous Cited/ null mutants. Ideally and for the future, a set of TGF-B
pathway regulated genes should be analysed to measure the signalling activity.
However, so far, there is little evidence demonstrating that TGF-B pathway may
contribute to the attenuated intestinal tumourigenesis in Min mice in the context of
knocking out Cited/ (Figure 5.20).
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Figure 5.20 Hypothetical relations between Cited1, Wnt and tumour
progression.
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In the Min mouse model, Cited deficiency does inhibit the intestinal tumour
progression, whichis consistent with the observation in the human colon cancercell
lines. Wnt pathway regulated genetranscriptions were elevated in both in vitro and
in vivo models. However, the underlying molecular mechanism involved in this
processisstill illusive. The Min modelhasits limitations, whilst it has been good for
studying life span. It has limitations when it comes to understanding the immediate
events following Apcloss.
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Chapter 6 Role of Cited1 loss in intestinal epithelium in
the inducible Apc knock-out mice
6.1 Introduction
Chapter 5 demonstrates the involvement of Cited! in mouse intestinal
tumourigenesis. Cited] deficiency significantly extended the Min mouse life span.
However, the underlying mechanism linking Cited! to the intestinal tumourigenesis
is still unclear. A different model was required to investigate the early effects of loss
of Cited1 in the intestine.
Asstated in chapter 1 and chapter 3, there is a conditional Cre-/oxP Apc knock-out
model available. The primary consequences of Apc loss in the intestine has been
investigated after inducing the Cre specific recombinasein the intestine of this model
(Sansom et al., 2004). Additionally, Cited1 was found to be a Myc-dependent Wnt
target, as it is over-expressed in this immediate model with Apc deletion and its over-
expression reversed to be normal with the rescued phenotype after losing both Apc
and Myc in mouseintestine (Sansom et al., 2007; Sansom et al., 2004). Takenall
abovetogether, the conditional Apc knock-out modelis a better tool for investigating
the primary phenotypic changes together with the underling molecular mechanisms
in the intestine.
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Since Cited] deficiency extended the Min mice life span, the research question is
whether knocking-out Cited/ on the Apc flox backgroundwill rescue or attenuate the
Apc loss imposed phenotypic changes.
6.2 Mouse models
Homozygous Cited] null Min mice were crossed onto the AhCre Apcflox
background to produce Cited1*’* Apc’(wild type), Cited1*’* Apc"" (Ape flox),
CitedI””Apc" (Apcflox plus Cited1 null) and CitedI”” Apc** (Cited1 null) cohorts.
Cited/ null mutants are global knockout to Cited1, rather than flox inducible mice.
There are 3 mice in each cohort and mice from all 4 cohorts carry the AhCre’ to be
comparable controls. All 12 mice were induced by injection of B-napthoflavone and
wereculled 4 daysafterthe first injection.
6.3 Confirmation ofApc and Cited] knock-outstatus in mice
6.3.1 Confirmation of Ape recombination after inducing Cre recombinase
The Apc recombination after being induced by B-napthoflavone was detected by
quantitative PCR using a pair of primers locating outside of the Cre-/oxP-Apc
construct. Here, qPCR is not used to measure Apc gene expression level, howeverit
is detecting the amplification product size as PCR product from the recombined Apc
allele is slightly smaller than the wild type allele after Cre-induced deletion.
According to the primer design (Dr. Zoe Burke, University of Bath), the PCR
product of wild type band is a size of 383bp and the recombined bandis a size of
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168bp. As shownon the gel of qPCR products from 4 cohorts, Ape was successfully
recombined in the Apc flox and Apc flox/Cited/ null cohorts (Figure 6.1, sample 4-
9). However, Apc remains wild type in the wild type cohort and Cited1 null cohort,
although those mice were also injected by the inducing reagent B-napthoflavone
(Figure 6.1, sample 1-3 and 10-12).
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Figure 6.1 Confirmation of wild type and recombined Apc expression in small
intestinal epithelial cells 4 days after the first injection of the cre-inducing agent B-
napthoflavone. Primers were designed by Dr. Z. Burke and kindly provided by Dr. K.
Reed. Gels show the amplified products from qPCR(of40 cycles) on Apc after
inducing cre recombinase. Bandsof wild type Apcare at the size of 383bp and bands of
recombined Apcare at 168bp. WT= wild type, AF=Apcflox/flox, AF+CN=Apc
flox/flox and Cited1 null, CN=Cited/ null. Three mice were being studied in each
cohort. There are 3 mice in each cohort.
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6.3.2 Confirmation of Cited1 status in mice
Quantitative PCR was used to confirm the Cited! status as stated in chapter 5 (5.3.1).
As expected, samples taken from wild type and Apc flox cohort generated melting
curve with a single peak showing the detectable Cited] mRNA expression (figure
6.2).
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Figure 6.2 Representative melting curve of wild type Cited] mRNA
expression in quantitative PCR from 3 mice.
Howeverthe delta Ct value is much lower for the Apc flox cohort than the wild type
cohort indicating the up-regulation of Cited] mRNA expression after Apc deletion
(figure 6.3) (a lower delta Ct value equates to increased amountofthe allele being
amplified within the sample, as fewer PCR cycles are required to reach a designed
cut-off point for PCR product produced). This up-regulation is statistically
significant (P<0.04, Mann-Whitney U test). Similar data has been demonstrated in
previous work andit is used as the positive control in the context of this new colony.
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Figure 6.3 Decreased delta Ct value of Cited1 in Apc flox cohort
indicates an up-regulation. Error bars indicate the standard error of
the mean.There are 3 mice in each cohort.
In the double null and Cited/ null cohorts, there was no melting curves with a single
peak suggesting that Cited] mRNA in samples taken from these 2 cohorts is
undetectable e.g. figure 6.4. The delta Ct values cannot be calculated as the samples
within the wild type and Apc flox cohorts. Therefore, the melting curve data
confirmed the Cited1 knock out status in the Cited/ single null and Cited/ null in
addition ofApc loss.
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Figure 6.4 Representative melting curve of knocking out Cited1. 199
6.4 Altered crypt-villus architecture in Apc Cited] double null mice
The histology of mouseintestinal tissue sections from 4 cohorts were examined by
haematoxylin and eosin staining (figure 6.5). In the Apc floxed mice, the important
feature is the altered crypt-villus architecture. The crypt-zone was no longer
condensed and located at the bottom of small intestine as in the wild type mice,
howeverit was elongated with crypt-like cells occupied the majority of the crypt-like
villus axis. This has been previously reported (Sansom et al., 2004) and it was used
as a positive control in this context.
In the Cited] knock-out mice, the morphology of the stained sections did not show
the obvious dramatic changes as in the Apc deleted sections. The crypt-villus
architecture is more similar to the wild type control tissues. Data suggests that losing
Cited1 alone is not sufficient to trigger large morphological alterations in mouse
small intestine.
Intriguingly, when Cited] was knocked out in addition to inducing Apc deletion in
mouse small intestine, the altered crypt-villus architecture showed an even more
severe phonotype than Apc flox cohort. The crypt zone in the small intestine of these
mice was wider than in the Apc flox mice. There seem to be a larger number of
crypt-like cells occupied in the small intestinal epithelium of the elongated crypt-like
zone.
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Figure 6.5 Morealtered crypt-villus architecture in double null mice 4 days after
the first injection of the cre-inducing agent B-napthoflavone. WT= wild type,
AF=Apcflox/flox, AF+CN=Apceflox/flox and Cited! null, CN=Cited1 null. One
representative image is shownfor each cohort. There are 3 mice in each cohort.
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This observation was the opposite of our expectations in light of the data from the
Cited] deficient Min mouse model. This enhanced alteration of crypt-villus
architecture in the double Apc Cited/ null cohort may also be accompanied with
altered patterns of proliferation, apoptosis and differentiation.
6.5 Increased proliferation in Apc Cited1 double null mouse intestinal
epithelium
In the previous study, the proliferation zone has been foundto increase after losing
Apc in mouse small intestine compared with the wild type control mice (Sansom et
al., 2004). The proliferation pattern of Apc Cited] double null mice was examined
following 2 hour BrdU labelling (mice were injected with BrdU and culled 2 hours
after) and analysed by BrdU immuno-histochemistry. Tissues taken from wild type,
Apc flox and Cited/ null were also examinedasthe controls.
In the wild type and Apc flox mice, the patterns of proliferation were similar as
shown previously in paper (Figure 6.6). In the Cited/ null cohort, the BrdU staining
did not show dramatic difference in proliferation from the wild type mice, although
the BrdU positive cells were slightly spread as compared with the defined
proliferation zone within the normal crypt. However, in the Ape Cited/ double null
mice, the image showed that the BrdU labelled proliferation zone were stretched
wider as compared with the mice from Apc flox cohort. This pattern ofproliferation
was observed in the Apc Cited] double null cohort whilst also altered more in the
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crypt-villus architecture with the elongated crypt-like zone in the mouse small
intestine.
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Figure 6.6 Increased proliferations in double null mice as compared to
Apc flox/flox mice, detected by BrdU immuno-histochemistry staining in
induced epithelium 2 hours after BrdU injection. WT= wild type,
AF=Apcflox/flox, AF+CN=Apcflox/flox and Cited/ null, CN=Cited/ null.
Onerepresentative image is shownfor each cohort. There are 3 mice in each
cohort.
203
The proportions of cells in S phase (BrdU positive cells) were then scored for their
position along the crypt-villus axis. Tissue sections from 3 mice of each cohort were
scored and 25 crypts (or 50 half crypts) were scored for each mouse using WinCrypt
program (kindly provided by Prof. M. Pritchard (Gastroenterology Unit, Liverpool).
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Figure 6.7 Position of BrdU positive cells within the crypt-villus
axis from the mouse cohorts at 2 hours following BrdU
injection. Position 0 represents the base of the crypt. Curve for each
cohort is the mean value of 3 mice in the cohort. WT= wild type,
AF=Apceflox/flox, AF+CN=Apceflox/flox and Cited/ null,
CN=Cited/ null. Data agreed with the scoring result by a master
project student in the University of Cardiff.
The BrdU positive cell percentage showed similar level of proliferation between
wild type and Cited] null cohort (figure 6.7). The proliferation level was
dramatically increased in the Apc flox mice compared with wild type mice, which
was one of the phenotypes associated with early colorectal lesions (Sansom etal.,
2004). This increased proliferation level was even higher in the Apc Cited/ double
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null mice. The cumulative frequency graph showsthe trend of BrdU positive cells
accumulation from the bottom of the crypts in 4 cohorts (figure 6.8). Wild type and
Cited] null cohort showed similar trend, however this cumulative frequency
significantly shifted to higher cell position in Apc flox cohort (D>Do0s,
Kolmogorov-Smirnov test) and even higher in double null cohort (D>Do0s,
Kolmogorov-Smirnovtest).
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Figure 6.8 Graph showingthe position of the BrdU-labelled cells 2 hours after
being labelled. WT= wild type, AF=Apcflox/flox, AF+CN=Apcflox/flox and Cited1
null, CN=Cited/ null. There are 3 mice in each cohort.
Taking the morphological changes together with the quantified proliferation index,
data suggests that there were morecells traversing the S phase in the proliferation
zone when crypt-like zone was elongated. Therefore, knocking out Cited] enhanced
the proliferation in the Apc flox mice.
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6.6 Increased apoptosis in Apc Cited1 double null mouse intestinal epithelium
Theintestinal crypts were scored for apoptotic bodies using haematoxylin and eosin
stained sections. Figure 6.9A shows the representative apoptotic bodies. Tissue
sections were taken from 3 mice from each cohort and 25 crypts (or 50 half crypts)
were scored for each mouse.
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Figure 6.9 Increased apoptosis in the double null mouse small intestinal
epithelium. (A) Representative image showing apoptotic bodies in haematoxylin
and eosin staining. (B) Scored apoptotic bodies in 4 cohorts. Data of apoptosis
level was confirmed by scoring an independent caspase 3 immunohistochemistry
experiment by Dr V. Meniel. There are 3 mice in each cohort.
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Tissues taken from wild type cohort showsbasal level of apoptosis in the mouse
small intestine after being injected of B-napthoflavone (figure 6.9B). All pairwise
comparisons were performed following Kruskal-Wallis ANOVA. There was not
much change in the number of apoptotic cells in the Cited/ null cohort compared
with the wild type mice (not significant). The level of apoptosis was significantly
elevated in the Apc flox cohort as observed previously (P<0.05, Kruskal-Wallis)
(Sansom et al., 2004). However, in the Apc Cited] double null cohort, a significant
much larger number of cells underwent the apoptotic process (P<0.05, Kruskal-
Wallis).
Active caspase 3 immuno-histochemistry was then used to confirm apoptosis as
observed from haematoxylin and eosin staining in 4 cohorts. The condensed dark
round cells labelled by the active caspase 3 antibody are cells going through
apoptosis. Again, the image of immuno-histochemistry assay implies that the
elevated apoptosis was enhanced by Cited/ loss on the Apc flox background (figure
6.10).
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Figure 6.10 Increased apoptosis in double null mice as detected by active
caspase3 immuno-histochemistry assay. WT= wild type, AF=Apcflox/flox,
AF+CN=Apeflox/flox and Cited] null, CN=Cited1 null. One representative imageis
shown for each cohort. There are 3 mice in each cohort.
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6.7 Wnt signalling regulation in Apc Cited] double null mouse intestinal
epithelium
In the Ape flox mice, the altered crypt-villus architecture was accompanied by
activated Wntsignalling (Sansom et al., 2004) and this phenotype was rescued with
reversed Wntsignalling activity in Apc Myc double null mutants (Sansom etal.,
2007). Cited1 is a myc-dependent Wnttarget. In the Apc Cited] double null mice,
the enhanced architecture alteration together with the increased proliferation and the
elevated apoptosis mayalso associate with the Wntsignalling pathway regulations.
6.7.1 Loss of Cited1 does not inhibit nuclear B-catenin translocation in the
double null (Ape ™" Cited1~") mousesmallintestinal epithelium
Nuclear B-catenin translocation is a critical event in activated Wntsignalling, which
wastested for in all 4 cohorts by immuno-histochemistry assay. In the wild type
mice, B-catenin does not translocate into nucleus (figure 6.11). When Ape was
deleted, B-catenin translocated into nucleus in the crypts, indicating activated Wnt
signalling in this cohort, which has been shown previously (Sansom et al., 2004).
There was no nuclear B-catenin observed in the Cited] knock-out mice, which is
similar to the wild type mice. Loss of both Cited] and Apc causedtranslocation of B-
catenin into nucleus. This data suggests that knocking out Cited] does not inhibit
nuclear B-catenin translocation in Apc deletionstrains.
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Figure 6.11 B-catenin translocation in Ape flox and Apcflox/Cited1 null
mousesmall intestinal epithelium. There are 3 mice in each cohort.
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6.7.2 Detection of Wnt signalling regulated gene transcription in double null
(Ape "" Cited1~") mousesmall intestinal epithelium
Axin2, CD44 and Myc mRNAexpression levels were then measured by relative
quantitative PCR. Fold changesof 3 target genes in Apc flox, Apc Cited1 double null
and Cited! null cohorts were all normalised to the wild type samples. All pairwise
comparisons were made following Kruskal-Wallis ANOVA.
Three known Wnt targets were slightly up-regulated in the Cited1 null mice
compared with wild type mice, however, not as muchas in the Apc flox intestinal
epithelium cells. In the Apc Cited] double null cohort, Axin2, CD44 and Myc all
showed same extend of the increased level of up-regulations as in the Apc flox
cohort compared with wild type cohort. Axin2 and CD44 weresignificantly over-
expressed (P<0.05, Kruskal-Wallis), however the increased expression of Myc was
not statistically significant (P>0.2, Kruskal-Wallis) (Figure 6.12). The later result
may be because there were only 3 mice beingtested in this preliminary study of the
Apc Cited] double null cohort.
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Figure 6.12 Wnt targets regulation in double null mouse small intestinal epithelium.
Axin2 and CD44weresignificantly up-regulated in the double null mouse small intestinal
epithelium. Error bars stand for the standard error of the mean. There are 3 mice in each
cohort.
The preliminary data suggests that Wnt signalling regulated gene transcription level
may increase after losing Cited] in addition of Apc deletion. However, Axin2 and
CD44 may not be the best candidates for measuring the effects of knocking out
Cited1 on Wnt signalling regulated gene transcription activity. CD44 has been
identified to be Myc independent. Although being Myc dependent, Axin2 could
possibly bring complexity into data interpretation as being both Wnt down stream
target and recruited as part of the B-catenin degradation complex in upstream.
Therefore, a series of Myc dependent Wnttarget gene expression would need to be
detected, to confirm the effects of Cited1 loss on the Wnt signalling regulated gene
transcription. As Cited1 was a Myc dependent Wnt regulated target, knocking out
Cited1 morelikely regulate part of the Myc-dependent Wntsignalling activity.
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6.8 Discussion
This immediate inducible model of Apc loss provided the opportunity to investigate
the early stages of intestinal tumourigenesis. However, the limited time did not allow
a comprehensive analysis enabling an understanding of the immediate alterations in
the small intestinal epithelium of the Apc Cited] double null mice. Preliminary
investigations were carried out to gain a general picture of the underlying process.
Data from the preliminary studies on this Cited/ null Apc flox mouse model shows
that knocking out Cited! induced more altered crypt-villus architecture with
increased proliferation and elevated apoptosis. Although the crypt-villus architecture
was morealtered with higher level of proliferation, only the remaining Apc deficient
proliferative cells would be able to develop tumours in the intestine. The higherlevel
of apoptosis in double null mice may tend to allow the Apc deficient cells die away
in this early stage model, which can possibly reduce later tumourigenic events.If this
is the case, this hypothesis would be consistent with the observation in Cited/ null
Min mouse model. However, 48 hours BrdU labelling in the B-napthoflavone
induced mice would be needed to investigate the migration speed of proliferative
cells to test whether Apc deficient cell would migrate quicker through the villus axis.
In the cohort with the additional loss of Cited] on Apc flox background, B-catenin
wasobservedto translocate into nucleus as was observed in the Apc flox mice. This
suggests that knocking out Cited1 is not sufficient to inhibit Wnt signalling activity
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at the point of nuclear B-catenin translocation. As Cited] is a Myc dependent Wnt
target, Axin2 and CD44are not the best candidates to be tested. In order to detect the
effect of losing Cited1 on Wnt signalling activity, a set of Myc dependent Wnt
targets need to be tested.
So far, data suggested that some mechanismsare possibly involved with Cited1 loss
to modulate Wnt signalling in downstream of B-catenin, in turn regulate intestinal
tumourigenesis. In order to determine the potentially mechanisms involved, a
comprehensive DNA microarray analysis needs to be performed.
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Chapter 7 Conclusion
The Clarke group developed the intestinal tissue specific conditional Cre-/oxP Apc
knock-out mouse model using Cyp1A1 promoter. This model resolved the difficulty
of Apc knock-out mice dying in utero and provided the possibility of investigating
the effects of immediate loss of functional Apcin the intestine in vivo, allowing the
identification of early phenotypic changes of Apc loss. An array analysis of this
model identified dysregulated genes by activated Wnt signalling pathway in small
intestine (Sansom et al., 2004). Using the same inducible deletion system, a double
knock-out of Apc and Myc appeared to have ‘wild type-like’ intestinal architecture.
The array analysis from this new cross identified 59% (27/46) of Wnt target genes
became normally expressed following loss of c-Myc (Sansom etal., 2007). A subset
of these changes (Axin2, Musashi, Sox17, Fzd6) were confirmed by real time
quantitative reverse PCR. Therefore Myc-dependent Wntsignalling regulated genes
are largely responsible for the Apc loss imposedintestinal architecture alteration.
To access the translational value of the observation from the mouse model, matching
paired normal mucosaand colorectal tumour tissues from colorectal cancer patient
were used. Data from homologous human gene expressions show that most of the
Wnt targets deregulated in the inducible Apc knock-out mouse model are also
deregulated in human colon cancer tissues, demonstrating the validity of this
strategy. Unfortunately, due to the project scale and time, there were not sufficient
data to allow sub-grouping linking the specific gene over-expression withthe clinical
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data, such asthe location of colorectal carcinogenesis event on intestine, the staging,
patient gender and age. From this data set, Cited! was found to be one of the genes
that are both up-regulated in mouse model and human colorectal cancers. It has been
previously unrecognized as being involved with colorectal carcinogenesis.
Altered expression of Cited] has previously been studied in melanoma, thyroid, and
breast cancers (Li et al., 1998; Nair et al., 2001; Scognamiglio et al., 2006). In my
project, the preliminary investigation on involvement of Cited1 in colorectal
carcinogenesis was carried out using siRNA treated human colon cancercell lines.
Following Cited/ expression reduction, decreased cell survival and proliferation was
observed in HCT116 cells. This was also confirmed in HT29 cells. The inhibition of
Cited] data demonstrates an inhibitory effect on cell proliferation implicating its
possible role in carcinogenesis. Although Axin2 and CD44 expression were
measured after reducing Cited] expression in cells, it was difficult to draw
conclusion from this data on the underlying molecular mechanisms.
Two transgenic mouse models were then employedto investigate the inhibitory role
of deficient Cited1 and to elucidate the underlying molecular mechanismsin the in
vivo setting. When crossing Cited/ null mice with Apc heterozygote Min mice, loss
of Cited1 significantly extended the life span of the Min mice by another ~250 days,
which almost double the latency in these animals. Tumour number was also
significantly reduced in Cited] null Min mice, whose life span was predominantly
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determined by the tumour numberin small intestine and large intestine rather than
the absolute tumour size. The increased tumour size in these mutants may be the
result of longer time frame for the tumour development in the longer surviving
animals. Therefore, Cited1 deficiency plays the inhibitory role in intestinal
tumourgenesis in the min mice intestine. In the Min Cited/ null model, deficient
Cited1 is probably preventing the normal epithelium from transforming into tumour
in Min mouseintestine, rather than killing cancerouscells and limiting those cells to
proliferate in human colon cancel lines, data from the studies of Min Cited/ null and
Apc Cited] double null models are quite consistent in terms of the inhibitory role of
deficient Cited1 in intestinal tumourigenesis.
The above studies support involvement of Cited] in colorectal carcinogenesis.
However, the results were only observed as the end point event. In the Apc Cited]
double null model, loss of Cited1 triggered more alerted crypt/villus architecture
with increased proliferation and apoptosis. This phenotype wasobserved4 daysafter
deleting Apc in the mice, this model mimicsthe initiation of the process of colorectal
carcinogenesis. The high level of apoptosis may tend to allow the proliferative cells
die away at early points, which makes the severe phenotype beneficial to the
mutants, leading to the longer life span as found in Min mice. The similar
phenomenon has been previously observed in limb morphogenesis, in which
apoptosis is a prominent feature, resulting in the inter-digital tissue repression
(Zuzarte-Luis and Hurle, 2002). In this process, the pattern of apoptosis determines
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the cell fate in the inter-digital area, leaving the correct structure and number of
digits (Zuzarte-Luis and Hurle, 2002). However, in the intestine of the mouse model,
the underlying mechanisms need investigating to support this preliminary
conclusion.
The immuno-histochemistry assay of B-catenin showedthe nuclear translocation in
Min adenomasandin intestinal epithelium ofApc/Cited/ double null mice. As being
downstream of Myc, losing Cited1 is not sufficient to reverse the nuclear B-catenin
translocation as loss ofMyc does in Apc null mice. DNAarray analysis identified the
Myc Maxinteraction as a potential underlying mechanism and similar observation
was described by Mariadason in regard of the intestinal epithelial cell maturation
along the crypt-villus axis (Mariadason et al., 2005). Wnt signalling activity was
confirmed to be maximal in the proliferative compartment and Myc protein
expression levels decrease from crypt to the top of the villus whilst MAX protein
expression level increases, which predominantly regulate the Myc targets
(Mariadason et al., 2005). This study implicates the relationships between
proliferation activity, Myc-MAX antagonising mechanism and Myc target genes in
the intestinal epithelium. Cited1 activates Smad4-dependenttranscription involved in
TGF-B signalling in kidney (Plisov et al., 2005) and Myc-Max, Mad-Max
regulations repress mammary epithelial cell growth are regulated by TGF-B (Siegel
et al., 2003b) As Cited1 is a Myctarget, loss of Cited1 may disturb the Myc-related
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regulations. This could be a potentially hypothetical mechanism modulating the
perturbed epithelial proliferation in the Cited] knock-out Apc null mice.
So far, from the data already generated in vitro and in vivo, I concludethat deficient
Cited1 inhibits the colorectal cancinogenesis, however the underlying mechanisms
are still elusive. In the future, I shall validate our cell line data on cell growth using
other colon cancer-derived cell lines with defective Wnt pathways, SW620 and
DLD1 cells. The effects of Cited! on cell cycle and apoptosis also need to be
determined by FACS-based analysis. To determine whether deficient Cited! is able
to modulate Wnt signalling directly, luciferase assays will be performed using the
Wnt responsive TOP-FLASH system. siRNA will be co-transfected with TOP-
FLASH and one of the four known Wnt pathway transducers (AN-LRP6; FlagAx,
AN beta-catenin or TCF4-VP16) (Brennan et al., 2004; Munemitsu et al., 1996;
Smalley et al., 1999; Wakita et al., 2001). The four transducers will represent the
Wntpathway from the receptor (LRP) through to the degradation complex (Axin2),
B-catenin and finally the transcription factor TCF-4. For the immediate Apc knock-
out model, 24 hours BrdU incorporation will be able to detect the proliferative cell
migration along the crypt/villus axis to define the fate of the proliferative cells. A
series of immuno-histochemistry of differentiation and apoptosis markers shall be
carried out to accomplish the characterisation of the phenotypic changes. A
comprehensive DNA microarray would be able to help elucidate underlying
molecular mechanism investigation.
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Taken together, this data demonstrates the validity of the Cre-/oxP-Apc strategy as
an early colorectal cancer model and Cited1 is part of the colorectal carcinogenesis
process.
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